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ABSTRACT
 Cancer is a class of diseases characterized by uncontrollable cell growth.
There are over 100 different types of cancer, and each of these cancers are
classified by the type of cell that it initially affects. For the purpose of this
research we will be focussing on prostate cancer (PC). Prostate cancer is the
second most common form of cancer in men around the world and annually
approximately 4500 men in South Africa are diagnosed making PC a global
epidemic.   Prostate cancer is a type of cancer which starts in the prostate it
is normally a walnut-sized gland found right below the bladder. PC follows
a natural course, starting as a tiny group of cancer cells that can grow into a
tumour. In some men if PC is not treated it may spread to surrounding tissue
by a process called direct invasion/ spread and could lead to death. 
Current diagnostic tests for prostate cancer have low specificity and poor
sensitivity. Although many PC's are  slow growing there is currently no test
to distinguish between these and cancers that will become aggressive and
life  threatening..  Therefore  the  need  for  a  less  invasive   early  detection
method with the ability to overcome the lack of specificity and sensitivity of
current available diagnostic test is required. Biomarkers have recently been
identified  as  a  viable  option  for  early  detection  of  disease  for  example
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biological indicators ie. DNA, RNA, proteins and microRNAs (miRNAs). 
Since first described in the 1990s, circulating  miRNAs have provided an
active  and  rapidly  evolving  area  of  research  that  has  the  potential  to
transform cancer diagnostics and prognostics. In particular, miRNAs could
provide  potentially  new  biomarkers  for  PC  as  diagnostic  molecules.
Circulating  miRNAs  are  highly  stable  and  are  both  detectable  and
quantifiable in a range of accessible bio-fluids,  having the potential to be
useful as diagnostic, prognostic and predictive biomarkers. In this study we
aimed to identify miRNAs as potential biomarkers to detect and  distinguish
between various types of  PC in its earliest stage. The major objectives of
the study were to identify miRNAs and their gene targets that play a critical
role in disease onset and progression to further understand their mechanism
of action in PC using several in silico methods, and to validate the potential
diagnostic miRNAs using qRT-PCR in several cell lines.
The identification of specific miRNAs and their targets was done using an
"in-house"  designed  pipeline.  Bioinformatic  analyses  was  done  using  a
number  of  databases  including  STRING,  DAVID,  DIANA  and  mFold
database,  and  these  combined with  programming  and statistical  analyses
was used for the identification of potential  miRNAs specific  to PC. Our
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study  identified  40  miRNAs  associated  with  PC  using  our  "in-house"
parameters in comparison to the 20-30 miRNAs known to be involved in PC
found  in  public  databases  e.g.  miRBase.  A  comparison  between  our
parameters and those used in public databases showed a higher degree of
specificity for the identification PC-associated miRNAs. 
Gene  targets  for  these  40  miRNAs  were  identified  using  the  publicly
available  TargetScan  database.  A  total  number  of   785  targets  were
identified.  The target  gene list  was streamlined by eliminating duplicates
using a Perl script, resulting in a final target list of 551 genes. The final
target gene list was subjected to Functional Annotation and cluster analyses
using DAVID. Seventy seven clusters were generated,   3 of which were
identified  as  clusters  of  processes  involved  in  cancer  onset  as  well  as
progression. These clusters contained a total of 21 gene targets. These gene
targets were then correlated to  the miRNAs identified by our "in-house"
technique. From the 40 miRNAs 13 were found to be of interest based on
Gene Ontology, Functional annotation and cluster analysis of their targeted
genes,  of  which  8  miRNAs  (MiR1-8)  were  tested  during  subsequent
sections of this study. 
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These selected miRNAs were analysed using different bioinformatics tools,
and were confirmed to be novel miRNAs associated with PC.
The identified miRNAs were experimentally validated  using qRT-PCR to
generate  expression  profiles  for  PC  as  well  as  various  other  cancers.
Prostate lines utilised in this study included PNT2C2 (normal) which was
compared to  BPH1 (Benign)  and LNCaP (Metastatic).  In  the   study the
expression profiles of eight potential miRNA biomarkers for the detection of
PC  was  determined  using  qRT-PCR,  and  to  distinguish  PC  from  other
cancers. 
QRT-PCR data  showed  that  miRNA-3  and  -5  were  up-regulated  in  the
BPH1 and LNCaP when compared to PNT2C2. In addition miRNA-8 was
also  shown to  be up-regulated  in  LNCaP. Based on these  results  it  was
shown that a  miRNA profile could be established  to distinguish between
BPH1  and  the  LNCaP  prostate  cell  lines.  The  results  suggest  that  one
miRNA as a diagnostic marker may be sufficient to differentiate between
different cancer cell lines. Furthermore by creating a unique profile for each
cancer  cell  line by using a  combination of  miRNAs could  be a  suitable
approach as well. 
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Finally, it was shown that through the use  of a single or combination of all
eight miRNAs a unique profile for all  the cancer cell lines tested in this
study  can  be  created.  This  is  an  important  finding  which  could  have
potential diagnostic or prognostic implications in clinical practice.
Keywords: Prostate cancer, miRNA, biomarker discovery, diagnostics,
early  detection,  cancer, specificity,  sensitivity,  qRT-PCR,  Expression,
Bioinformatics.
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CHAPTER1
Introduction
Cancer can broadly be described as a group of more than  200 different
types of diseases that has the ability to affect any cell in any organ of the
body (Fayed, 2009). It is as a result of a series of molecular events that
ultimately compromise the normal functioning or properties of that specific
cell in a specific  part of the body (Hartwell, 2012). In the case of normal
cells  they  are  subjected  to  signals  that  would  allow the  cell  to  divide,
differentiate  into  another  cell  or  perish  (Hejmadi,  2010).  Where  as  in
cancer  cells  these  processes  are  hindered  as  a  result  of  mutated  genes
which lead to uncontrollable cell growth and eventually tumour formation.
 The general principle on which modern cancer biology rests, is the change
of  these  normal  cells  as  a  result  of  changes  in  the  networks  on  the
molecular,  biochemical  and  cellular  level  and  on  each  level  there  is  a
number  of  ways  disturbances  can  occur  (Hejmadi,  2010).  General
disturbances  in  the  normal  processing  and  pathways  in  the  cell  with
regards to cancer can result in the loss of normal cell growth, of which the
normal tissues have a constant controlled balance of new cell growth and
the death of old cells (American Cancer Society, 2012). In normal tissues,
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the rates of new cell growth and  cell death are kept in balance, and when
this balance is compromised or altered it results in the uncontrolled growth
of cells with the loss of the cells ability to undergo apoptosis or cell suicide
mechanisms which are  used by the cell to self-destruct  and maintain cell
homeostasis (Kleinsmith et al., 2011). 
Abnormalities which make cancer cells different from normal cells usually
result from protein coding genes that govern cell division or genes which
are linked to cell division (Thiel, 2010). As time progresses, these genes
which play a pivotal role in repairing DNA damage,  become more mutated
and may become non- functional. It then cascades from mutations within
the parent cell and is passed on to the daughter cells. Some mutated cells
die but some of them have a selective advantage allowing it to multiply
more rapidly than the normal cells, which is descriptive of cancer cells.
These  cells  show  enhanced  growth  that  have  gained  functions  usually
repressed in normal cells (Thiel, 2010).
Cancer cells have the ability to develop  a degree of self-sufficiency which
aid  in  their  proliferation  and  uncontrolled  growth,  if  left  to  follow  its
natural  course  it  would  spread  and  lead  to  an  almost  definite  case  of
fatality. Data shows that 90% of cancer-related deaths are as a result of
                                    2
 
 
 
 
metastasis-  tumour  spreading  (Hejmadi,  2010).  The  changes  that  these
cells  inherit  allow  the  cell  and  its  progeny  to  grow  and  divide  in  the
presence of normal cells. In the presence of cancer cells these inherited
changes  would  naturally  inhibit  the  growth of  cells  which  are  in  close
proximity  and  therefore  the  ability  to  do  so  allow them to  spread  and
invade other organs (Thiel, 2010).
As a result of the increase in cell proliferation more cells keep dividing and
the division of the excess amount of the cells,  which is not needed by the
body  then  forms  a  mass  of  abnormal  tissue  referred  to  as  a  tumour
(ADSTR, 2013).  Tumours are  classified into two forms, which can either
be  malignant  or  benign.  A malignant  tumour  can  be  described  as  a
cancerous  tumour,  that  has  the  ability  to  invade  and  cause  damage  to
nearby  tissues.  Due  to  their  cancerous  nature  the  cells  metastasise  by
breaking  away  and  entering  the  bloodstream  and  lymphatic  system,
causing havoc by forming tumours elsewhere in the body (MHS, 2010). A
benign tumour is not cancerous, and are usually removable and  also do not
possess  the ability to spread to other parts of the body and spread to other
tissues (MHS, 2010). 
Tumours  are  classified  according  to  their  origin  and  tissue  types,  with
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origins as organs such as the liver and breast amongst others. Classification
on the basis of the type of  cancer are divided into 5 major categories, they
include (a) carcinomas which is cancer starting in the epithelial cells that
form a lining internally or externally of organs inside the body. There  are
many types  of  carcinomas two of  the  most  common  types  include  (i)
adenocarcinomas which develops in an organ or gland and (ii) squamous
cell  carcinomas  which  affect  the  squamous  epithelium (Mandal,  2010).
The  (b)  sarcomas  are  cancers  that  stems  from  the  connective  and
supportive tissues which include muscles, bones, cartilage and fat (Fendler,
2011).  The (c) myelomas are the cancers’ that arise in the plasma cells of
bone marrow and is classified as a type of blood cancer (Hejmadi, 2010).
(d) Leukaemias are  types  of cancer  that  are  clustered under the blood
cancers  group  (Fendler,  2011). (e) Lymphomas  are  lymphatic  system
cancers  that  affect  the  lymph  nodes  in  specific  areas  of  the  body
(Kleinsmit, et al., 2011).
1. Hallmarks of Cancer
Functional capabilities that categorise cancer cells include self-sufficiency
in growth signals, insensitivity to anti-growth signals, the ability to evade
programmed cell-death. They also invade tissue and metastasise to other
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organs in the body, have replicative potential and the ability to form their
own blood vessels for nutritive purposes (Negrini  et al., 2010). Genomic
instability was also considered as one of the hallmarks of cancer however
it is now considered  separately because it is not a functional capability of
cancerous cells but a property that gives rise to the hallmarks of cancer as a
result of acquisition (Negrini et al., 2010). Additional hallmarks are related
to the presence of stress in cancer cells such as DNA damage and DNA
replication, oxidative stresses, proteotoxic stresses and metabolic stresses
(Negrini  et  al., 2010).  Five  new  hallmarks  were  also  added  and  is
qualitatively  different  from  the  original  hallmarks  in  that  they  do  not
describe functional capabilities of cancers but rather the state of cancer
cells  which  are  characterised  by  the  presence  of  the  aforementioned
stresses.
Sporadic and inherited cancers
There  are  two  main  categories  of  cancer  (I)  sporadic  cancers  and  (ii)
hereditory cancers (Figure 1.1). Ninety to ninety fiver percent of cancers
are  sporadic  with  the  remaining  5-10%  being  hereditory  (Lee  and
Muller.2010)
Sporadic cancers occur by chance in certain cells as a result of a mutation
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(Darrough, 2008). Individuals who develop sporadic cancers did not inherit
the  cancer  from  parent  cells  thus  only  the  tumour  cells  contain  the
mutations which cannot be passed on to future generations (Adams, 2011).
Hereditary cancer is inherited from an already mutated parent gene inside
the  ovum or  sperm cell,  the  gene  is  then  passed  down at  the  time  of
conception  (Darrough,  2008)  These  germline  mutations  predispose
members of a family to the onset of  a particular cancer(Adams, 2011).
Figure  1.1:  Graphical  representation  of  the  difference  between
sporadic  and hereditary cancer history. Where the image on the  left
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shows the sporadic occurrence of cancer in a single individual. The image
on the right shows hereditary cancer where mutated genes are passed on to
future  generations  increasing  the  risk  of  cancer  development  in
downstream generations (Taken from Darrough 2008)\
1.1 Genetics of cancer
A normal cell needs to undergo several changes in order to become a cancer
cell. Of these changes,  mutational changes are considered one of the key
alterations. Because of these changes, cancer can therefore be classified as
a genetic disease on the cellular and inheritance level (Ponder, 1992). It is
estimated that about 35000 genes in the human genome have been known
to have some sort of association with various cancers (Thiel, 2010). 
Mutations  in  genes  result  in  altered  proteins,  such changes  could  occur
during cell  division or as a result of external agents or a random event.
Most cancers  result  from mutations in  somatic  cell  or  in  germline cells
(Yuluğ,  2012).   A  germline  mutation  is  any  detectable  and  heritable
variation  in  the  lineage  of  germ  cells.  Mutations  in  these  cells  are
transmitted  to  offspring.  Mutations  of  this  nature  gives  rise  to  a
constitutional mutation in the offspring, that is, a mutation that is present in
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virtually every cell. A constitutional mutation can also occur very soon after
fertilisation, or continue from a previous constitutional mutation in a parent
( Hanahan and Weinberg., 2011). Somatic mutations however are described
as a change in the genetic structure that is not inherited from a parent, and
also not passed to offspring (Capaccio et al., 2010). The distinction between
germline  and  somatic  mutations  is  important  in  animals  that  have  a
dedicated germ line to produce reproductive cells. These mutations are not
only known to lead to cancer but are also seen as precursors for disease as
they  can  also  be  passed  down  to  subsequent  generations  (Park  and
Vogelstein, 2003).  
1.2 Genes responsible for genetic malfunction 
Malfunctioning  genes  have  been  classed  into  two  main  groups  called
oncogenes  and  tumour  suppressor  genes.  Tumour  suppressor  genes  are
genes whose gene products inhibit cell division or cause cell death. Tumour
suppressor  genes  with  a  subtype  of  mismatch  DNA repair  genes.  DNA
mismatch repair genes play a role in preventing mutations which could lead
to  cancer  (Hejmadi,  2010).  Oncogenes  play  a  role  in  the  production  of
proteins  that  enhances  cell  proliferation  or  inhibits  cell  death.  The
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aforementioned  genes usually play a role in the maintenance of normal
genomic stability and are involved in the regulation of the cell cycle (Devi,
2005).
 
1.2.1 Oncogenic gain of function mutations from proto-oncogenes
Proto-oncogenes  are  gatekeeping  genes  whose  products  control  cell
proliferation. They mutate and are converted to oncogenes  this may cause
a change in the protein structure, causing an increase in protein (enzyme)
activity or a loss of regulation and thus and renders the gene in a state of
continuous activation (American Cancer Society, 2012). They also encode
growth  promoting  signal  molecules  and  their  antiapoptotic  receptor
proteins with transcription factors genes (Park and Vogelstein, 2003). 
There are several mechanisms by which proto-oncogenes are converted to a
oncogenes. These include point mutations, chromosomal translocation and
amplification. During conversions by point mutations  a single base pair is
mutated in a proto-oncogene. The result of this mutation leads to a protein
whose product is constantly being produced (Thiel,  2010). Chromosomal
translocation is divided into two parts that make them different from point
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mutations, the conversion is the first part which is the  fusion of two genes
resulting in a hybrid gene this gene then encodes for a chimeric protein.
The second part is a change within a promoter of a growth regulatory gene
affecting gene expression (Lodish  et al., 2003). Amplification is the last
known mechanism where there is DNA replication of a segment of DNA
containing a proto-oncogene which then results in the over production of
the  encoded protein  (Lodish  et  al., 2003).  The protein  product  of  point
mutations and the fusion of genes as a result of chromosomal translocation
are different from the original protein that would have been encoded by a
functional proto-oncogene (Lodish  et al., 2003).  The protein product of
chromosomal translocation and amplification results  in  the same protein
product as the original, the only difference is that the normal production
levels of the protein are no longer as before, with  this overproduction leads
to oncogenesis (Lodish et al., 2003).
1.2.2 Oncogenesis gain of function from mutated tumour suppressor 
genes
Suppressor genes control the rate of cell growth and  division.  Mutations in
these genes result  in cells that no longer show contact inhibition (Thiel,
2010). In contrast to oncogenes, tumour suppressors suppress the ability of
mutated genes to proliferate. In the event that these suppressor genes are no
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longer present or non functional, a cell would then exhibit uncontrolled cell
proliferation  which  could  lead  to  the  formation  of   malignancies
(Hohenstein,  2004).  The  concept  of  tumour  suppressor  genes  was  first
described  by  Alfred  Knudson  using  statistical  analysis.  The  Knudson
hypothesis  (also  known  as  two-hit  hypothesis)  (Figure  1.2)  is  the
hypothesis  that  cancer  is  the result  of accumulated mutations  to  a  cell's
DNA.  It  was  first  proposed  by  Carl  O.  Nordling  in  1953,  and  later
formulated by Alfred G. Knudson in 1971. Knudson's work led indirectly to
the identification of cancer-related genes. (Lodish et al., 2003)
Knudson  performed  a  study  on  children  suffering  from  retinoblastoma
(Lodish  et  al., 2003).  In  a  normal  cell  there  are  two  alleles  of  tumour
suppressor genes.  The inactivation of the first allele by point mutations,
small  insertion/deletions,  structural  changes  or  loss  of  chromosomal
function can be considered as the first hit,  usually also considered to be
unchanged (Nowak et al., 2003). The second hit results in the inactivation
of the second allele with a decreased rate of production of protein  as a
result of the mutations caused by the first hit event coupled with mitotic
recombination. Large deletions or chromosomal losses do not act as a first
or second hit as such mutations would be lethal to the cell (Nowak et al.,
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2003). With tumour suppressor genes two alleles must be lost in order to
promote tumour development  (Hejmadi,  2010).
Figure 1.2: Knudson’s two-hit hypothesis for tumourigenesis involving
a tumour suppressor gene (TSG). One pair of chromosomes is depicted,
with one TSG [the normal gene (grey), the mutated gene (red), and deletion
of the gene (absence) are shown]. (a) Normal individuals have two normal
copies of the TSG, so two independent ‘hits’ (mutations) are required in the
same cell to initiate a cancer. (b) Individuals with a germ line mutation of
the  TSG  already  have  a  first  ‘hit’  in  every  cell  and  require  only  one
                                    12
 
 
 
 
subsequent ‘hit’ in a cell to initiate a cancer 
In  numerous  cancers  tumour  suppressor  genes  have  deletions  or  point
mutations  that  stop  the  production  or  induce  the  production  of  a  non
functional protein (Hejmadi, 2010). Also there are a large number of these
genes that have been hypothesised to exist and many of them  have been
identified  in  being  linked  to  cancer  development  (Park  and  Vogelstein,
2003).
1.2.3 DNA mismatch repair genes 
DNA mismatch  repair  (MMR)  genes  correct  mismatches  in  the  DNA
generated during  replication, thereby preventing mutations from becoming
permanent in dividing cells.  Because MMR genes reduce the number of
replication-associated  errors,  defects  in  MMR  genes  increase  the
spontaneous mutation rate  (Lodish  et al., 2003). Inactivation of MMR in
human  cells  is  associated  with  hereditary  and  sporadic  human  cancers
(Christmann et al., 2003). Since the MMR gene  system is required for cell
cycle arrest and/or programmed cell death in response to certain types of
DNA damage,  MMR  genes  play  a  role  in  the  DNA damage  response
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pathway  that  eliminates  severely  damaged  cells  and  prevents  both
mutagenesis  in  the  short  term  and  tumourigenesis  in  the  long  term.
(Darrough, 2008).  
There are  at  least  three  ways in  which  mismatched nucleotides  arise  in
DNA,  these  include  physical/chemical,  insertions/deletions  and  genetic
recombination to DNA and its precursors.  Physical or chemical means are
represented by actual damage to the DNA and its precursors. Insertions or
deletions  are  represented  by   mis-incorporation  of  nucleotides  in  DNA
during the replication process and genetic recombination produces regions
of heteroduplexity in the regions of the DNA (Christmann  et al., 2003).
DNA mismatch repair genes are inactivated in human cancers and because
of their cellular function it might be argued that they form a unique subset
of tumour suppressor genes (Park and Vogelstein, 2003). DNA mismatch
repair systems correct DNA base pairing errors in newly replicated DNA.
Mispaired nucleotides present after replication of DNA along with small
insertion or deletion mutations that tend to occur at repetitive sequences
(Masuda  et al., 2011). Mismatch repair system is an excision/resynthesis
system and can be divided into 4 phases namely recognition of a mismatch,
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recruitment of repair enzymes, excision of the incorrect sequences and then
finally  re-synthesis  by  DNA  polymerase  using  a  parental  strand  as  a
template (Masuda et al., 2011). 
A new pathogenetic mechanism leading to cancer has been delineated in
recent years when human homologues of DNA mismatch repair  (MMR)
genes have been identified and shown to be involved in various types of
cancer.  Germ  line  mutations  of  MMR  genes  cause  susceptibility  to  a
hereditary  form of  colon  cancer,  hereditary  non-polyposis  colon  cancer
(HNPCC)  (Levinson  and  Gutman,  1987;  Strand  et  al., 1993),  which
represents  one  of  the  most  common  syndromes  associated  with  cancer
predisposition in man. The existence of mismatch repair (MMR) enzymes
in bacteria  has been known for at  least  two decades and more recently,
similar  activities  have  been  identified  in  yeast  and  higher  eukaryotes
(Modrich,  1991).  The  discovery  of  human  MMR  genes  was  greatly
facilitated by advances made in genetic studies of hereditary nonpolyposis
colorectal cancer (HNPCC). After the first HNPCC susceptibility locus was
mapped to chromosome 2p by linkage analysis (Peltomaki et al., 1993), it
was  found  that  tumours  from  HNPCC  patients  showed  instability  at
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multiple random microsatellite sequences throughout the genome (Aaltonen
et al., 1993). A similar phenotype had previously been observed in bacterial
and yeast strains with DNA mismatch repair gene mutations (Levinson and
Gutman,  1987;  Strand  et  al., 1993).  These  data  together  provided  a
functional clue that resulted in the identification of human homologues of
bacterial and yeast MMR genes
1.2.4 Model of Carcinogenesis in HNPCC and Sporadic tumours with 
MMR Deficiency
Molecular genetic studies support the idea that multiple genetic changes are
necessary  for  tumourigenesis.  Statistically,  it  has  been  estimated  that
colorectal  tumours  require  four  to  seven  mutations  to  develop  (Renan,
1993).  Colorectal  carcinoma  cell  lines  with  MMR  deficiency  are
hypermutable  with  mutation  rates  that  can  be  several  hundredfold
compared to normal human cells (Parsons et al., 1993, Bhattacharyya et al.,
1994).  Importantly,  mutations  in  HNPCC-related  MMR  genes  cause
significantly elevated mutation rates not only in repetitive sequences but in
non repetitive gene sequences (such as the locus for hypoxanthine guanine
phosphoribosyltransferase) as well (Bhattacharyya et al., 1994). Figure  1.3
shows  a  model  of  colon  cancer  development  in  HNPCC.  The  basic
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principles of this model are applicable to any tumours with inactivation of
both copies  of a MMR gene as an early event  in their  pathogenesis.  In
tumours with MMR deficiency, a classical tumour suppressor mechanism is
supported in that two hits are required to cause a phenotypic effect (Parsons
et al., 1993; Liu  et al., 1995; Hemminki  et al., 1994). Most MMR gene
mutations are point mutations resulting in truncated protein products (Lui
et al., 1996; de la Chapella and Peltomaki, 1995). Loss of  critical MMR
activity as a consequence of these mutations is presumed to occur early in
tumour development, already at the adenoma stage (Shibata  et al., 1994).
Ensuring  genetic  destabilization  initiates  a  cascade  of  further  mutations
(Loeb, 1994), probably targeting  different genes in tumours from different
organs.  In  colon  cancer,  multiple  somatic  mutations,  primarily  single
nucleotide  deletions  and  G:C  to  A:T  transitions,  have  been  reported  to
occur  in  the  APC  and  p53  genes  (Lazar  et  al., 1994).  Furthermore,
inactivating  frame-shift  mutations  in  a  polyadenine  tract  located  in  the
coding sequence of the transforming growth factor  β-receptor II (TGFβ-
RII) gene are frequent in colon cancer, but rare in endometrial cancers with
microsatellite  instability, which  suggests  different  pathogenetic  routes  in
these  tumours  (Markowitz  et  al., 1995;  Myeroff  et  al.  1995).  In  some
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instances,  even one hit  (constitutional  heterozygosity  for  an MMR gene
mutation)  may be  sufficient  for  MMR deficiency to  become manifested
(Parsons et al., 1995).
Figure 1.3: Graphical representation of the  a model of colon cancer
development in HNPCC. The basic principles of this model are applicable
to any tumours with inactivation of both copies of a MMR gene as an early
event in their pathogenesis. (Taken from Renan, 1993)
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1.3 What is the prostate?
The  prostate  is  a  walnut  sized  gland  located  beneath  the  bladder
surrounding the urethra and lies in the pelvic cavity immediately in front of
the rectum (CANSA, 2013). The prostate starts to develop before birth and
grows rapidly during puberty as a result  of the male hormone androgen
which is testosterone that is converted into dihydrotestosterone (DHT) the
main  signalling  hormone  for  the  prostate  to  grow  (American  Cancer
Society, 2012).  It  usually  stays  the  same size  in  adults  or  grows really
slowly as long as these hormones are present (American Cancer Society,
2012).  It  produces  seminal  fluid  assisting  transport  of  sperm  during
ejaculation and forms part of the male reproductive system (Herbst, 2013).
The  prostate  is  muscular  and partly  glandular,  made  up of  three  lobes:
central lobe and 2 adjacent lobes, it possesses ducts which enter into the
prostatic portion of the urethra (Figure 1.4) (MHS, 2010).  
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Figure 1.4: Diagram illustrating cancerous tissue in the prostate gland 
and normal prostate gland Adopted from (MHS, 2010)
1.3.1 What is Prostate cancer  
Prostate  cancer  is  caused  by  changes  such  as  insertions,  deletions  and
genetic recombination in the DNA of a normal prostate cell. DNA makes up
the genes,  which control  how cells  behave.  Approximately 5 to 10% of
prostate  cancers  are  linked  to  these  inherited  changes  in  the  DNA
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(American Cancer Society, 2012).  In essence, it is these changes that bring
about abnormal growth in normal prostate tissue (CANSA, 2013). There
are  different  types  of  prostate  cancer  which  include  adenocarcinomas,
squamous and small  cell  carcinomas (CANSA, 2013).  Adenocarcinomas
are  the  most  common  form of  prostate  cancer  and  originates  from the
epithelial cells in the main glandular zone of the prostate (Herbst, 2013).
Squamous cell carcinomas are small round cells and usually forms at the
nerve cells.  These cells  usually  form a very aggressive type of  prostate
cancer  and  because  of  the  decrease  in  detection  ability  associated  with
squamous cells,  cancer is generally detected at the very late stage (Herbst,
2013).
1.3.2 Genetics of prostate cancer  
Prostate cancer genetics is a complex process as there are many genes and
risk factors that aid in its pathogenesis (Hughes  et al., 2013). Molecular
studies  have  provided  unexpected  clues  on  prostate  cancer  and  its
progression  (Nelson  et  al., 2003).  Genetic  factors  are  able  to  influence
prostate  cancer  at  many different  stages  through susceptible  genes   that
could possibly have a role in the hereditary form of prostate cancer, yet this
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is  not  completely  understood  (Rebbeck,  2005).   Candidate  genes
functioning in body involving the male hormones, for example testosterone,
has an effect on prostate growth as well as genes responding to the  immune
systems  response  to  tumour  growth  (Rebbeck,  2005).  Chromosomal
regions containing extensive gene  families proved helpful for identifying
important cancer susceptibility genes (Zhang  et al., 2003). Somatic gene
defects  found  in  prostate  cancer  cells  contain  somatic  mutations,  gene
deletions,  gene  amplification,  chromosomal  rearrangements  and  DNA
methylation and most abnormalities reported were found at chromosomes
7p, 7q, 8q and Xq and losses at 8p, 10q, 13q and 16q as indicated in Figure
1.5 (Nelson  et al., 2003).  Furthermore, these somatic changes in tumour
suppressor genes targets genes in regions of chromosomes 7p, 7q, 8q and
Xq (Figure 1.5)(Nelson  et al., 2003).  Genetic instability  and changes in
gene expression, also contribute to genetics of prostate cancer (De Marzo et
al. 2003). Gene expression changes include proliferation genes, androgen
receptors and finally  apoptosis  and stress related genes (DeMarzo  et al.
2003). 
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Figure 1.5: Molecular Pathogenesis of Prostate Cancer (Adopted from 
Nelson et al 2003 )
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1.4 Risk factors involved in prostate cancer
1.4.1 Age
Studies have shown that   the incidence of PC increases with age  (Herbst,
2013).  However,  it  mostly affects  men older  than 50 years  but it  is  not
uncommon for  PC to develop in  men 40 years  and younger  (American
Cancer Society, 2012).
1.4.2 Nationality and Ethnicity
The incidence of prostate cancer is more prevalent in certain ethnic groups.
According to a study done in the Western Cape by Heyns  et al., 2011, it
was found that the incidence  of prostate cancer in white men were much
higher as a result of many clinicopathological factors,  when compared to
coloured  and  black  men  in  the  population.   However,  according  to  the
Cancer Association of South Africa the prevalence of prostate cancer in
black men is on the increase Fisher et al., 2011.  In the USA the prevalence
of  prostate  cancer  in  African-American  men  was  much  higher  when
compared  to  other  ethnic  groups  and  was  diagnosed  at  much  more
advanced stages and was twice as  likely to lead to death when compared to
the  rest  of  the  male  population.  It  also  occurred  less  often  in  Asian-
American  and Hispanic  or  Latino  men than in  non-Hispanic  (American
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Cancer  Society,  2012).   These  findings  could  be  as  a  result  of  the
complexity of the gene pool  in mixed populations.  Due to  this  genetic
complexity and the variability of  the disease it could be a defining factor
for the increase in incidence rates in populations with mix race descent.
1.4.3 Diet and Lifestyle
Diet  and  lifestyle  are  also  major  contributing  risk  factors  in  the
development of prostate cancer. Western industrialized countries diets has
shown  to  be  a  contributing  factor  to  prostate  cancer,  whereas  a  diet
containing  high  fat,  excess  fibre,  soy  protein,  vitamin  E,  selenium,
carotenoids and herbal preparations all have a decreasing effect on prostate
cancer risk (American Cancer Society, 2012).  Lifestyle factors also play a
role such as lack of exercise, increased alcohol intake, tobacco usage, sun
exposure and  also include environmental factors such as where one works
and working with chemicals that could be carcinogenic (MHS, 2010).
1.4.4 Genetics 
PC is hereditary, hence having a father or brother with PC usually doubles
the risk of being confronted with the disease and risk increases when more
than one family member is affected. It could also occur by chance, through
acquiring  somatic  genes  in  your  life  time  (MHS,  2010).  Finally,
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inflammation of the prostate, vasectomy and viral infections increase the
risk as they have an effect on the properties of the normal cells inside the
prostate and cause changes that can result in oncogenesis (MHS, 2010).
1.5 Staging and Grading of Prostate Cancer
Cancer  is  classified according to  stages  of progression.  There are  many
classification  methods  used  to  determine  the  stages  of  cancer.  The
prognosis of prostate cancer depends on how fast the cancer has spread at
the  time of  diagnosis  (CANSA, 2013;  American  Cancer  Society, 2012).
These systems of staging are used to describe how far the cancer has spread
and to accurately identify the stage of prostate cancer and are inevitably
extremely important as it helps with providing the patient with the optimal
treatment needed (CANSA, 2013). Figure 1.6  illustrates one method of
prostate cancer staging called the Number Staging Method. In Stage I the
cancer is found in the prostate this stage of prostate cancer is microscopic
and  usually  goes  undetected  using  the  current  diagnostic  methods
(CANSA, 2013). In Stage II the tumour has grown in size but is confined to
the prostate and has not extended beyond the prostate. Stage III is where
the cancer has slightly spread outside the prostate but barely  to nearby
tissue, such as the seminal vesicles (CANSA, 2013). Lastly, Stage IV is
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where the cancer has metastasised outside the prostate to other tissues, this
stage of cancer spreads most commonly to the lymph nodes, bones, liver or
lungs  (CANSA, 2013). 
Figure 1.6: Classification of prostate cancer at its different stages using
the Number Staging Method. From left to right. Normal prostate, Stage I:
Cancer found in the prostate gland but is very small undetected by DRE,
Stage II: Cancer has grown inside the prostate but is limited to only the
prostate,  Stage  III:  Cancer  has  spread  to  most   of  the  prostate  and  to
seminal vesicles outside of the prostate but very minimal and Stage IV: The
cancer has taken  over all of the prostate and has metastasised  to other
organs in the body. 
(Adopted from www.medicalook.com/Cancer/Prostate_cancer.html )
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1.6 Signs and symptoms early and late warning signs of cancer 
Prostate cancer is usually asymptomatic which means that there is no early
signs of the disease, therefore, prostate cancer screening is vital by going
for  annual  physical  examinations  and   blood  tests  to  deliver  the  best
possibility  of  identifying  this  disease  while  it  is  still  in  its  early  stages
(MHS,  2010). Common  symptoms  of  prostate  cancer  initially  starts
affecting a man’s urinary system, such as weak or interrupted flow of urine
(dribbling), an increased sensation to urinate especially at night, the feeling
of  urine  staying behind in  the  bladder  or  holding back  urine,  difficulty
urinating, inability to control the flow of urine also a painful or burning
sensation when urinating and lastly an increased sense of discomfort in the
pelvic area as well as swelling in the legs (MHS, 2010; CANSA, 2013). In
the case of when the cancer has become more advanced blood might be
found  in  the  urine  or  semen,  inability  to  ejaculate  as  well  as  erectile
dysfunction,  pain  in  the  hips,  back,  chest  as  well  as  pelvic  discomfort
transforming into pain, weakness or numbness in the legs and feet, loss of
bowel and bladder control, difficulty in urinating then turns to the complete
inability  to  pass  urine  and lastly  weight  loss  and  bone  pain  (American
Cancer Society, 2012; CANSA, 2013). However, it  should be noted that
these symptoms are not only limited to prostate cancer.
                                    28
 
 
 
 
Another Staging method is known as the TNM staging method. The TNM
system is one of the most widely used cancer staging systems. This system
has been accepted by the Union for International Cancer Control (UICC)
and the American Joint  Committee on Cancer  (AJCC) (CANSA, 2013).
Most  medical  facilities  use  the  TNM system as  their  main  method  for
cancer  reporting.  The  TNM  system  is  based  on  the  size  and/or  extent
(reach) of the primary tumour (T), the amount of spread to nearby lymph
nodes  (N),  and  the  presence  of  metastasis  (M)  or  secondary  tumours
formed by the spread of cancer cells to other parts of the body. A number is
added to each letter to indicate the size and/or extent of the primary tumour
and the  degree  of  cancer  spread (CANSA 2013).  Examples  of  how the
system is implemented is available below
• Primary Tumour (T)
TX: Primary tumour cannot be evaluated; T0: No evidence of 
primary tumour; Tis: Carcinoma in situ (CIS; abnormal cells are 
present but have not spread to neighbouring tissue; although not 
cancer, CIS may become cancer and is sometimes called pre 
invasive cancer); T1, T2, T3, T4: Size and/or extent of the primary 
tumour
• Regional Lymph Nodes (N)
NX: Regional lymph nodes cannot be evaluated; N0: No regional 
lymph node involvement
N1, N2, N3: Degree of regional lymph node involvement (number 
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and location of lymph nodes)
• Distant Metastasis (M)
MX: Distant metastasis cannot be evaluated; M0: No distant 
metastasis; M1: Distant metastasis is present
Additionally  grading  methods  also  exist  one  such  method  is  the  The
Gleason grading system. This system is used  to help evaluate the prognosis
of men with prostate cancer using samples from a prostate biopsy. Together
with other parameters, it is incorporated into a strategy of prostate cancer
staging  which  predicts  prognosis  and helps  guide  therapy.  The Gleason
grading system for PC tissue  is  based on how the tissue looks under a
microscope. Gleason scores range from 2 to 10 and indicate how likely it is
that a tumour will spread. A low Gleason score means the cancer tissue is
similar to normal prostate tissue and the tumour is less likely to spread; a
high Gleason score means the cancer tissue is very different from normal
and the tumour is more likely to spread  (Brase et al., 2011).
1.7  Screening and diagnosis of prostate cancer
Screening for prostate cancer aids in the early diagnosis of its malignancy
before  the  patient  presents  any  symptoms,  therefore  making  the
management of prostate cancer more efficient and the delivery of a wider
range of therapeutic modalities (Stravidis et al., 2010; Hoffman, 2011; Wolf
et  al., 2010).  The  basis  of  urological  examinations  for  prostatic  cancer
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screening are called “the diagnostic  triad” which consists  of  the Digital
Rectal  Examination  (DRE)  ,  prostate  specific  antigen  (PSA)  test  and
investigation with the aid of the trans rectal ultrasound biopsy (Stravidis et
al., 2010; Qaseem et al., 2013)
1.7.1 Digital Rectal Examination (DRE)
The DRE is a procedure where a doctor would insert a lubricated gloved
finger into the rectum to examine the prostate for any abnormalities such as
bumps or hard areas (Figure 1.7) (American Cancer Society, 2012, CRUK,
2012, MHS, 2012, They, 2012). The limitations to this method  is because
only the posterior and lateral part of the prostate can be palpated this then
leaves  40-50%  of  cancers  beyond  reach,  meaning  a  possible  false
diagnoses. It therefore poses a disadvantage not only giving a false negative
diagnosis but also lacking in sensitivity and specificity in males that are
asymptomatic (American Cancer Society, 2010; Feightner 2008).
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Figure 1.7: Digital rectal exam: side view of the male reproductive and
urinary anatomy, including the prostate, rectum, and bladder.  Where
the clinician inserts the forefinger into the anus to determine if irregularities
exist  within  the  prostate.  Also  depicting  4  stages  indicating  the  various
degrees of PC development where  T1 is the earliest stage of PC and T4
shows PC during metastasis (taken from American Cancer Society, 2012)
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1.7.2 The Prostate Specific Antigen (PSA) test
PSA test is a  diagnostic blood test in which  the PSA levels ins the blood
are measured as depicted in Figure 1.8 (MHS, 2010).  It is performed to
determine  the  incidence  of  any  prostate  abnormalities  which  include
prostate cancer (CANSA, 2013). PSA is a protein produced by the cells in
the  prostate  gland  in  normal,  cancerous  and  benign  prostate  tissue
(American Cancer Society, 2010; CANSA, 2013). PSA is mostly found in
semen and a small amount enters into the bloodstream. The PSA levels in
healthy  men  are  supposed  to  be  less  than  4  nano-grams  per  millilitre
(ng/ml),  however, in cancer  cells  the PSA levels are increased therefore
causing the PSA levels in the blood to rise (ACS American Cancer Society,
2010; CANSA, 2013). PSA test is the most widely used test for the possible
detection  and  confirmation  of  prostate  cancer  (CANSA,  2013).  The
limitation  of  this  test  is  that  if  a  high  PSA level  is  found  it  does  not
conclude that a patient has prostate cancer but it could also indicate other
problems or abnormalities (CANSA, 2013). Factors that may affect PSA
levels causing it to be higher could be due to an enlarged prostate usually in
elderly men above the age of 50 years, inflammation of the prostate gland
(prostatitis), also infection of the bladder, recent ejaculation, bicycle riding,
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urological procedures such as the DRE, certain medication, herbal mixtures
and obesity (American Cancer Society, 2012; CANSA, 2013). 
If results from the DRE and PSA blood test are abnormal it may suggest
that the patient has prostate cancer and a physician would then schedule a
trans rectal biopsy better known as  a prostate biopsy.
Figure 1.8: Graphical representation of the method used to extract a
sample to do a PSA diagnostic screen. Prostate-specific antigen (PSA) is
a  glycoprotein  in  the  cytoplasm  of  prostatic  epithelial  cells.  It  can  be
detected in the blood of all adult men. The PSA level is increased in men
with prostate cancer but can also be increased somewhat in other disorders
of the prostate (taken from CANSA, 2013).
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1.7.3 Transrectal ultrasound and biopsy
In the event of abnormal DRE and PSA blood test results a trans rectal
ultrasound biopsy better known as a prostate biopsy procedure would be
performed as a further screening measure (Simmons et al., 2011; Stavridis
et al., 2010; Wolf et al., 2010).  A core needle biopsy is the main method to
diagnose prostate cancer,  specimens are acquired by a urologist who treats
issues regarding the male reproductive system. A prostate biopsy involves
the  removal  of  prostate  tissue  for  analysis  by  a  histopathologist  for
cancerous tissue (Figure 1.9B) (CANSA, 2013; American Cancer Society,
2012). 
A trans rectal ultrasound is used as a guide to insert thin hollow needles
through the wall of the rectum into the prostate gland. When these needles
are pulled out, small samples of prostate tissue are removed, this process is
repeated eight to 36 times (Figure 1.9 A) (American Cancer Society, 2012;
Simmons  et al., 2011). The disadvantage to this method is that it is very
invasive  as  it  causes  discomfort  and  pain.  Furthermore,  it  could  cause
infection  and there  is  also the risk of  a  false  negative   diagnosis;  even
though many samples are taken the biopsies might still miss a tumour if
none of the needles pass through it (American Cancer Society, 2012).
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The trans rectal ultrasound can be used to determine the presence of cancer
in the prostate, here a doctor inserts a lubricated probe into the rectum of
the  male  to  check for  abnormal  areas.  The probe then sends out  sound
waves that bounce off the prostate and these results are fed into a computer
which  then  produces  an  image  of  the  results  and is  called  a  sonogram
(CANSA, 2013). The limitation to this is that if the cancer is still  in its
early stages before the tumour can be seen it cannot always be detected,
using this method (CANSA, 2013).
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AB
Figure 1.9: Image of current detection method namely the  Ultasound
and Prostate  biopsy.  Where  figure  A represents  the  trans  rectal  ultra
sound being inserted into the anus to get a clearer look at the status of the
prostate.  Figure B represents the procedure for the biopsy where a syringe
is  inserted  into  the  penis  to  extract  a  sample  from the  prostate  gland
(Taken from American Cancer Society, 2012).
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1.7.4 Computed tomography (CT) scan
A computed tomography, commonly known as a CT scan, is a specialised
x-ray test  producing a detailed outline of cross sectional images of  the
body  (American Cancer Society, 2012). This scan takes several pictures of
the  specific  area  of  the  body  under  observation  and  rotates  around  the
subject  while  it  takes  these  pictures  (American  Cancer  Society,  2012).
These  results  are  then  fed  into  a  computer  where  pictures  are  then
combined into images of “slices” of that specific part of the body. In order
for these images to be produced a patient will receive an intravenous line
through which a contrast dye is injected allowing better outlining of one’s
body structures on the inside (American Cancer Society, 2012). However,
there are limitations to  this  screening method in that some individuals are
allergic to the dye used and get allergic reactions, such as the appearance of
hives. If more severe, it can lead to difficulty in breathing, and low blood
pressure (American Cancer Society, 2013).
1.7.5 Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) can also be used to diagnose prostate
cancer.  This  technique  is  based  on  the  use  of  radio  waves  and  strong
magnets instead of x-rays, the energy of the radio waves are absorbed into
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the body and a specific  pattern is created by the type of body tissue and by
tumours  or cell  masses (MHS, 2010).  The uniquely created patterns are
then translated by a computer to give a very detailed image of the part of
the body being examined (American Cancer Society, 2012). This method
produces very clear images of the prostate and is useful in showing if the
cancer has spread to other parts  of the body. Despite all  the advantages
mentioned, it cannot provide vital information about early stage PC cases.
Additionally, men may experience allergic reactions due to the dye, whilst
men afraid of confined places might be traumatised after such a scan and
the  clicking  and  buzzing  noises  generated  during  the  scan  might  be
irritating as the scan may take up to an hour (CANSA, 2013). Lastly, due to
the magnetic nature of the MRI machine, men with pacemakers or other
metal  medical  implants  cannot  go  for  a  MRI  scan  (American  Cancer
Society, 2012). 
An  ideal  screening  test  requires  it  to  be  minimally  invasive,  accurate,
conveniently available and should be available to the general population at
a low cost aiding a better disease outcome because of an accurate and early
diagnosis (Stravidis  et al., 2010). With all the diagnostic tests, even with
                                    39
 
 
 
 
the benefit associated with it, it has a number of potential harms not only
physically but psychological as well (Carter et al., 2013)
1.8. Biomarkers and their roles in cancer therapy and diagnosis
A  molecular  biomarker,  according  to  the  National  Cancer  Institute  is
classified as a biological molecule present in blood, bodily fluids or tissues
that  provides  an  indication  of  a  normal  or  abnormal  process  or  of  a
condition or a disease. The common characteristics of a biomarker  are their
inexpensiveness,  reliability  and  ease  of  expression  remaining  unaltered
under diseased conditions (Verma et al., 2011). A biomarker should allow
the detection of a tumour before a symptomatic mass or other symptoms
develop   (Verma  et  al., 2011).  These  molecules  are  used  as  aids  to
characterize tumour composition for improvement of screening accuracy as
well as avoidance of invasive methods for diagnosis. Also should have a
high specificity  of diagnosis as well  as prognosis of the disease for the
reduction of false-positives and negatives (Madu & Lu, 2010; Verma et al.,
2011). 
Biomarkers  have  the  ability  to  supply  information  regarding  the
progression (prognostic), the efficacy of treatment as well as the possible
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re-occurrence of the cancer (predictive) (Madu & Lu, 2010; Verma et al.,
2011; Haj-Ahmad, 2013). Diagnostic biomarkers are used for the diagnosis
of disease with a very high success rate. These biomarkers ideally target
specific molecular events based on the differences between cancerous and
non-cancerous cells necessary for a specific cancer type to progress and
ideally  prevent  the  use  of  conventional  detection  methods  (Haj-Ahmad,
2013; RAN, 2012; Verma et al., 2011).
The  first  cancer  marker  ever  reported  was  the  light  chain  of
immunoglobulin  in  the  urine,  as  identified  in  75%  of  patients  with
myeloma  in  1848  study  (Jones,  1848).  The  test  for  this  marker  is  still
employed  by  clinicians  today,  but  with  use  of  modern  quantification
techniques. From 1930 to 1960, scientists identified numerous hormones,
enzymes  and  other  proteins,  the  concentration  of  which  was  altered  in
biological fluids from patients with cancer. The modern era of monitoring
malignant disease, however, began in the 1960s with the discovery of the
alpha-fetoprotein  (Abelev  et  al., 1963)   and  carcinoembryonic  antigen
(CEA)  (Gold  and  Freedman,  1965),   which  was  facilitated  by  the
introduction of immunological techniques such as the radio-immunoassay.
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In the 1980s, the era of hybridoma technology enabled development of the
ovarian epithelial cancer marker carbohydrate antigen (CA) 125 (Bast  et
al., 1981).  In  1980,  prostate-specific  antigen  (PSA [KLK3]),  considered
one of  the best  cancer  markers,  was also discovered (Papsidero  et  al.,
1980). 
Every era,  biomarker  discovery seems to be associated closely with the
emergence of a new and powerful analytical technologies. The past decade
has witnessed an impressive growth in the field of large-scale and high-
throughput biology such as Next Generation Sequencing (NGS), which has
contributed to an era of new technological development. The completion of
a number of genome-sequencing projects, the discovery of oncogenes and
tumour-suppressor genes, and recent advances in genomic and proteomic
technologies, together with powerful bioinformatics tools, will have a direct
and  major  impact  on  the  way  the  search  for  cancer  biomarkers  is
conducted. Early discoveries of cancer biomarkers were based mainly on
empirical  observations,  such  as  the  over  expression  of  CEA (Gold  and
Freedman,  1965).  The  modern  technologies  are  capable  of  performing
parallel  rather  than  serial  analyses,  and  they  can  help  to  identify
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distinguishing  patterns  and  multiple  markers  rather  than  just  a  single
marker. Such strategies represent a central component and a paradigm shift
in the search for novel biomarkers 
There  are  different  biomarkers  with  each  having  their  own  respective
function  with  their  own  molecular,  biochemical  and  physiological
properties (RAN, 2012; Verma et al., 2012). These biomarker types include
physiologic,  anatomic,  genetic  and  proteomic  biomarkers  (RAN,  2012;
Verma et al., 2012). The approach for biomarker discovery employs one of
four  practices  for  discovery  viz.  proteomics  based,  nucleic  acid  based,
metabolomics and in silico approaches which falls under the scope of this
project for biomarker discovery (RAN, 2012; Haj – Ahmad, 2013).  The
advantages of using an  in silico  approach involves the use of computer
algorithms to search for biomarkers where curated experiments have been
made  publicly  available  allowing  one  to  conduct  more  than  one
computerized  search  for  all  genomic  data  sets  available  to  identify  a
molecule as a potential biomarker (RAN, 2012). 
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1.8.1 Biomarker discovery using Gene expression profiling technology
Genomic  microarrays  represent  a  highly  powerful  technology  for  gene-
expression  studies.  Microarray  experiments  are  usually  performed  with
DNA or RNA isolated from tissues, which are labelled with a detectable
marker  and  allowed  to  hybridize  to  arrays  comprised  of  gene-specific
probes that represent thousands of individual genes (Quackenbush, 2006).
The greater the degree of hybridization, the more intense the signal, thus
implying a higher relative level of expression. 
The  massive  amount  of  data  per  experiment  means  that  the  molecular
markers  and  their  expression  patterns  need  to  be  analysed  by elaborate
computational tools to detect emerging patterns from these huge datasets.
Two basic forms of analysis exists which are unsupervised and supervised
hierarchical  clustering  algorithms  (Eisen  et  al., 1998);  the  latter  tools
identifies gene-expression patterns that discriminate tumours on the basis of
predefined clinical information whilst the former looks at gene expression
generally throughout a system. (Golub et al., 1999). 
The  cancer  sub-classification  hypothesis  states  that  gene-expression
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patterns  identified  with  DNA  micro-arrays  can  predict  the  clinical
behaviour of tumours (Perou  et al., 2000). The proof-of-principle for the
cancer  sub-classification  hypothesis  has  been  provided  for  various
malignancies,  such as leukaemia,  breast  cancers and many other tumour
types (Alizadeh  et al., 2001; Weigelt  et al., 2005; Alizadeh  et al., 2000;
Rosenwald et al., 2002; Pomeroy et al., 2002; lizuka et al., 2004; Chen et
al., 2007). For example, results from gene-array technologies have enabled
breast cancers to be classified into prognostic categories dependent on the
expression  of  certain  genes.  The  70-gene-panel  micro-array  study  of
survival  prediction  led  to  the  development  of  MammaPrint® (Agendia,
Amsterdam,  The  Netherlands)  (van  de  Vijver  et  al., 2002),  which  in
February 2007 became the first multigene panel test to be approved by the
FDA for predicting breast cancer relapse as an in silico method. 
Similarly, Oncotype DX® (Genomic Health, Redwood City, CA) another
genomic micro-array, is based on quantitative real-time PCR and has been
commercially available since 2004  (Paik et al., 2004). Oncotype DX® and
MammaPrint® uses different analytical platforms and despite their similar
clinical indication,  they have only a single gene overlap in their  panels.
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Nevertheless, over the past decade, a tremendous growth in the application
of  gene-expression  profiling  has  been  witnessed.  This  growth  has
contributed  to  the  cancer  sub-classification  theory  (Perou  et  al., 2000),
insights into cancer pathogenesis, and the discovery of a large number of
diagnostic markers (Pollack, 2007)
1.9. The need for bioinformatics in Biomarker discovery
Bioinformatics  leads  a  researcher  to  better  understand,  organise  and
associate molecules on a greater scale (Settles, 2008). There are many areas
and subsequent applications in bioinformatics,  areas including genomics,
proteomics  and phylogenetics  with applications  relating  to   the  medical
field such as diagnosis of disease, drug design and discovery to name a few
as  well  as  agriculture  and  microbial  genome  applications  (Mascrenghe,
2004;  Madhani,  2006).  Bioinformatics  is  currently  employed  for  the
improvement of  the drug discovery pipeline.  It is an inexpensive method
and   less  labour  intensive  and  time  consuming  when  compared  to
traditional  molecular methods. Therefore with the aid of bioinformatics as
a   research  tool  it  is  possible   to   generate  a  list  of  priority
genes/proteins/miRNA in a short space of time and through an enrichment
process of these lists eliminating those which appear not to be useful targets
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or a priority based on  search criteria and the statistical analysis performed
(Madhani, 2006). 
New resources will  most likely identify novel protein,  genetic and low-
molecular-weight  cancer  markers,  which  may  impact  on  cancer  care.
Furthermore,  with  advances  in  genomic  and  proteomic  technologies,
human diseases may be classified on the basis  of  molecular  rather  than
morphological  analysis.  Moreover,  bioinformatics  will  serve  to  link
scientific  data  with  clinical  information.  Despite  the  optimism,   the
National  Academy  of  Clinical  Biochemistry  do  not  encourage  the
widespread  use  of  tumour  markers  unless  they  affect  patient  outcome
measures (Bast et al., 2001). There is, however, a general agreement that a
combination of multiple biomarkers may increase diagnostic sensitivity and
specificity over use of individual markers. This is particularly important in
relation to the recent development of powerful bioinformatics algorithms,
which can interpret  multiple  parameters much more efficiently  than can
more-traditional approaches (Finne et al., 2000; Stephen et al., 2002). The
most accurate, individualized, predictive assessment for patients might be
attained through the use of artificial neural networks (Stephen et al., 2002).
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There is  no doubt that if  these new technological advances  prove to be
successful in identifying cancer biomarkers for early cancer detection, the
clinical benefits are likely to be enormous.
1.10. The importance of  MicroRNAs as biomarkers in cancer 
miRNA  research  has  received  an  increasing  amount  of  interest
(Buckingham, 2003). miRNAs are made up of phylogenetically conserved
endogenous  small  non  coding  single  RNA  genes  (Buckingham,  2003;
Nilsen, 2007; Zhao and Srivastava, 2007; Tanzer et al., 2008; Sotiropoulou
et al., 2009; Sato  et al., 2011; Martinez-Sanchez and Murphy, 2013). In
humans  they  make  up  about  1-3%  of  the  human  genome,  and
approximately 80% of these miRNA genes are located in the introns of both
protein and non-coding genes (Buckingham, 2003; Nilsen, 2007; Zhao and
Srivastava, 2007; Tanzer et al., 2008; Sotiropoulou et al., 2009; Sato et al.,
2011;  Martinez-Sanchez  and  Murphy,  2013).  MiRNAs  were  found  to
influence  the  developmental  timing,  organ  development,  cell
differentiation,  proliferation and most significantly  apoptosis  of cells in
several  organisms  (Davis  and  Hata,  2009;  Sotiropoulou  et  al., 2009;
Pritchard et al., 2012;).
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MiRNAs are small, non-coding subset of RNAs which consist of about 18-
25 nucleotides and bind to the 3' untranslated region of messenger RNAs
(mRNAs)  (Wach  et  al., 2011).  By  this  action,  they  cause  post-
transcriptional inhibition or degradation of target mRNA, depending on the
degree of complementary base pairing (Doench and Sharp., 2004; Vella et
al., 2004 and Xu et al., 2011). miRNAs were first discovered in 1993 while
studying  Caenorhabditis  elegans  (Lee  et  al., 1993).  The  first  miRNA
discovered was lin-4.  It  is  a  small,  non-coding RNA molecule that  was
found to play a role in controlling the timing of  larval development  in C.
elegans through a negative effect on lin-14 expression (Lee  et al., 1993;
Wightman  et al., 1993; Vandenboom  et al., 2008).  Seven years later, in
2000,  let-7,  the  second  miRNA was  discovered,  let-7  miRNA is  often
repressed in human cancer cells, suggesting that they may target oncogenes
and be functionally equivalent to a tumour suppressor (Lee et al., 1993). In
fact, recent studies indicate that let-7 miRNA suppresses expression of Ras
and other oncogenic proteins (Doench and Sharo., 2004; Vella et al., 2004
and Xu et al., 2011). This suggests that re-expression of miRNA that down
regulate  oncogenic  proteins  could  be  a  useful  therapeutic  approach  for
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human  cancer (Reinhart  et  al., 2000;  Griffiths-Jones  et  al., 2006;
Vandenboom et al., 2008). During the past 12 years, significant advances
have been made in miRNA research leading to the discovery of over 4,500
miRNAs in vertebrates, flies, worms, plants, and viruses (Ambros, 2003;
Griffiths-Jones  et al., 2006; Vandenboom et al., 2008) out of which more
than  1,000  miRNAs  are  fully  characterized  with  and  associated  with  a
particular disease and this number is expected to grow in the coming years. 
MiRNAs  are  constantly  implicated  in  the  regulation  of  an  increasing
number of physiological processes. It is also believed now that they play an
important role in the regulation of many cellular functions ranging from
maintenance  to  differentiation  and  tissue  development,  metabolism  and
cell cycle regulation (Bushati and Cohen, 2007; Stefani and Slack, 2008;
Gangaraju and Lin, 2009; Coppola et al., 2010). All of these facts leads to
the conclusion that aberrant expression of miRNAs will have an impact on
various biological processes in which they are implicated, which will result
in a variety of pathological events such as inflammation (Baltimore et al.,
2008;  Cullen,  2009;  Coppola  et  al., 2010),  cardiovascular  diseases
(Latronico  et al., 2009), neurodegenerative diseases (Bushati and Cohen,
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2008) and most importantly, cancer (Coppola et al., 2010). 
The role of miRNAs in cellular growth, differentiation and apoptosis  of
cancer  cells  through their  interactions  with their  target  mRNA has been
well studied (Kloosterman and Plasterk, 2006; Baranwal and Alahari, 2010;
Pang  et  al., 2010).  miRNAs  may  be  oncogenic  or  tumour  suppressor
molecules (Pang  et al., 2010; Vrba  et al., 2010), as oncogenic molecules
being  up-regulated  whilst  as  tumour  suppressor  molecules  being  down-
regulated in  cancers.  Generally, the importance of miRNAs in cancer  is
emphasized by the fact that around 50% of all miRNA genes are positioned
in the so called 'fragile sites', the cancer associated genomic regions which
are repeatedly changed in cancer. A lot of information has already been
identified about aberrant miRNAs expression in cancers; the understanding
of the functional importance of these aberrations has not been molecularly
exploited (Aqeilan, 2010). 
1.10.1 Biogenesis of miRNAs
The biogenesis of miRNA involves many critical steps; the initial phase is
the  transcription  by  RNA polymerase  II  that  leads  to  the  formation  of
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primary miRNA (pri-miRNA) which comprises of hundreds to thousands of
nucleotides (Lee et al., 2004; Vandenboom et al., 2008). The second phase
is catalysed by a ribonuclease called ribonuclease III (RNase III), Drosha.
This step leads to the split of pri-miRNA and results in what is called a
precursor miRNA (pre-miRNAs), which usually comprises of around 70
nucleotides,  and this  phase is  accomplished with the help of DGCR8, a
protein that helps to ensure  perfect and efficient processing of pri-miRNA
into pre-miRNAs (Lee et al., 2003; Denli et al., 2004; Vandenboom et al.,
2008). Thereafter, a nuclear export factor, called exportin 5, binds to the
pre-miRNAs and transports it into the cytoplasm where the next processing
phase take place (Yi et al., 2003; Bohnsack et al., 2004, Vandenboom et al.,
2008). Here another RNase III Pol, Dicer, interacts with the pre-miRNAs,
and the outcome of this process is the formation of a RNA duplex of around
22 nucleotides, which is the mature miRNA consisting of a double-stranded
duplex. Dicer usually operates with the help of the  trans-activator RNA
(transacting  response)-binding  protein  (TRBP)  (Bernstein  et  al., 2001;
Ketting  et  al., 2001,  Vandenboom  et  al., 2008).  Subsequently, all  these
steps allow the mature miRNA interact with the RNA-induced silencing
complex  (RISC)  (Hammond  et  al., 2000;  Schwarz  et  al., 2002;
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Vandenboom  et  al., 2008),  and ultimately allow miRNA to control  post
transcriptional regulation of functional mRNAs ( Figure 1.10).  miRNAs
have  the  ability  to  not  only  target  several  hundred  genes  but  also  to
negatively regulate original mRNA instruction by translational repression
or decay depending on the binding conformations leading to no or very
little protein production (Nazarov et al., 2013; Wang, 2008; Erson & Petty,
2008; Nilsen, 2007; Pritchard et al., 2012; Fabian et al., 2010; Cuperus et
al., 2011 ; Davis & Hata, 2009). 
The significance of cancer causing miRNAs (oncomiRs) was established
because  of  its  involvement  in  many  cellular  processes  such  as  cell
differentiation,  proliferation and more importantly   apoptosis  relevant  to
this research.   miRNA expression was found to show a relationship with
many cancers and genes thought to function as both tumour suppressors
and  oncogenes  (Esqauela-Kerscher  &  Slack,  2006).  miRNA  over
expression  in  tumours  are  considered  oncogenic  as  they  inhibit  tumour
suppressor  genes,  cell  cycle,  differentiation  and apoptotic  control  genes
whilst  for  miRNA  under-expression  these  miRNAs  are  considered  as
tumour  suppressors  and have  the  opposite  effect  to  oncogenic  miRNAs
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(Sapre & Selth, 2013 and  Lopez-Camarillo et al., 2013).
MiRNA-mRNA mediated interactions show promising implementation for
biomarkers,  and  have  provided  the  potential  to  a  more  in  depth
understanding of diseases and the observation of certain processes in the
body and can help combat  all  the current issues with current  diagnostic
tests  such  as  specificity,  sensitivity  and  minimal  invasiveness
(VandenBoom  et al., 2008; Sapre & Selth, 2013; Lopez-Camarillo  et al.,
2013; Wang, 2008; Esquela-Kerscher & Slack, 2006). 
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Figure  1.10:  The  miRNA  biogenesis  pathway  in  vertebrate  cells.
Artificial siRNAs can enter this pathway as synthetic siRNA duplexes, as
shRNAs transcribed by Pol II or as artificial pri-miRNAs (shRNA-mir). For
simplicity, not all factors involved in miRNA biogenesis are shown. Ago2,
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Argonaute-2;  Exp5,  Exportin-5  (taken  from  Yi  et  al., 2003).
1.10.2 miRNA and cancer stem cells in prostate cancer
Cancer stem cells (CSCs), also called tumour-initiating cells, are a group of
cells  which  play  an  important  role  in  the  progression  of  cancer  and its
metastasis (Visvader & Linderman, 2008) . The CSCs hypothesis assumes
that cancers are basically derived from a small fraction of cancer cells that
have  exclusive  ability  to  self-renew  and  initiate/maintain  the  tumour
(Papagiannakopoulos & Kosik, 2008; DeSano & Xhu, 2009). This specific
ability of CSCs allowing the initiation of the development of cancer was
documented first in human leukaemia (Dick, 1996; Jin  et al., 2006) . For
the isolation and identification of CSCs, many markers have been used.
Previously,  CD44  (an  adhesion  molecule)  was  used  to  identify  CSCs,
individually or in some instances in combination with other markers. It was
shown that Prostate CSCs that have increased clonogenic potential (Collins
et al., 2005), tumour initiating ability and metastatic capabilities   have  an
increased CD44+ cell population (Patrawala et al., 2006). 
Emerging evidence suggests that miRNAs may function as the regulators of
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CSC characteristics (Croce & Calin, 2005; Yu et al., 2007; Shimono et al.,
2009; Melton et al., 2010). Studies have clearly shown that the expression
levels  of  certain  miRNAs in  stem cells  are  different  from other  normal
tissues (Suh et al., 2004; DeSano & Xu, 2009), suggesting that miRNAs are
important  regulators  of  CSC function.  One example  is  miR-34a,  a  p53
target (Bommer  et al., 2007; Chang  et al., 2007; He  et al., 2007; Raver-
Shapira  et al., 2007; Tarasov  et al., 2007), which has strong anti-tumour
and anti-metastatic effects (Liu et al., 2011). Studies have shown that miR-
34a  is  down  regulated  in  CD44+  PC cells,  and  its  over-  expression  in
CD44+  PC  cells  resulted  in  the  inhibition  of  clonogenic  growth  and
inhibition  of  metastatic  behaviour  and  tumour  regeneration  (Liu  et  al.,
2011). The miR-34a was also established as an important negative regulator
of CD44+ PC cells, and it is assumed that this decreased expression of miR-
34a in CD44+  PC cells (including CSCs) plays an important role in PC
development and metastasis (Liu et al., 2011). Moreover, the expression of
miR-34a  antagomirs  in  CD44-  prostate  cancer  cells  promoted  tumour
development and metastasis (Liu et al., 2011). 
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Taking into consideration the prevalent expression of CD44 in CSCs and
the role of CD44 in mediating CSC migration and homing, suggesting its
role in metastasis in various malignancies including PC  and thus targeting
of miR-34a pathways could become innovative treatment strategies for PC
(Liu  et al., 2011). Further studies are under way in order to establish the
molecular interplay between miRNAs and CSCs in PC and other human
malignancies (Liu et al., 2011). 
1.10.3  The  role  of  miRNAs  in  the  processes  of  Epithelial-to-
Mesenchymal Transition (EMT) in PC 
The  process  of  EMT  is  defined  as  one  where  epithelial  cells  acquire
phenotypic  characteristics  of  mesenchymal  cells  whereby  the  epithelial
cells  change  their  epithelial  cobblestone  phenotype  to  a  mesenchymal
elongated  fibroblastic  phenotype,  which  contributes  to  increased  cell
motility and invasion that is required for the metastatic process (Kong  et
al., 2009; Kong et al., 2010; Peng et al., 2011). During EMT, cancer cells
lose  epithelial  cell-cell  junctions  associated  with  a  decrease  in  the
expression  of  epithelial  proteins  such  as  E-cadherin  and  junction
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plakoglobin, and the increase in expression of mesenchymal markers such
as vimentin, fibronectin and α-smooth muscle actin. 
These  changes  are  also  associated  with  augmented  activity  of  matrix
metalloproteinases (MMPs), such as MMP2, MMP3, MMP9, which leads
to an invasive phenotype (Thiery et al., 2009). All of the above mentioned
processes  lead to  increased  invasion  and migration  of  tumours  in  many
cancers including PC (Leshem et al., 2011). Because the miRNAs are part
of the cellular signaling circuit  that controls EMT (Kalluri  & Weinberg,
2009),  it  has been suggested that  many miRNAs families,  including the
miR-200  and miR-205 families, play important roles in controlling EMT
(Bracken et al., 2009; Zeisberg & Neilson, 2009; Ahmad et al., 2011). 
The miRNAs  143 and  145 are  two miRNAs that are assumed to play a
role in EMT In PC. MiR-143 and miR-145 are dysregulated in  the primary
cancer  when  compared  with  normal  prostate  tissue  (Ozen  et  al., 2008;
Clape et al., 2009; Fu et al., 2010; Schaefer et al., 2010). The up-regulation
of  miR-143  in  prostate  cancer  cells  represses  mesenchymal  markers
                                    59
 
 
 
 
(vimentin and fibronectin) and increases the epithelial marker E-cadherin
(Peng et al., 2011), while the up-regulation of miR-145 leads to the same
effects except for in this case an increase in vimentin is seen (Peng et al.,
2011). Previous studies show that miRs-143 and -145 may be suppressors
of EMT, and based on the fact that EMT plays an important role in invasion
and  migration  consistent  with  mesenchymal  characteristics  allowing
detachment and movement of cells from the primary tumour (Micalizzi et
al., 2010).  Therefore,  it  can be assumed that miRs-143 and -145 inhibit
invasion and migration in prostate cancer. 
The role of most miRNAs in regulating EMT is still not clear with just a
few  miRNAs being evaluated for their role in EMT of PC (Kong  et al.,
2009; Kong et al., 2010; Peng  et al., 2011) (Table 1.1 ). With the crucial
role  of  miRNAs in EMT, it  is  expected  that  the regulation of  EMT by
miRNAs in PC will be the focus of many research areas in the future.  
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Table 1.1: Regulation of EMT in PC by miRNAs 
1.10.4  The  relationship  between  circulating  miRNAs  and  tumour
progression in prostate cancer
Circulating miRNAs have been suggested as encouraging biomarkers for
the  non-invasive diagnosis in many tumours (Brase  et al., 2011). It has
been proposed that miRNAs profiles in tumour cells have  prognostic value
for some cancer  patients,  and a  similar correlation with serum miRNAs
profiles should emerge as a viable approach (Brase et al., 2011).  Brase et
al.,2011  found that  miR-375 was  the  top  marker  in  a  screening study
(metastatic vs. localized prostate cancer) and that its expression is higher in
prostate cancer tissue compared to normal epithelium (Brase et al., 2011).
The study also found that miR-375 was strongly related to the  lymph-node
status of the PC patients,  no significant difference was observed in the
serum levels of patients with Gleason score 7 and 8 tumours. 
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Based on these findings it seems that the circulating level of miR-375 is
associated  mainly  with  systemic  disease  (lymph  node  involvement  and
metastasis) rather than the grading of primary prostate cancer (Brase et al.,
2011). However, the definite role of miR-375 in prostate cancer is still not
very clear. 
miR-141 and miR-200b (both belonging to the same family of miRNAs)
were reported to be the most frequently over regulated miRNAs in prostate
epithelial  cells  in  comparison  with  prostate  stromal  cells  (Brase  et  al.,
2011). However, the circulating levels of miR-141 were found to be much
higher in the serum of patients with high-risk tumours when compared to
intermediate-risk samples. Also, circulating levels of miR-141 have been
found  to  differentiate  between  patients  with  metastatic  PC  and  healthy
controls (Brase et al., 2011). 
Based  on  these  limited  studies,  one  could  conclude  that  circulating
miRNAs  may  offer  a  good  perspective  as  non-invasive  biomarkers  for
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tumour progression, including prostate cancer, but further research has to
be done in this field in order to reach a better understanding of the role of
miRNAs in the serum or plasma (Brase et al., 2011). 
1.11 The specific roles of certain miRNAs in prostate cancer
As mentioned above, miRNAs are known to play important roles in the
progression of different cancers, including PC. Some miRNAs can function
as tumour suppressors wherein their elevated levels are indicators of good
prognosis   (Brase  et  al., 2011).  On  the  contrary,  other  miRNAs  are
promoters  of  carcinogenesis  and  their  expression  levels  are  elevated  in
advanced stage of some cancers, which clearly suggests that these miRNAs
may offer attractive targets for therapeutics  and diagnostics. The figure
below  shows  the  categorisation  of   the  various  known  miRNAs  as
oncogenes and tumour suppressors (Figure 1.11)
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Figure 1.11 : Schematic representation of tumour suppressive miRNAs
(blue)  and  oncogenic  miRNAs (red)  in  the  prostatic  tumourigenesis
progression from PIN to metastatic  castrate-resistant prostate cancer
CRPC (taken from  Brase et al., 2011)
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1.11.1 Tumour suppressor miRNAs
1.11.1.1 The role of miRNA-15a and miRNA-16
Both  of  these  miRNAs  work  as  tumour  suppressors  mediated  through
deregulation  of  multiple  oncogenes,  which  include:  BCL2,  MCL1,
CCND1,  and  WNT3A  (Aqeilan  et  al., 2010).  The  aforementioned
oncogenes  can  promote  cell  proliferation,  cell  survival  and  invasion
(Aqeilan  et  al., 2010).  The down regulation of these miRNAs has been
reported in many malignancies including: Chronic Lymphocytic Leukaemia
(CLL), Pituitary adenoma, and Prostate carcinoma (Aqeilan  et al., 2010).
The miR-15a and miR-16 are both located at 13q14.3, and the deletions at
this  location  have  been reported  in  many malignancies  including:  CLL,
Multiple Myeloma (MM), Mantle cell lymphoma, and Prostate carcinoma
(Aqeilan et al., 2010). 
In  a  recent  study, the  expression  of  miR-15a,  miR-16-1  in  PC samples
showed consistent down regulation of these genes in around 80% of cancer
samples  compared  with  that  of  normal  samples  (Aqeilan  et  al., 2010).
Studies have also shown that miR-15a, miR-16-1 are down regulated in
pituitary adenomas in comparison with normal pituitary, which basically
enhances the assumption that  they work as tumour suppressors and that
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their knock down by allelic loss may contribute to tumourigenesis. 
BCL2 is  an  oncoprotein  that  performs an  important  role  in  the  genetic
program  of  the  eukaryotic  cell.  It  prevents  cell  death  and  its  over-
expression was found to be related with  many cancers such as: leukaemia,
lymphoma,  and  carcinomas  in  general  (Aqeilan  et  al., 2010).  It  was
reported that miR-15a, miR-16-1 sequences and BCL2 mRNA sequences
shares  a  high  degree  of  complementarity  ,  and  thus  the  previous
information collectively suggests that miR-15a, miR-16-1 could suppress
BCL2 by post transcriptional repression (Aqeilan et al., 2010). It has been
reported that miR-15a, miR-16-1 cluster targets not only BCL2 but also
CCD1 (encoding cyclin D1) and WNT3A mRNAs, which promote many
prostate  carcinogenic  features  including;  survival,  proliferation,  and
invasion (Aqeilan et al., 2010). The in vivo knock down of miR-15a, miR-
16-1  resulted  in  hyperplasia  associated  with  CCD1  and  WNT3A  up
regulation. The aforementioned evidence suggest that loss of miR-15a and
miR-16-1 may be a significant pathogenic event during the development of
PC (Aqeilan et al., 2010). 
The  miR-15  and  miR-16  are  usually  down-modulated  in  the  tumour
sustaining stroma, an observation that can be explained by the effect of
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cancer cells on the stroma (Musumeci et al., 2011). The miR-15 and miR-
16 have a tumour suppressor activity on both the cancer cell level and at the
stromal microenvironment (Musumeci  et al., 2011). Recently, it was also
proposed that miR-15 and miR-16 direct the expression of VEGF and IL-6,
two  factors  that  stimulate  tumour  angiogenesis  and  bone  metastasis,
respectively  (Musumeci  et  al., 2011).  Moreover,  it  was  shown  that  re-
expression of miR-15 and miR-16 in cancer-associated fibroblasts (CAFs)
will cause attenuation of the stromal support capability, and this will result
in a decrease in cell proliferation and migration in primary and metastatic
tumours (Musumeci et al., 2011). These observations lead to the conclusion
that  in  the  context  of  prostate  cancer,  miR-15  and  miR-16  are  tumour
suppressors, at least, on two levels such as at the levels of tumour cell and
stromal cells. 
1.11.1.2The role of miR-143 and miR-145
Studies have shown that miR-143 is considerably decreased in PC, and its
expression  is  further  decreased  during  cancer  progression  (Clape  et  al.,
2009).  K-RAS  (V-Ki-ras2  Kirsten  rat  sarcoma),  a  key  molecule  of
EGFR/RAS/mitogen-activated protein kinase (MAPK) signalling pathway,
is a viral oncogene homolog that was incriminated in cell proliferation and
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migration in response to growth factors. The MAPK pathway also works at
another  level  through  its  effect  on  Androgen  receptors  (AR),  where  it
increases AR in response to low androgen, and this is considered a main
process in Androgen derivation therapy relapse. K-RAS is a potential target
of miR-143 (Friedman  et al., 2009), thereby lower levels of miR-143 in
prostate cancer cells may be incriminated in carcinogenesis due to the lack
of its inhibitory effect on K-RAS and MAPK pathways. 
Xu et  al.  2011 showed  that  miR-143 regulates  K-RAS,  p-ERK1/2,  and
cyclin  D1  and  plays  a  role  in  cell  proliferation,  migration,  and
chemosensitivity  in  prostate  cancer  (Xu  et  al., 2011).  The  study  also
showed  that  miR-143  over-expression  in  prostate  cancer  cells  represses
proliferation and migration, thereby augmenting sensitivity to docetaxel by
affecting  EGFR/RAS/MAPK  pathway. The  expressions  of  miRNAs-143
and -145 (another miRNA which is assumed to be a tumour suppressor)
were  found  to  be  down-regulated  considerably  in  metastatic  samples
(Friedman et al., 2009). Exploring the correlation of the levels of miRNAs-
143 and -145 with clinico-pathological features of PC showed that down-
regulation of miRNAs-143 and -145 were negatively associated with bone
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metastasis,  the Gleason score and the levels of free PSA in primary PC
patients (Friedman et al., 2009). Over-expression of miR-143 and -145 by
retroviral  transfection decreased the ability of migration and invasion  in
vitro, and tumour development and bone invasion in vivo of PC-3 cells (a
human  PC  cell  line  originated  from  a  bone  metastatic  PC  specimen)
(Friedman  et  al., 2009).  Their  up-regulation  also  enhanced  E-cadherin
expression and decreased fibronectin expression in PC-3 cells with features
of a less invasive morphologic pattern (Friedman et al., 2009). 
The information above suggests that miRs-143 and -145 are related to bone
metastasis of PC and may play a biological role in this process (Friedman
et al., 2009). One could postulate that the possibility of using them in the
clinical setting as biomarkers to individualize different stages of human PC
and could predict the development of bone metastasis in patients well ahead
of time (Friedman et al., 2009). Even though up-regulation of miRNAs-143
and -145 are found to suppress the aggressiveness and EMT of PC-3 cells
with regard to bone metastasis, it did not have the same effects on LNCaP
cells that was derived from metastatic lymph node (Friedman et al., 2009).
Deregulation  of  miRs-143  and  -145  was  not  found  in  lymph  node
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metastasis  in  comparison  to  primary  PC  specimens.  This  information
suggests that miR-143 and -145 may have a cell type-specific activity and
could  suppress  only  bone  metastasis  without  inhibiting  lymph  node
metastasis, and that the loss of these miRNAs could selectively promote
metastasis, which could be due to deregulated expression of other miRNAs
such as miR-221 (Friedman et al., 2009). 
1.11.1.3 The role of miRNA-200
Recent  studies  have  shown that  the  miR-200 family  controls  epithelial-
mesenchymal  transition  (EMT)  by  targeting  zinc-finger  E-box  binding
homebox  1  (ZEB1)  and ZEB2 (Kong  et  al., 2009;  Ahmad et  al.  2011;
Ahmad et al 2011) . There is enough evidence to suggest that the processes
of EMT can be elicited by various growth factors, such as transforming
growth factor β and platelet-derived growth factor-D (PDGF-D), which is
expressed  in  PC  tissue  (Kong  et  al., 2009).  It  was  shown  that  over-
expression of PDGF-D in PC3 cells (prostate cancer cell lines with high
metastatic potential) leads to the acquisition of the EMT phenotype (Kong
et al., 2009). 
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It was also proved that significant down-regulation of the miR-200 family
in PC3 PDGF-D cells and in PC3 cells exposed to purified active PDGF-D
protein,  resulted  in  the  up-regulation  of  ZEB1,  ZEB2,  and  Snail2
expression (a transcription factor which belongs to the snail protein family
and  plays  critical  roles  in  the  formation  of  tissues  during  embryonic
development) (Kong et al., 2009). Interestingly, re-expression of miR-200b
in PC3 PDGF-D cells led to reversal of the EMT phenotype accompanied
with the down-regulation of ZEB1, ZEB2, and Snail2 expression, and all of
these  events  were associated with  greater  expression levels  of  epithelial
markers (Kong et al., 2009). Moreover, it was proved that transfection of
PC3 PDGF-D cells with miR-200b considerably decreased the expression
of ZEB1, ZEB2, and Snail2 at  both the mRNA and protein levels,  with
simultaneous  greater  expression  levels  of  epithelial  markers  such  as  E-
cadherin,  stratifin,  CRB3,  EPCM,  F11R,  and  connexin  26,  all  of  these
events  collectively  led  to  the  inhibition  of  cell  migration  and  invasion
(Kong et al., 2009). In a breast cancer model, studies have shown that  in
vivo  manipulation of miR-200b leads to significantly reduced pulmonary
metastases  of  breast  cancer  cells  (Ahmad  et  al., 2011)  which  further
supports the role of the miR-200 family in metastases of human cancers. 
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It  is  well  known  that  NF-κB  plays  an  essential  role  in  facilitating  the
processes  of EMT induced by different  factors  through up-regulation of
ZEB1 and ZEB2, which in turn suppress the expression of miR-200 family
members by binding to the E-box sequence of the miR-200 promoter (Kong
et al., 2009). Whereas miR-200 can down-regulate the expression of ZEB1
and  ZEB2  by  interacting  with  the  3'-UTR of  ZEB1 and  ZEB2 mRNA
(Kong  et  al., 2009).  All  of  these  findings  suggest  a  double-negative
feedback  loop  between  miR-200  and  ZEB1/ZEB2  that  permits  the
preservation of the EMT phenotype,  even after withdrawal of the initial
inducing signal, which might become a critical target for the reversal of
EMT (Ahmad  et  al., 2011).  From these  facts,  it  can  be  concluded that
PDGF-D-stimulated  attainment  of  the  EMT phenotype  in  PC3  cells  is,
partly, an outcome of suppression of miR-200 and that new strategies in
which miR-200 would be up-regulated will become an auspicious approach
for the treatment of invasive prostate cancer (Kong et al., 2009). 
1.11.1.4 The importance of miRNA-488
Another miRNA that has been associated with PC is miR-488. The miR-
488 is encoded by the  AsTN1 gene. Two mature molecules result from the
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processing  of  its  precursors:  miR-488*  and  miR-488  with   both  forms
expressed  predominantly  in  human  brain  tissue  (Sikand  et  al., 2010).
Studies have shown that miR-488* was not expressed in several prostate
cancer  cell  lines,  although  the  aetiology  is  still  unclear  and  thus  it  is
currently under  further investigation  (Sikand et al., 2010). 
Androgen receptor (AR) is a direct target of miR-488, as miR-488 has a
binding site at the 3'UTR of the  AR gene where it binds and suppresses its
expression (Sikand  et al., 2010). It was shown that cells transfected with
miR-488 result in reduced expression of AR in both Androgen-dependent
(LNCaP)  and Androgen-independent  (C4-2B)  PC cells.  In  both  the  cell
lines, treatment with miR-488 mimics was found to retard the growth of
these cells, but this was not the fact with AR-negative DU145 cells (Sikand
et al., 2010), suggesting the regulatory role of miR-488 on AR expression.
These  results  suggest  that  miR-488 could  function  as  a  tumour  growth
suppressor, which is mediated by deregulation of AR expression (Sikand et
al., 2010). 
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Although it is still too premature to make conclusions, the results of these
studies clearly showed that miR-488* transfection into LNCaP and C4-2B
cells  led  to  the  repression  of  AR  expression,  thereby  suggesting  that
development of ways  to increase the levels of endogenous miR-488* could
have a great impact on designing novel treatment strategies for PC. 
1.11.2 Tumour promoter oncomiRNAs
The miRNA expression profiling analyses have shown that many miRNAs
are up-regulated in prostate cancer (Pang  et al., 2010). These oncogenic
miRNAs  suppress  the  apoptosis-related  genes,  so  their  over-expression
leads to increased tumour growth and metastasis (Pang et al., 2010). 
1.11.2.1 The role of miRNA -221 and miRNA-222
The miR-221 and miR-222 are  both  considered  as  oncogenic  and were
found to be associated with the development  and metastasis  of  prostate
cancer  (Pang  et  al., 2010).  One  of  the  methods  through  which  these
miRNAs elicit  their  effect  is  by  binding  to  one  of  their  target  mRNA,
p27kip1 and cause suppression, which results in tumour growth (Galardi et
al., 2007; Sun et al., 2009) . Another suggested action for these molecules
is  their  role  in  the  development  or  maintenance  of  castration-resistant
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prostate  cancer  (CRPC) phenotype through a mechanism that  is  not  yet
clearly understood, although it may be through influencing response of AR-
mediated signalling in prostate cancer cells (Sun et al., 2009). 
Sudies have shown that miR-221 levels are up-regulated in both Androgen
Dependant  Prostate  Cancer  (ADPC) and Androgen Independent  Prostate
Cancer  (AIPC)  compared  to  normal  controls  (Zheng  et  al., 2011).  One
pathologic process that plays an important role in the carcinogenesis and
hormone therapy failure in  PC is  neuroendocrine differentiation (NE),  a
process  that  is  associated  with  tumour  progression  and  poor  prognosis.
Studies have shown that miR-221 is capable of inducing NE differentiation
in LNCaP cells in an androgen deprived environment, which may lead to
Androgen Independence  (AI)  (Zheng  et  al., 2011).  It  was  revealed  that
miR-221 stimulates the growth of LNCaP and LNCaP-AI cells, and it is
consistent with findings that the ectopic introduction of miR-221 in low
expressing LNCaP cells, bolstered their growth potential by inducing a G1-
S shift in the cell cycle (Zheng et al., 2011). 
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One paradox to mention about miR-221 is that although the expression of
miR-221 is higher in LNCaP-AI cells (which are more invasive) compared
to  LNCaP (which  are  less  invasive),  suggesting  that  miR-221 promotes
invasion  of  PC cells  (Zheng  et  al., 2011),  whereas  the  up-regulation  of
miR-221  in  LNCaP  cells  did  not  increase  its  ability  of  increased  cell
migration, whilst the invasion capacity of LNCaP-AI cells was deregulated
by knock-down of miR-221 expression. 
The  aforementioned  facts  can  be  explained  by  assuming  that  other
pathways are involved in regulating the migration capability of cells during
the progression of ADPC into AIPC. It was further concluded that miR-221
could  influence  PC  via  regulation  of  DVL2  (Dishevelled  2),  which  in
summary  is  an  important  intracellular  mediator  of  the  WNT signalling
pathway. An important  target  gene  for  WNT is  MMP-7 (a  regulator  of
cellular adhesion molecules which controls cellular adhesion, invasion, and
migration), and the activation of MMP-7 was found to greatly strengthen
the capability to destroy the  extracellular matrix, especially in cancer cells
(Zheng et al., 2011), suggesting that miR-221 may play an important role in
the regulation of invasion and metastasis. 
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1.11.2.2The role of miR-21
Another  onco-miRNA is  miR-21;  it  is  usually  up-regulated  in  prostate
cancer and plays a role in tumour growth, invasion, and metastasis (Si  et
al., 2007;  Li  et  al., 2009).  Recently,  miR-21  was  individualized  as  an
oncogene which is up-regulated in various cancers (glioma, breast cancer,
colorectal  cancer,  stomach/gastric  cancer,  hepatocellular  carcinoma,
pancreatic cancer, lung cancer, cholangiocarcinoma, leukemia, and prostate
cancer. (Li  et al., 2009). Anti-sense studies of miRNA-21 in glioblastoma
cell lines revealed that it directs cell growth by inhibiting apoptosis while it
does not influence cell proliferation (Li et al., 2009). Previous  studies have
revealed an increase in apoptosis in DU145 and PC-3 cells after blocking
miR-21 function,  while  LNCaP cells,  which  have  low level  of  miR-21,
showed no changes in apoptosis in response to miR-21 blockade (Si et al.,
2007; Li  et al., 2009). The information mentioned above insinuated that
miR-21 plays an important role in the resistance to apoptosis observed in
DU145 and PC-3 cells  (Li  et al., 2009).  These results  also suggest  that
miR-21 might have a role to play in AR-negative cells but this needs to be
further investigated. 
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Many genes have been identified as targets of miR-21 in carcinogenesis
including;  tropomyosine  (TPM1),  Programme  cell  death  protein  4
(PDCD4), and MARCKS (a gene which encodes myristoylated alanine-rich
C-kinase substrate) (Li et al., 2009). It has been shown that MARCKS  has
high frequency frame-shift  mutations during carcinogenesis in hereditary
nonpolyposis  colorectal  cancer  (HNPCC)  (Li  et  al., 2009).  It  was  also
revealed  that  the  expression  of  MARCKS  is  down-regulated  in
Hepatocellular  carcinoma (HCC)  tissues  in  comparison  with  cirrhotic,
benign  liver  tissues  (Li  et  al., 2009).  MARCKS  plays  a  part  in  TPA-
mediated cellular migration in neuroblastoma, probably through its effect as
a downstream target of Protein kinase C epsilon (Li et al., 2009). 
All these results suggest that MARCKS plays a role in tumourigenesis, and
the effect of miR-21 on PC cell motility and invasion may in part be due to
its regulation of MARCKS gene. Recent studies have also shown that in the
presence of androgen, AR can bind to miPPR-21, a miR-21 promoter, and
this  results  in  the  over-expression  of  miR-21  at  its  transcription  level,
leading to castration resistance (Ribas et al., 2009). In support of what has
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been mentioned above, anti-miR-21 may augment the sensitivity of prostate
cancer cells to apoptosis (Li  et al., 2009), and also negatively affect the
motility and invasive characteristic of cancer cells (Li et al., 2009). 
In summary, it appears that miR-21 plays an essential role in apoptosis and
metastasis of PC (Li et al., 2009). Since no effective therapy is available to
cure PC, in part due to the resistance of androgen-independent advanced
prostate cancer cells to apoptotic death, gene therapy that targets miR-21
may be a potential alternative therapy for androgen-independent PC that
have an up-regulated expression of miR-21.  Moreover, it  is  tempting to
speculate that natural agents (nutraceuticals) could serve as a therapeutic
strategy for PC because many of these agents could inhibit the expression
of miR-21 as suggested by recent results in cancer of the pancreas  (Boa et
al., 2011). 
1.11.2.3 The role of miRNA-125b
Another onco-miRNA is miR-125b which is considered very important for
cell  proliferation  (Lee  et  al., 2005)  and  it  is  over-expressed  in  prostate
cancer  (Pang  et  al., 2010).  It  has  been  reported  that  the  reduction  of
miRNA-125b was found to be associated with the regulation of cellular
proliferation  of  cancer  cells,  and  this  effect  was  attenuated  by  co-
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transfection of mature miRNA (Lee  et al., 2005). The biological role of
miR-125b in PC-3 cells was studied and it was revealed that the depletion
of  miR-125b by numerous  transfections  of  si-125b2 was followed by a
substantial proliferation defect in PC-3 cells (Lee et al., 2005). This growth
defect was not associated with aberrant accumulation of cells in one stage
of cell  cycle  or by apoptosis.  Also,  the depletion of miR-125b by 2'-O-
methyl oligonucleotide showed the same phenotype with a similar effect on
cell proliferation (Lee et al., 2005). 
Studies have also shown that transfection of mature synthetic miR-125b
causes PC cell growth (Lee et al., 2005; Ali  et al., 2010), and this was in
part due to its effect on the 3'UTR of BAK1 (a pro-apoptotic member of the
BCL-2 gene family that is involved in initiating apoptosis) transcript (Shi
et  al., 2007).  Nonetheless,  down-regulation  of  BAK-1  only,  could  not
attenuate miR-125b's growth stimulatory effect, suggesting that there are
other targets for miR-125b in prostate cancer cells (Lee et al., 2005; Shi et
al., 2007).  Some  recent  reports  individualized  EIF4EBP1  (Eukaryotic
translation initiation factor 4E-binding protein 1, a gene that encodes one
member of a family of translation repressors proteins) as another specific
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target for miR-125b in PC (Ozen et al., 2008), but it is still not conclusive,
suggesting that future in-depth investigation is warranted. 
1.12. Conclusions and perspectives
Prostate cancer (PC) is considered to be the most diagnosed cancer  (Peng
et al., 2011) and the second leading cause of cancer death in men older than
40 years of age in the USA (Hao et al., 2011). Similarly in South Africa PC
is rated the most common cancer in Black African men and the second most
common  in  white  South  African  males  with  more  than  4300  newly
diagnosed  cases  annuallly  and  nearly  2000  deaths  associated  with  the
disease (ACS, 2012).  The major problem of PC is  the development and
acquisition of castrate resistant prostate cancer (CRPC) phenotype which
eventually  leads  to  the development  of  skeletal  metastasis  (mCRPC),  at
which point it becomes an incurable disease (Peng et al., 2011). Therefore,
investigations are underway to find the molecular basis of mCRPC so that
novel  therapeutic  strategies  could  be  devised.  To that  end  many  novel
molecules  are  being  tested  and  interrogated,  among  which  microRNAs
(miRNAs) are becoming an attractive area of research. 
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The roles of miRNAs in PC are becoming clearer  by understanding the
interactions between miRNAs and their targets and the resulting impact on
carcinogenesis of the prostate (Shi et al., 2007; Lu et al., 2008; Pang et al.,
2010). It is believed that several miRNAs and their targets are aberrantly
expressed in  PC which,  in  turn,  alter  the cellular  growth,  invasion,  and
metastatic potential of prostate cancer cells. The abnormal expressions of
certain  miRNAs  are  now considered  valuable  biomarkers  for  diagnosis,
prognosis and classification of PC (Mattie et al., 2006; Porkka et al., 2007;
Pang et al., 2010). All of the above information underscores the importance
of the biology of miRNAs in PC. Their specific abnormalities, and how one
could regulate their expressions will likely become novel avenues by which
newer therapeutic strategies could be developed for the treatment of PC.
Research  investigations  focused  on  miRNAs  have  suggested  a  strong
prognostic and therapeutic importance of miRNAs in PC. Such studies have
established an intimate relationship between prostate cancer and miRNA
with emerging data clearly suggesting that miRNA is a very promising field
although further in-depth mechanistic studies are required to ascertain the
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role of specific miRNA(s) and relevant target(s) in the development and
progression of PC especially the emergence of metastatic castrate resistant
prostate  cancer.  Once  the   additional  scientific  knowledge  is  gained  it
would be easier to focus on the development of strategies for up-regulation
and down-regulation of specific miRNA as a novel and targeted therapeutic
approach for the treatment of PC. For example, recent  studies with miR-21
in pancreatic and colon cancer models have shown that targeted regulation
of this miRNA can lead to effective anticancer therapy (Luscombe  et al.,
2001; Ali et al., 2010; Bao et al., 2011; Ali et al., 2011; Ali et al., 2012; Yu
et al., 2012). 
Based  on  these  studies  we  hypothesise  that  the  identification  of  key
miRNAs and their targets that are intimately involved with the development
and  progression  of  PC  and  parallel  development  of  strategies  for
deregulation  of  miRNAs  would  allow  inhibition  of  tumour  growth,
invasion,  angiogenesis  and  metastasis  in  PC,  which  is  expected  to  be
clinically useful for the management of patients diagnosed with PC. 
The main aim of this study is therefore  to identify specific miRNAs as
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biomarkers for the early detection of prostate cancer. Individual objectives
include: 
• To identify  miRNA and  gene  targets  that  play  a  critical  role  in
disease to further understand their mechanism of action in PC using
several in silico methods. 
• To  validate  the  potential  diagnostic  miRNAs in cell  lines  using
molecular techniques. 
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CHAPTER 2
Identification of miRNAs as key indicators for the presence of  Prostate
Cancer (PC) using in silico methods
2.1 Introduction
2.1.1 Problem identification
Cancer is a class of diseases characterized by uncontrollable cell growth.
There are over 100 different types of cancer, that are classified by the type
of cell that it initially affects (Meltzer, 2005; Croce, 2005). For the purpose
of this research we will be focussing on prostate cancer (PC). PC is the
second most common form of cancer in men around the world (Figure 2.1
and Figure 2.2) and approximately 4500 men in South Africa are annually
diagnosed  with  the  disease  making  PC  a  global  epidemic   (American
Cancer Society, 2012) (Figure 2.1).  PC follows a natural course, starting as
a tiny group of cancer cells that can grow into a tumour. In some men if PC
is not treated it may spread to surrounding tissue by a process called direct
invasion  or  spread  and  could  lead  to  death  (American  Cancer  Society,
2009 ). 
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2.1.2 Current diagnostic method
At present, diagnosis of PC derives from serum prostate-specific antigen
(PSA)  (Maricone,  2011) measurement,  digital  rectal  examination
histopathological evaluation of prostate needle biopsies (Essink-Bot et al.,
1998) and ultra sound examination of tumours  (Bonekamp  et al., 2011).
Organ-confined  prostate  cancer  is  treated  with  surgery  (radical
prostatectomy) or radiation therapy, and an increase in PSA level usually
represents  the  first  sign  of  recurrence  of  disease  following  treatment
(Damber and Aus, 2008). Androgen deprivation is the current therapy of
choice for patients with metastatic disease. The PSA test has been examined
in several observational settings for initial diagnosis of disease, as a tool to
monitor for recurrence after initial therapy, and for prognosis of outcomes
after therapy. There is no specific PSA value which can provide assurance
that there is  no risk of developing PC. Parameter estimates for this  test
include sensitivity in the range of 70% (Partin and Oesterling, 1994).
Due to the high genetic variability in the course of PC, development or
progression, novel biomarkers are strongly needed at the time of diagnosis
to  facilitate  treatment  planning.  However,  current  prognostic  tools
(nomograms)  exclusively  rely  on  pathological  and  clinical  parameters
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(Damber  and  Aus,  2008).  Therefore,  understanding  the  molecular
alterations that distinguish the progressive from a non-progressive disease
will allow not only the identification of novel biomarkers to be included in
clinical  nomograms  for  improving  their  predictive  power,  but  will  also
provide  mechanistic  information  for  the  discovery  of  new  therapeutic
targets and the design of tailored therapeutic interventions.
Several diagnostic methods are currently being employed, however they are
invasive  and  lack  specificity  and  sensitivity  (American  Cancer  Society,
2012; Djulbegovic  et al., 2010). Therefore, the need for a less invasive,
early detection method with the ability to overcome the lack of specificity
and sensitivity is required. Biomarkers have recently been identified as a
viable option for the early detection of disease which acts  as biological
indicators for disease i.e. DNA, RNA, proteins and microRNAs (miRNA).
Eradication of advanced PC still represents an unsolved clinical problem,
making  the  development  of  alternative  treatment  approaches  highly
desirable.
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Figure 2.1: Analysis of cancer deaths in the United States of America for
the period 2004-2009 (adapted from American Cancer Society, 2009)
Figure 2.2:  Estimation of new cancer cases and deaths in the United States
for the period 2009-2014 (adapted from American Cancer Society, 2014)
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2.1.3 OMICs based technologies for biomarker identification 
The  rapid  evolution  of  high-throughput  technologies  designed  for  the
screening of  biomedical  samples  with the  latest  breakthroughs in  whole
genome sequencing and microRNA (miRNA) profiling has given birth to a
number of biological  disciplines devoted to  the generation and study of
multiple  OMICs  generated  data  for  the  identification  of  potential
biomarkers (Dayeti  et al., 2012). A number of OMICS fields have been
dedicated to identifying various types of biomarkers for the detection of
diseases.  These  biomarkers  include  genetic,  expression,  protein,
metabolomic  and  miRNA biomarkers   (Lui  et  al., 2008;  Dayati  et  al.,
2012). This study will focus on various strategies that have been used to
identify  miRNA  biomarkers.   Figure  2.3   summarizes  the  latest
technologies  used  as  well  as  diversification  of  the  biomarker  types  and
underlying data types depending on the nature of changes detected by the
respective technology.
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2.1.4 Expression Biomarkers
Expression  profiling  studies  using  microarrays  and  other  methods  have
shown that miRNAs are dysregulated in a wide variety of human cancers.
In some instances, the expression of selected miRNAs or specific miRNA
signatures was found to correlate with diverse clinico-pathological features
of disease and were able to predict patient clinical outcome and/or response
to  treatment  (Garzon  et  al., 2006).  Such  findings  have  highlighted  the
potential  of  miRNAs  as  new  diagnostic  or  prognostic/predictive
biomarkers. Moreover, the role of miRNAs functioning as oncogenes and
tumour suppressors,  as emerged from functional  studies in  experimental
models (Garzon et al., 2006), has generated great interest in their possible
use as novel targets or tools for anticancer therapies.
2.1.5 MiRNA biomarkers 
MiRNAs  are  a  class  of  naturally  occurring,  small  non-coding  RNA
molecules,  about  18–25  nucleotides  in  length.  MiRNAs  are  partially
complementary to one or more messenger RNA (mRNA) molecules, and
their main function, to down regulate gene expression, is well documented,
that include translational repression, mRNA cleavage,  and de-adenylation
(Flopowics, 2005; He et al., 2005; Mraz et al., 2009). The involvement of
                                    91
 
 
 
 
miRNAs in key cellular processes such as proliferation and cell death and
their  well  known  negative  control  over  the  expression  of  numerous
oncoproteins  make  them  prime  candidates  as  cancer  biomarkers
(Flopowics, 2005; He  et al., 2005). It has also been reported that cancer-
specific miRNAs are detected in the blood at the earliest stages of tumour
development and increase in their concentration as the  tumour progresses
over  time,  thus  making  them  an  indicator  of  the  tumour  growth
(Krutovskikh  and  Herceg,  2010).  Moreover,  unlike  other  types  of
biomarkers, miRNAs are remarkably stable in circulation, formalin-fixed
paraffin embedded tissue, serum and urine thus making them potentially
robust oncology biomarkers (He  et al., 2005). Functional miRNA species
have  mostly  been  validated  in  vitro using  luciferase  reporter  activity
(Krutovskikh and Herceg, 2010). 
Micro-array profiling is a powerful high-throughput technology capable of
monitoring the expression of thousands of small non-coding RNAs at once
within tens of samples processed in parallel in a single experiment (Lui et
al., 2008).  Serial  Analysis  of  Gene  Expression  (SAGE),  Stem-loop
quantitative Real Time Polymerase Chain Reaction (qRT-PCR) for mature
miRNAs, qRT-PCR for precursor miRNAs and bead-based technologies are
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also  frequently  used  for  miRNA profiling  (Chang-Gong  et  al., 2008).
However, no miRNA biomarker currently exists in cancer clinical practice
(Dayeti et al., 2012). It is noteworthy that the field of genomics generating
genetic biomarkers witnessed a remarkable rise in clinical acceptance after
the  sequencing  of  all  human  genes  through  the  human  genome project
(Dayeti et al., 2012). 
Similar  effort  is  needed to discover  and characterize all  the miRNAs in
human  cells  in  order  to  transform  the  potential  of  miRNAs  as  cancer
biomarker  into  clinical  success.  Further  understanding on how miRNAs
compete with proteins to bind and control the expression of mRNA as well
as the functional interaction networks through which miRNAs exert their
tissue  specific  role,  is  needed  for  future  clinical  translation  of  these
molecules (Krutovskikh and Herceg, 2010). 
Although transcriptomics technology (micro-array analysis), is one of the
oldest  and  widely  used  high  throughput  technologies,  most  candidate
biomarkers are reported in genomic and  by proteomics research (Figure
2.4) (Dayeti et al., 2012). Stability of the signal from genomic analysis as
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well as higher stability of the protein versus mRNA might be the reason for
those  biomarkers  outweighing  the  transcriptomics  derived  biomarkers.
Comparing the number of approved biomarkers to those mentioned in the
public domain (e.g. GIOBIOM,  (GV BIO Online Biomarker Database))
available at  http://  www.gvkbio.com  , reveals that the majority of candidate
biomarkers either failed or have not reached the clinical setting yet (Dayeti
et al., 2012).
Figure 2.4: Current contribution of OMICs technologies in oncology
biomarker  discovery. In  red:  total  number  of  candidate  biomarkers
reported  in  the  public  domain.  In  blue:  number  of  FDA  approved
biomarkers in current clinical practice for oncology (Adopted from Dayeti
et al., 2012).
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Even in the event of a strong signal being derived from high-throughput
technologies,  its  conversion  to  clinical  practice  meets  a  number  of
associated  challenges,  the  first  of  which  is  its  functional  interpretation.
Interpretation  of  the  high-throughput  data  in  the  context  of  molecular
patho-physiology of underlying disease and specific treatment is the current
rate-limiting  step in  the  biomarker  identification  and validation  pipeline
(Dayeti  et  al., 2012).  If  properly  identified,  extracted  and  interpreted,
OMICs  data  sets  can  provide  valuable  biological  insights.  Functional
analysis of OMICs data requires knowledge on the molecular interactions
and  pathways  underlying  pathophysiology  of  diseases  and  the  mode  of
action of treatment regimes. 
Accumulated  biological  knowledge across  different   levels,  needs  to  be
collected, annotated, translated into a computer-readable format, and stored
in  a  semantically  enhanced  knowledge  base.  A knowledge  base  of  this
magnitude could then be used for knowledge-based analysis of OMICs data
sets  through  integrative  approaches  that  aims  at  finding  key  biological
processes, pathways, interaction modules or causative network signatures
within  disease  onset  and  progression.  In  addition  identifying  molecules
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involved in these pathways and processes could lead to potential candidate
biomarkers.
In  this  study  we  aim  to  provide  an  integrative  method  to  successfully
identify miRNAs as specific biomarkers associated with the early detection
of PC through data mining and various in silico methods (programming and
statistical analyses).
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2.2 Methods
Figure 2.5: Flow Chart representing the  in silico  methods employed
during Phase 1 of this study.
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2.2.1 Database search and data retrieval
Publicly  available  databases  such  as  MiRBase
(http://www.mirbase.org/search.html) (Griffiths-Jones et al., 2006) and the
Gene  Expression  Omnibus  (GEO)  available  at
http://www.ncbi.nlm.nih.gov/  geo (Barrett  et  al., 2013)  were scanned  for
miRNAs  and their implication in PC. The miRBase database was searched
for sequence specific info that implicated known miRNAs in PC. GEO was
scanned  for  micro-array  data  available  on  known  miRNAs  that  have
previously been implicated in PC. 
The  miRBase  database  is  a  searchable  database  of  published  miRNA
sequences and annotation. Each entry in the miRBase Sequence database
represents a predicted hairpin portion of a miRNA transcript (termed mir in
the database), with information on the location and sequence of the mature
miRNA sequence (termed miR) (Griffiths-Jones et al., 2008). Both hairpin
and mature sequences are available for searching and browsing, and entries
may  be  retrieved  by  name,  keyword,  references  and  annotation.  All
sequence and annotation data are also available for downloading from the
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miRBase registry (Griffiths-Jones, 2004). The miRBase registry provides
miRNA gene hunters with unique names for novel miRNA genes prior to
publication of results (Griffiths-Jones, et al., 2006). The MiRbase database
was mined for all known miRNAs associated with PC. Parameters of the
search included, but not limited to terms, such as human, prostate-specific,
cancer, early stage etc. 
The  GEO  is  an  international  public  repository  that  archives  and  freely
distributes  micro-array,  next-generation  sequencing,  and  other  forms  of
high-throughput  functional  genomics  data  submitted  by  the  research
community  (Barrett  et  al., 2013).   The  repository  supports  MIAME-
compliant data submissions.  Tools are  provided to  help users query and
download  experiments  and  curated  gene  expression  profiles.  The  three
main goals of GEO are to provide a robust, versatile database in which to
efficiently store high-throughput functional genomic data.  In addition, to
offer simple submission procedures and formats that support complete and
well-annotated data deposits from the research community. Furthermore, to
provide user-friendly mechanisms that allow users to query, locate, review
and download studies and gene expression profiles of interests  (Barrett  et
al., 2013). 
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For the purpose of this study micro array datasets were used. These micro-
array datasets contained data for human prostate cancer specific miRNAs.
Datasets labelled GSE4574 and GSE45604 were retrieved from the GEO
database. 
Data  from  both  databases  were  retrieved  and  a  separate  list  for  each
database was compiled and streamlined. The miRNA list from GEO was
prioritised based on the miRNA fold change expression and a p value of  >
0.05. After prioritization 60 miRNAs were identified as being implication
in PC from GEO and 50 from miRBase.  Both the lists, one from miRBase
and the other from GEO were combined and duplicates were eliminated
using a Perl script (See Appendix A). 
A combined list of 40 known miRNAs was generated that included their
accession numbers and links to publications, describing the association of
these  miRNAs  to  PC.  Data  was  exported  or  retrieved  and  saved  in
compatible formats for further analysis.
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2.2.2 Target gene prediction using the 40 identified prostate miRNAs 
The 40 miRNAs identified were used as individual queries to predict the
target genes they are known to regulate. Target predictions were performed
using  the  miRDB  database  available  at  http://www.mirdb.org/cgi-
bin/search.cgi (Wong  and  Wang,  2015),  the  Gene  Expression  Omnibus
database  available  at  http://www.ncbi.nlm.nih.gov/geo/  (Barrett  et  al.,
2013) and the target scan database available at  http://www.targetscan.org/
(Friedman et al., 2009).
The  miRDB  is  an  online  database  for  miRNA  target  prediction  and
functional annotations. All the targets were predicted by a bioinformatics
tool, MirTarget, which was developed by analyzing thousands of miRNA-
target interactions from high-throughput sequencing experiments. Common
features associated with miRNA target  binding have been identified and
used to  predict  miRNA targets  with  machine learning methods.  miRDB
hosts predicted miRNA targets in five species: human, mouse, rat, dog and
chicken. As a recent update, users may provide their  own sequences for
customized target prediction. 
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The  GEO  database  as  described  in  section  2.2.1,  houses  an  array  of
information. Micro-array experiments present in the database incorporates
information on gene targets that interact with the respective miRNAs of
interest. 
TargetScan  predicts  biological  targets  of  miRNAs  by  searching  for  the
presence of conserved 8mer and 7mer sites that match the seed region of
each miRNA (Lewis et al., 2005). As an further option, non-conserved sites
can  also  be  predicted.  In  addition,  the  tool  can  also  identify  sites  with
mismatches in the seed region that are compensated for by conserved 3'
pairing (Friedman et al., 2009). In mammals, predictions are ranked based
on  the  predicted  efficacy  of  targeting  as  calculated  using  the  context+
scores of the sites (Grimson  et al., 2007 and Garcia  et al., 2011). As an
option,  predictions  are  also  ranked  by  their  probability  of  conserved
targeting  (PCT)  (Friedman  et  al., 2009).  TargetScanHuman  considers
matches  to  annotated  human  UTRs  and  their  orthologs,  as  defined  by
UCSC  whole-genome  alignments.  Conserved  targeting  has  also  been
                                    102
 
 
 
 
detected within open reading frames (ORFs). TargetScan uses the miRNA
ID information as   a  query  to  extract  target  gene information from all
available experiments publicly available
Three separate  databases were used in this study to improve robustness
whilst adding value to the predictions that were  made. Each  miRNA  was
used as a query to identify specific target genes for each miRNA. Gene
targets from all of the databases for each of the  miRNAs were collated  and
saved for further analyses.
2.2.3 Prioritising the miRNA and target gene lists
For the purpose of this research the target gene lists containing 800 or less
targets  were  included  in  the  study. Only  gene  targets  predicted  with  a
confidence level of more than 80% was included for downstream analysis.
Each of the separate files generated for the target genes of interest were
catalogued using a command line interface. Duplications were eliminated
from these files using a Perl  script (See Appendix A),  with this  process
being  repeated  twice  to  ensure  that  all  duplicates  in  the  final  file  were
removed. A final gene list of 551 genes were identified as being targeted by
the  40 identified prostate cancer miRNAs. 
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2.2.4 Functional Annotation of predicted gene targets using DAVID
Functional annotation of the 551 target genes identified was done using the
The  Database  for  Annotation,  Visualization  and  Integrated  Discovery
(DAVID)  version  6.7  (Huang  et  al.,2009a  and  Huang  et  al., 2009b).
DAVID consists of an integrated biological knowledge-base and analytic
tools  aimed  at  systematically  extracting  biological  meaning  from  large
gene/protein lists. DAVID, is a high-throughput and integrated data-mining
environment, to analyse gene lists derived from high-throughput genomic
experiments. 
The  initial  procedure  required  uploading  of  a  gene  list  containing  any
number of common gene identifiers followed by analysis using one or more
text  and  pathway-mining  tools  such  as  gene  functional  classification,
functional annotation chart or clustering and functional annotation table. By
following  this  protocol,  investigators  are  able  to  gain  an  in-depth
understanding of the biological themes in lists of genes that are enriched in
genome-scale  studies.  The  database  is  available  at  the  following   URL
(http://david.abcc.ncifcrf.gov/). The 551 gene targets IDs were used as a
query in DAVID to identify which functional annotations were assigned to
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the identified gene targets. Once the genes were uploaded multiple species
were identified as being part of the gene list of interest. Only genes present
in the species,  Homo Sapiens, were subsequently analysed. A total of 497
genes  corresponded  to  Homo  Sapiens.  The  genes  and  their  functional
annotations were then subjected to K-means clustering a tool available in
DAVID (Huang et al., 2009b) where 77 clusters were generated. 
Clusters generated were individually investigated to select clusters of genes
that are involved in biological process, present in the membrane region and
that were involved in pathways that are known to play a critical role in the
onset  and  progression of cancer. From the 77 clusters,  3  clusters  were
found to be of interest namely cluster 7, 13 and 21.  Gene lists representing
clusters 7, 13 and 21  were combined and processed, using a Perl script (see
Appendix A) to eliminate any duplicated genes within the gene lists, with a
final list of 21 genes identified. The identified target genes were then cross-
referenced back to the list of 40 identified miRNAs for their involvement in
PC.  A total of 13 miRNAs involved in PC were identified and used for the
subsequent analyses in this study.
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2.2.5 Co-expression analyses using the STRING databases
This section, describes the methodologies employed for the co-expression
analyses of genes targeted by miRNAs implicated in prostate cancer using
publicly available  databases.  Gene IDs for 21 genes,  targeted by the 13
miRNAs implicated in prostate cancer were used as input for the generation
of a gene network using the STRING DB version 9. (Snel  et al., 2000;
Meiring,  2003;  Franceschini  et  al., 2013).  STRING an  online  database
(http://string-db.org/), for the identification of protein-protein interactions,
focuses  on  functional  protein  association.  Protein-protein  interaction
networks are an important ingredient for the systems-level understanding of
cellular processes. Such networks can be used for filtering and assessing
functional  genomics  data  and  for  providing  an  intuitive  platform  for
annotating structural, functional and evolutionary properties of proteins, all
of  which  is  made  possible  by  interrogating  protein-protein  interactions
between genes. Exploring the predicted interaction networks can suggest
new directions for future experimental research and provide cross-species
predictions for efficient interaction mapping.
This  tool  was  used  to  generate  gene  networks  of  the  protein-protein
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interactions  between  co-expressed  genes  to  determine  if  any  known
interactions exists between the 21 genes and also amongst the 21 genes and
important proteins implicated in the progression of PC  (Franceschini et al.,
2013).  The  21  genes  were  used  as  driver  genes  to  produce  expression
networks.  To produce each of the expression networks,  parameters were
judiciously chosen as a follows: (i) a confidence level of 0.7, (ii) a network
depth of 4 and (iii) restricting to show only the top 50 interactions between
the 21 genes targeted by the identified miRNAs. 
2.2.6 Expression profiling for genes targeted by miRNAs
Micro-array data files containing expression data for  all 21  target genes
were  downloaded  and  extracted  from  Gene  Expression  Atlas  (GEA)
available  at  (http://www.ebi.ac.uk/gxa/). Files  containing  data  on   the
expression level of the 21 genes in various cancers were extracted from
GEA using a Perl script (see Appendix A).  Fold change expression values
for tumour vs normal tissue were extracted for each of the cancer types and
documented in Excel spread sheets. These files were analysed using an R
script (see Appendix A) to produce a graphical representation of the cancer
type that indicate the activity of the target genes. Individual  graphs for
                                    107
 
 
 
 
each target gene were generated, plotting all the cancer types on one graph.
2.2.7 Pathway Analyses using mirPath in DIANA tools
Pathway analysis  for  this  section of  the  project  was achieved using the
mirPath  (Vlachos  et  al., 2012)  software  tool  in  the  DIANA database
(DIANA-miRPath v2.0) accessible at  http://www.microrna.gr/miRPathv2  .
New  modules  enable  the  DIANA-miRPath  server  to  annotate  all  the
predicted  and  experimentally  validated  miRNA  targets  in  a  selected
molecular  pathway  (Reverse  Search  module).  DIANA-miRPath  is  an
efficient and yet easy to use tool that can be incorporated successfully into
miRNA-related analysis pipelines. 
DIANA-miRPath performs miRNA pathway analysis,  providing accurate
statistics and is able to accommodate advanced pipelines generated by the
user. The miRPath tool can utilize predicted miRNA targets provided by the
DIANA-microT-CDS  (Maragkakis  et  al., 2009)  algorithm  and/or
experimentally  validated  miRNA  interactions  derived  from  DIANA-
TarBase v6.0 (Vergoulis  et al., 2012). The tool is  capable of combining
results with merging and meta-analysis algorithms, performing hierarchical
clustering of miRNAs and pathways based on their interaction levels, as
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well as being able to generate sophisticated visualization of results, such as
dendrograms or miRNA versus pathway heat maps.
From the 40 miRNAs identified further analyses revealed that 13 of the
miRNAs  were  of  interest  of  which  8  (MiR1-8)  were  tested  during
subsequent  sections  of  this  study and  the  remaining  5  were  tested  in  a
parallel study. This database (DIANA-miRPath) was used  to determine the
involvement and implication of the 8 selected miRNAs in cancer causing
pathways and to further implicate them in the progression of PC. 
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2.3 Results
2.3.1 Data retrieval 
Public databases such as miRBase and GEO were searched for miRNAs
implicated  in  PC.  Duplicates  were  removed  using  a  Perl  script  (See
Appendix  A)  and a  total  of  50  and  60 miRNAs  were  identified  from
miRBase and GEO respectively. Datasets were combined (110 genes) and
duplicates were once again removed to  produce a final list of 40 miRNAs
implicated in PC. Results from  Table 2.1 below indicates the process used
to retrieve datasets from known miRNA databases and to identify miRNAs.
Table: 2.1: Tabular representation of  miRNA dataset retrieval from 2 
public databases
Database name miRBase GEO
Number of miRNAs
identified
60 455
Number of datasets
retrieved
1 2
Number of miRNAs after
duplicates are removed
50 60
Datasets from both
databases combined 
110
Total combined list of
miRNAs after duplicates are
removed
40
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2.3.2 Target predictions
The  40 miRNAs identified in section 2.3.1 were used as  queries in three
publicly  available  target  search  databases  namely  MiRDB,  GEO  and
TargetScan.  MiRNAs were individually used as a query to identify specific
target genes associated with each miRNA. Table 2.2 indicates the combined
total  number  of  target  genes  identified  from  each  database  for  the  40
identified miRNAs. 
Table 2.2 Tabular representation of the number of target genes 
identified  
Database Name Initial No.of target genes 
identified
MiRDB 7063
GEO 14638
TargetScan 21986
2.3.3 Prioritization of target gene lists
Target gene lists  for each of the miRNAs from the respective databases
were prioritised using the following parameters : (a) only miRNA targeted
gene lists generated that contained 800 or less genes were included in the
study for further analyses. (b) only gene targets with a prediction score of
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80% and more were taken into account. (c) eliminating duplicates. Table
2.3 shows the prioritised number of target genes for each database as well
as the final number of target genes identified.
Table 2.3: Prioritization of target genes identified for the 40 miRNAs 
implicated in PC
Stage of prioritization Database
MiRDB GEO TargetScan
Number of target genes
after applying criteria (a) 3321 5865 7898
After applying criteria (c) 1805 3065 5923
Number of target genes
after applying criteria (b) 803 925 1078
Number of target genes
after combining  and
applying criteria (c)
551
2.3.4 Functional Annotation using DAVID
The  551  genes  identified  in  section  2.3.3  were  subjected  to  functional
annotation and cluster analyses. In total, 77 clusters were generated  and the
annotation terms associated with the target genes were characterised into 3
categories namely Biological Processes (BP), Molecular Function (MF) and
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Cellular Components (CC). Three (7, 13, 21) of the 77 clusters, were found
to be of interest and contained  a total of 41 target genes. Gene duplicates
were eliminated and a total number of 21 target genes (Figure 2.4),  were
associated  with  biological  processes  such  as  “regulation  of  Apoptosis”,
“Programmed cell  death” and  “regulation of cell  death” as  depicted in
Figure 2.6. For the category Molecular Function (MF) it was shown that
more than 40% of the identified target genes were associated with “metal
ion  binding”,  “metal  binding”,  “ion  binding”  and  “cation  binding”  as
indicated in Figure 2.7. The target genes were also strongly associated to
cellular components  such as  “membrane enclosed lumen” and intracellular
organelle lumen” as depicted in Figure 2.8.
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Figure  2.6:  Graphical  representation  of  the  functional  annotation
terms under the category biological processes (BP), associated with the
target genes for the identified miRNAs. The magenta bars represent the
percentage of genes associated with a specific term.
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Figure  2.7:  Graphical  representation  of  the  functional  annotation
terms under the category molecular function (MF), associated with the
target genes for the identified miRNAs.  The magenta bars represent the
percentage of genes associated with a specific term. 
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Figure  2.8:  Graphical  representation  of  the  functional  annotation
terms under the category cellular components (CC), associated with
the target genes for the identified miRNAs. The magenta bars represent
the percentage of genes associated with a specific term. 
                                    116
 
 
 
 
Table 2.4: Tabular representation of the miRNAs and their identified
gene specific targets: Column 1 indicates miRNAs, Column 2 represents
the confidence level of the prediction Column 3 indicates the gene specific
target  for  each  of  the  potential  diagnostic  miRNAs  and  Column  4
represents the description of the targets identified.
                                    117
 
 
 
 
2.3.5 Co-expression Analysis Using STRING
The 21 genes were used as driver genes to produce expression networks
using the parameters as described in section 2.2.5.  The results in Figure 2.9
shows a clear link between 12 of the 21 target genes as shown in the blue
network  present  in  the  overall  gene  network.  Gene  targets  BFAR  and
CFLAR are seen to be connected to one another. The remaining 7 genes did
not have any connection to one another or the rest of the target genes as
seen by the nodes in the upper right quadrant of Figure 2.9.
Figure  2.9:   Protein  Network  Visualization  generated  by  STRING.
STRING analysis shows the interactions of the 21 miRNA targeted genes
clustered together using MCL clustering. The nodes represent genes and the
lines  joining  them  represent  the  evidence  available  for  the  connection
between genes.
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2.3.6 Expression profiling of 21 target genes using GEA
Figure 2.10 indicates the fold change expression of 20 of the target genes in
various types of cancer tissue. The fold change was calculated relative to
the genes expression value obtained in cancer vs normal tissue. From the
graph it is clear that 3 types of cancer showed a higher degree of expression
for  the  target  genes.  These  cancers  included  breast,  liver  and  prostate
cancer. A number of genes showed a significant increase in expression in
cancerous tissue compared to normal tissue.  In breast cancer tissue some of
the target genes (SH3RF1, MNT, PRKCI, RAB27A and LIG 4) showed a
2.5-4 fold change in expression compared to normal breast tissue. Whereas
ADNP, ATM, BFAR and BTG2 showed a fold change of between 6 and 8
in breast cancer tissue compared to normal breast tissue (Figure 2.10). In
liver  cancer  two  genes  (CFLAR  and  BFAR)  showed  a   fold  change
expression  of  14  and  11  respectively  when  compared  to  normal  liver
tissues. In PC tissue, the expression of  6 target genes (SH3RF1, TMX1,
MNT, PRKCI, CFLAR and ING4)  were  increased as opposed to normal
prostate tissue (Figure 2.10). Amongst these six genes whose expression
levels were significantly increased in prostate cancer tissues, SH3RF1 and
ING4  showed  the  lowest  fold  change  in  expression.  MNT had  a  fold
change value of 6, whereas genes TMX1, PRKCI and CFLAR recorded the
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highest fold change (7.5) in PC
Figure 2.10:   Graphical representation of the fold change expression in
tumour Vs normal  tissue for  20 target genes of the identified miRNAs.
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2.3.7 Pathway Analysis using DIANA-mirPath
In silico pathway analysis tools (DIANA-miRPath v2.0, and target database
microT-CDS) were utilized to obtain predicted gene targets and associated
KEGG (Kyoto Encyclopedia of Genes and Genomes) (Kanehisa and Goto
2000) pathways of MiR1-8.  In total, 33 KEGG pathways were identified
that are associated with MiR1-8 as shown in Figure 2.11.  Pathways were
selected based on the following criteria: smallest P-values for the union of
common pathways targeted by all miRNAs and the largest number of genes
represented  in  those  pathways.  Some  of  the  pathways  associated  with
miRNA1-8 included pathways in cancer (prostate cancer, colorectal cancer,
basal  cell  carcinoma,  small  lung  cancer),  PI3K  (phosphoinositide  3-
kinase)/Akt  signalling  pathway,  TFG-beta  signalling  pathway,  cell
structure-related  pathways,  (focal  adhesion),  cell  function  pathways
(ubiquitin proteolysis). A complete list of pathways and their associated p-
values is included in Appendix A. Collectively these results lend support to
the identified miRNAs potential link to cancer and more specifically PC.
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Figure 2.11:  Graphical representation of the association of miRNA1-8
and various cancer causing related pathways.  The red blocks indicated
the strongest association (associations with log  p-values smaller the -9.5).
Orange blocks show intermediate association and yellow blocks (with log
p-values ranging between 0 and -1.5) show the poorest association between
miRNA1-8 and the pathways identified.
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2.4 Discussion
MiRNAs have been found to be down-regulated in a number of tumours
and in some cases the re-introduction of these miRNAs have been shown to
impair the viability of cancer cells (Davis & Hata, 2009; Sotiropoulou  et
al., 2009; Pritchard  et al., 2012). The value of miRNA profiles in tumour
diagnostics is well established for example, 16 miRNAs have been shown
to be strongly down regulated in breast cancer (Aqeilan et al., 2010). These
markers may be used in the development of drug resistant and treatment
selection  tests.  MiRNAs have also  been shown to  be  involved in  other
processes  besides  translational  gene  silencing.  Currently,  evidence  to
support this are through studies that show that mature mammalian miRNAs
can be imported into the nucleus and secreted from the cell (Garzon et al.,
2006).  These results  suggest  that  miRNAs may regulate  transcription or
paracrine signalling. 
Unlike siRNAs, miRNAs are endogenous and therefore have the potential
to  enhance  the  understanding  of  the  regulation  of  particular  genes.  In
addition, miRNAs are now seen as an additional layer of gene regulation
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which can be dysregulated in disease (Ozen et al., 2008; Clape et al., 2009;
Fu et al., 2010; Schaefer et al., 2010).
From  the  in-silico methods  employed  as  described  in  section  2.2,  40
miRNAs were identified as being previously implicated in prostate cancer
as indicated in Table 2.1.   A new pipeline was generated using selective
terms and parameters to identify miRNAs and their target genes associated
with  PC.  Information  from  various  databases  was  pooled  together  to
generate a list of potential miRNAs as biomarkers for PC. The retrieved list
was  further  refined  using  various  in  silico tools  which  incorporates
statistical analysis to prioritise the miRNA list. 
This  proved  that  our  “in-house”  technique  was  more  specific  for  the
identification and the prioritisation of PC-associated miRNAs. Using the 40
miRNAs as queries, 551 target genes were identified for the list of input
miRNAs. Bioinformatics analysis which included functional annotation and
cluster  analyses  revealed  a  prioritised  target  gene  list  of  21  genes  of
interest. These target genes were found to be targeted by 13 of the initial 40
miRNAs identified as depicted in Table 2.4. 
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The gene targets for these 13 miRNA as indicated in Table 2.4 showed a
strong association to known processes involved in apoptosis and cell cycle
regulation processes. MiRNA-8 was predicted to have a strong association
of 95% with CFLAR (Table 2.4), a gene that is known to be involved in the
regulation of Caspase-8 and FADD (Goa et al., 2006), two crucial genes in
the regulation of apoptosis. 
Studies by Gao and colleagues in 2005 and 2006  demonstrated that the
Androgen receptor pathway directly targets the CFLAR gene, this finding
resulted  in  the  identification  of  three  functional  antioxidant  responsive
elements (AREs) such as par-4 in the CFLAR promoter (Gao et al., 2005).
They have further  illustrated that  par-4 functions  as an AR cofactor  for
androgen-driven  CFLAR  gene  expression.  In  order  to  validate  their
findings Goa (2006)  conducted experiments to observe the activity of a
par-4  enhanced  androgen-driven  CFLAR  promoter  in  a  transient
transnfection  assay  (Goa  et  al., 2006).   Chromatin  immunoprecipitation
analysis  indicated   that  par-4  was  capable  of  directly  binding   to  the
promoter  region  of  CFLAR during  androgen  treatment  when  using  the
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LNCaP  cell  line.  These  results  suggested  that  par-4  directly  targeted
CFLAR.
The  androgen  pathway  exerts  a  protective  effect  in  the  prostate  gland
(Hakimi  et  al., 1996)  and  in  androgen-sensitive  human  prostate  cancer
LNCaP cells (Coffey  et al., 2002). Although the mechanisms underlying
these effects have not been clearly defined, androgen’s effects on both pro-
apoptotic  and  anti-apoptotic  gene  expression  have  been  demonstrated
(Coffey et al. 2002). Gao and colleagues (2006) observed  that AR and par-
4  levels  gradually  decreased  and  increased  respectively  in  all  epithelial
cells following castration, they also found that a few epithelial cells lose
CFLAR  expression  following  castration  (Gao  et  al.,  2006).  Most
interestingly and significantly, from this study was the fact that apoptosis
was only detected in the epithelial cells that did not express CFLAR. These
finding may suggest that predictions made earlier could possibly indicate,
that  the  target  gene  CFLAR,  is  indeed  involved  in  the  relevant  cancer
causing pathways as well as PC. 
Since a clear link has been established between dysregulation of apoptosis
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and cancer, this miRNA would be expected to potentially be involved in the
regulation of apoptosis and therefore play a role in cancer development.
This  miRNA also  regulates  the  gene,  CSRNP3,  a  crucial  gene  in  the
regulation of apoptosis and thus a definitive link of the miRNAs to cancer
is expected. 
In addition to results in Table 2.4,  miRNAs 3 and 5 showed association to
genes  involved  in  apoptosis  and  cell  growth  regulation.  The  data  as
summarized in  Table 2.4 would suggest that the targets  of the miRNAs
selected in this study have strong association with genes that are associated
with crucial processes in cell growth, cell death regulation and therefore
potentially cancer development.  
Functional  annotation analyses  showed that  the targets  of these selected
miRNA could be implicated in processes linked to cancer as shown in the
Gene Ontology (GO) analysis  performed in this  study. The target genes
were  found  to  be  highly  associated  to  biological  processes  such  as
“regulation  of  transcription”,  “regulation  of  apoptosis”  and programmed
cell-death as depicted in Figure 2.6. With respect to biological processes
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identified for these selected targets, the process of apoptosis is crucial in
cancer,  as  dysregulation  of  this  process  is  known to  be involved in  the
development of cancer  (Ozen  et al., 2008; Clape  et al., 2009; Fu  et al.,
2010;  Schaefer  et  al., 2010).   All  21  gene  targets  identified  for  the  13
miRNAs were associated with these processes as depicted in Figure 2.6. 
Furthermore, Figure 2.7 indicates that more than 40% of the target genes
were  found to be associated with Molecular functions such as “metal ion
binding”, “ion binding”, “metal binding” and “cation binding” this finding
was  significant  as  many  diseases  including  cancer   are  associated  with
metal  ion  imbalance   (Williams,  2014).  A metal  ion  imbalance  may  be
regarded as  a deficiency of the essential metals, overload of either essential
or  non-essential  metals  or  perturbation  of  the  overall  natural  balance.
Results  as depicted in Figure 2.8 shows that the targets of the miRNAs
were also strongly associated with membrane bound proteins. This finding
was significant as molecules that are membrane bound  are easily excreted
into  bodily fluids such as blood, saliva and urine which makes them good
targets for diagnostic purposes and drug targeting.
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STRING analysis as described in section 2.3 and illustrated in Figure 2.9
showed links based on experimental evidence between some of the target
genes associated with the miRNAs. However, a number of the 13 miRNA
targets (7 miRNA targets)  showed no association with any other  known
protein networks. The reason for this could be that the database was in the
process  of  being  updated  or  that  these  genes  have  not  previously  been
linked to  cancer  causing pathways and specifically  PC.  The targets  that
showed strong  links  with  one  another  in  a  biological  network  were  all
associated with apoptosis regulation and cell growth.  Two of the genes,
LIG4 and ATM, showed a strong association with more than one of the
targets of the miRNAs (Figure 2.9). 
Five  of  the target  genes,  PTPRC, LIG4,  ATM, TNFSF15 and RAB27A
showed a  direct  association  and two target  genes  YWHAZ and PRKCI
showed  an  indirect  association  with  the  tumour  necrosis  factor
(TNFSF13B) as depicted in Figure 2.9 in the blue network cluster. This
suggests that these targets could be potential regulators of tumour growth.
A recent study by Ishiguro and colleagues (2009) using the prostate cancer
cell line DU145, revealed that PRKCI is involved in prostate cancer growth
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both in vivo and in vitro (Ishiguro et al., 2009). Furthermore, depletion of
PRKCI in DU145 cells suppressed NFκB and AP-1 activities, transcription
and secretion  of  IL-6,  as  well  as  suppressing cell  growth,  but  not  IL-6
signalling.  The  group  concluded  that  enhanced  PRKCI  expression  in
prostate cancer cells results in overproduction and secretion of a prostate
growth factor, IL-6, at the transcription level (Ishiguro  et al., 2009).  The
study further reported that this forms an autocrine loop contributing to the
growth of prostate cancer (Ishiguro et al., 2009, Nguyen et al., 2014). The
PRKCI-dependent expression of IL-6 mRNA is also observed for another
androgen-independent prostate cell line, PC-3, suggesting the generality of
this  regulation (Ishiguro  et al., 2009, Nguyen  et al., 2014). The specific
over-expression of PRKCI in epithelial cells but not in stromal cells of the
prostate further  supports  such an autocrine mechanism. It  is  known that
most of androgen-independent prostate cancer tissues over-express and/or
express  mutated  AR  that  is  still  activated  by  lower  concentrations  of
androgen, estrogen and anti-androgen drugs (Ishiguro et al., 2009, Nguyen
et al., 2014). 
Taken  together,  the  pathway  might  cooperate  with  the  deregulated  AR
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system to  regulate  proliferation  of  hormone-independent  prostate  cancer
cells.  These results  allow us to  confidently establish a link between the
target genes and the miRNAs identified in this chapter and by implications
to pathways involved in PC. This evidence supports  our hypothesis  that
these miRNAs might have a role in the regulation of the development of
tumour cells, and thus possible implications in the progression of PC such
that they are potential biomarkers for PC diagnosis.
Furthermore, experimental evidence looking at the ubiquitously expressed
YWHAZ  protein  (a  target  gene  of  MiR9)  with  a  96%  confidence  as
depicted in Table 2.4. Recent research suggests that YWHAZ may play a
central role in regulating multiple pathways responsible for cancer initiation
and progression. 
A study by Murata et al., 2012 showed that the expression of YWHAZ was
up-regulated in LNCaP cells treated with androgen. Murata and colleagues
(2012)  also  found that  this  gene  provided favourable  conditions  for  the
survival  of prostate  cancer as it  contributed readily to cell  proliferation,
motility and acquired resistance to etoposide-induced apoptosis as a result
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of its ectopic expression in LNCaP cells (Murata et al., 2012; Rüenauver et
al., 2014).  Murata  (2012)  and  colleagues  further  investigated  the
clincopathological  influence  YWHAZ had  on  PC (Murata  et  al., 2012;
Rüenauver et al., 2014). This study revealed that YWHAZ had an increased
level of expression during the later stages of PC including  lymph-node
metastasis  (Murata  et  al., 2012;  Rüenauver  et  al., 2014).  YWHAZ was
described as an androgen-regulated tumour-promoting factor in PC cells by
this  study  (Murata  et  al., 2012;  Rüenauver  et  al., 2014).  These  finding
strongly suggest  a link between the target  gene YWHAZ and  miRNAs
identified lending more credibility to the miRNAs as biomarkers for PC. 
No direct links to known regulators of cancer were identified for ING4,
PAK7, CLN8, CSRNP3, ACVR1C, ADNP using STRING. However, in a
recent study by Berger and colleagues (2014) they identified the chromatin
remodelling protein,  ING4, as a  crucial  switch downstream of Myc and
Pten  that  is  required  for  human prostate  epithelial  differentiation.  Myc-
induced transient expression of ING4, is required for the differentiation of
basal epithelial cells into luminal cells, while sustained ING4 expression
induces  apoptosis  (Berger  et  al., 2014).   The  study  showed  that  ING4
expression is lost in >60% of human primary prostate tumours.  
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They  further  established  that   by  blocking  ING4 expression,  Pten  loss,
prevents differentiation and this phenomena is then  rescued by ING4 re-
expression (Berger et al., 2014). Pten or ING4 loss generates tumour cells
that co-express basal and luminal markers, indicating prostate oncogenesis
occurs through disruption of an intermediate step in the prostate epithelial
differentiation  program  (Berger  et  al., 2014).   This  finding  led  to  the
identification of a new epithelial cell differentiation switch involving Myc,
Pten,  and  ING4,  which  when  disrupted  leads  to  prostate  tumorigenesis
(Berger  et al., 2014). There has been no previous studies indicating that
Myc over-expression and Pten loss are common genetic abnormalities in
prostate cancer. The study by Berger  (2014) is the first demonstration that
transient  ING4  expression  is  absolutely  required  for  epithelial
differentiation, its expression is dependent on Myc and Pten, and it is lost in
the majority of human prostate cancers. 
The study by Berger and colleagues in 2014 is the first demonstration that
the loss of function of ING4, either directly or indirectly through loss of
Pten  function,  promotes  Myc-driven  oncogenesis  by  deregulating
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differentiation (Berger et al., 2014). The results from Berger (2014) is thus
the first evidence that links the function of the identified target genes in
relation to PC and by implication,  supports the notion that the miRNAs
that  regulate  the  expression  of  these  target  genes  are  vital  in  the
proliferation of PC.  Based on the ontology data retrieved from the target
search  for  these  genes,  they  showed  strong  association  to  apoptosis
regulation  and  cell  growth.  Therefore,  they  were  selected  as  potential
targets of the identified miRNAs as shown from the analysed data in Table
2.4 and Figure 2.6, 2.7 and 2.8.
From the expression profiling results as described in section 2.2.6 and as
depicted  in  Figure  2.10,  of  the  21  genes  targeted  by  the  selected  13
miRNAs, it is clear that there is a link between the expression of the target
genes and the progression of cancer. Furthermore, there is clear evidence
that these target genes are further implicated in PC as seen in the level of
fold change expression in PC tissue as depicted in Figure 2.10. As a result
of  these  genes  being  targeted  by  the  13  miRNAs  of  interest  we  could
deduce that these miRNAs could play a potential role in the progression of
disease and specifically in the progression of PC. 
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Pathway Analyses performed using DIANA as described in section 2.2.7
and presented in Figure 2.11 represents a heat map of the 8 unique miRNAs
that were not associated with PC in the public databases.  Five miRNAs
(MiR1, 3, 4, 5 and 8) showed a very strong association with PC based on
log scores retrieved from the database, whereas MiR2, 6 and 7 showed a
slightly weaker association with PC. Based on the data shown in Figure
2.11 the five miRNAs that showed strong association with PC, also have
predicted associations with other cancers.  These findings in combination
with the expression profiling,   functional annotation and cluster analysis
results further implicates the identified miRNAs in cancer causing and PC
pathways. 
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CHAPTER 3
Molecular validation of identified miRNAs as biomarkers for the early
detection of Prostate Cancer (PC) using qRT-PCR
3.1 Introduction
MicroRNAs  (miRNAs)  are  short  strands  of  RNA  that  act  as  post-
transcriptional  regulators.  Current  research  on  miRNA  expression  in
various disease processes from cancer to cardiovascular disease indicates
that miRNAs play a vital role in disease pathogenesis and have potential as
biomarkers and therapeutic agents (Buckingham, 2003; Nilsen, 2007; Zhao
and Srivastava, 2007; Tanzer et al., 2008; Sotiropoulou et al., 2009; Sato et
al., 2011; Martinez-Sanchez and Murphy, 2013). 
Routine diagnostic methods for the early detection of PC include digital
rectal  examination  (DREs)  and  prostate-specific  antigen  (PSA)  testing
(American Cancer  Society, 2012;  CANSA, 2013).  The PSA test  is  non-
specific,  due  to  the  fact  that  elevated  PSA levels  measured  in  benign
prostatic hyperplasia (BPH), infection, and/or chronic inflammation, may
lead  to  confounding  outcomes.  Other  blood  based  biomarkers  such  as
human glandular kallikrein 2 (hK2), urokinase plasminogen activator (uPA)
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and  its  receptor  (uPAR),  transforming  growth  factor-beta  1  (TGF-  β1);
interleukin-6 (IL-6) and its receptor (IL-6R) have been studied alone or in
combination with PSA and suggested for diagnosis, staging, prognostics,
(Ishiguro  et  al., 2009,  Nguyen  et  al., 2014).  and monitoring of  prostate
cancer.  However,  since  we  are  studying  a  disease  that  has  a  highly
heterogeneous  nature,  there  is  a  an  urgent  need  to  identify  additional
biomarkers for better prediction of disease progression and prognosis to aid
in clinical decision making with respect to treatment options.
MicroRNAs (miRNAs) are small (18 to 25 nucleotides), highly conserved,
non-coding  RNA  molecules  that  regulate  gene  expression  post-
transcriptionally  (Buckingham,  2003;  Nilsen,  2007;  2007;  Tanzer  et  al.,
2008; Sotiropoulou et al., 2009; Sato et al., 2011). Computational analysis
performed on miRNA expression profiles suggests that more than 60% of
gene transcripts  in  mammals  are  potentially  regulated  by miRNA either
directly  or indirectly  (Zhao and Srivastava,  2007;  Martinez-Sanchez and
Murphy, 2013). miRNAs play key regulatory roles in cell cycle control, cell
proliferation  and  differentiation,  and  the  regulation  of  apoptosis
(Buckingham, 2003; Nilsen, 2007; Zhao and Srivastava, 2007; Tanzer  et
al., 2008; Sotiropoulou  et al., 2009; Sato  et al., 2011; Martinez-Sanchez
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and Murphy, 2013). Recent studies have implicated various miRNAs in the
development  and  progression  of  multiple  human  cancers  and  also  as
potential biomarker in cancer diagnosis and prognosis (Li et al., 2009).
In the present study, we utilized qRT-PCR for the expression analysis of
miRNAs  identified  in  chapter  2,  which  offers  many  advantages  for
miRNAs with known sequences. Quantitative real-time PCR is considered
the gold standard for miRNA expression profiling  due to its unparalleled
sensitivity and specificity (van Rooij, 2011; Dedeoğlu, 2014; Stokowy  et
al., 2014; Usó  et al., 2014). Some of the main advantages of using this
methods  includes  (a)  high  sensitivity  to  the  single  cell  level,  (b)  high
specificity to the disease of interest, (c) it does not require a large volume
of RNA (Usó  et al., 2014) and (d) that it is a high throughput technique.
Additionally, this method is less time-consuming compared to microarrays
and NGS and the results do not require to be analysed/processed by bio-
statisticians (Usó et al., 2014).
Expression profiling of the identified miRNAs was performed in 3 prostate
cell  lines  a  Benign  prostatic  hyperplasia  (BPH1),  metastatic  cancer
(LNCaP) and 1 corresponding  normal control (PNT2C2) cell line to study
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the  expression  of   miRNAs  associated  with  the  detection  of  PC.  The
identified miRNAs were further validated in a larger sample set consisting
of an additional 6 non PC cancer cell lines and two adjacent normal control
cell lines. Our main aim therefore was to establish which of the  in silico
identified miRNAs were specific for PC, and secondly whether a definitive
miRNA profile for PC could be established  to distinguish it from the rest
of  the  cancer  cell  lines  using  qRT-PCR.  The  expectation  was  that  each
cancer cell line will have a unique miRNA profile, and that these unique
profiles could be used to differentiate cancer types from each other and
potentially for diagnostics.
The main aim of this section of the study is thus to molecularly validate the
identified  miRNAs (in  Chapter  2)  as  potential  biomarkers  for  the  early
detection of  PC using qRT-PCR.
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3.2 Molecular Methods:
For the molecular validation part  of this study 11 human cell lines were 
cultured and tested in Phase II of the study.
Figure:  3.1 Flow chart  representing the methodologies employed  in
Phase II of the study.
                                    140
 
 
 
 
Table 3.1:  Tabular representation of the cell lines used to investigate
the  specificity  and  sensitivity  of  miRNA  1-8  in  cancer.  Column  1
represents  the  ATCC  cell  line  name.  Column  2,  3  and  4  gives  the
description  and status  of  each  cell  line  at  the  point  of  immortalization,
respectively.   Column  5  and  6  indicates  the  media  and  supplement
requirement for optimal growth. 
Name Description Status Cell type Media used Supplement
BPH1 Benign Prostatic 
Hyperplasia
Benign Prostate
adherent
RPMI 1640 FBS, Penstrep
LNCaP AR-sensitive 
human prostate 
adenocarcinoma 
Maligna
nt
Prostate
suspension
RPMI 1640 FBS, Penstrep
PNT2C2 Human prostate 
epithelial
Normal Prostate 
adherent
RPMI
164 0
FBS, Penstrep
MCF7 Michigan cancer 
foundation 7
Cancer Breast
adherent
DMEM FBS, Penstrep
MCF12
A
Michigan cancer 
foundation 12 
epithelial
Normal Breast 
mammary gland
adherent
DMEM-F12 FBS, Penstrep, 
Insulin, hydro-
cortisone
HePG2 Liver Carcinoma Cancer Liver, adherent DMEM FBS, Penstrep
A549 Adenocarcinoma  
human alveolar 
basal epithelial 
cells
Cancer Lung, adherent DMEM FBS, Penstrep
Caski Cervical  
squamous 
carcinoma
Cancer Cervical 
adherent
RPMI 1640 FBS, Penstrep
CaOV3 Adenocarcinoma 
primary ovarian
Cancer Ovarian
adherent
DMEM FBS, Penstrep
HT29 Colorectal 
adenocarcinoma
Cancer Colon, adherent DMEM FBS, Penstrep
KMST Embryonic 
Fibroblast
Normal Skin, adherent DMEM FBS, Penstrep
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Table 3.1 above represent the cell lines used in this study. The panel was
selected to contain 3 prostate cell  lines two of which were classified as
malignant PC and benign  Prostate  (LNCaP and BPH1 respectively). The
third cell line PNT2C2 served as the control cell line for prostate cancer.
These  3 cell  lines  were  selected  to  represent  different  types  of  prostate
tissue  including  PC as  well  as  to  determine  whether  miRNA 1-8  were
differentially expressed in PC. 
The other  cell  lines  indicated  in  the  table  represented  different  cancers.
These cell lines were selected to evaluate the differential expression of the
eight  miRNAs.  The  main  purpose  of  this  was  to  establish  whether  the
selected miRNA was specific to prostate cancer or if it was expressed in
other cancers. 
3.2.1 Cell Culture
 Thawing frozen cells for tissue culture
The  following  protocol  describes  a  general  procedure for  thawing  cryo
preserved cells.  For  detailed  protocols,  refer  to  the  cell-specific  product
insert. Cryovials containing the liquid nitrogen frozen cells were removed
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from storage and placed in a 37 °C water bath. Cells were thawed rapidly
for less than 1 minute until only a small piece of ice remained in the tube.
The tubes were transferred to a laminar flow hood and wiped down with
ethanol at a concentration of 70% before opening the vials. A volume of 1
ml of pre-warmed complete media was added drop wise  to the cryovial
containing  the  thawed  cells.  The  cell  suspension  was  centrifuged  at
approximately  200  ×  g  for  5–10  minutes  using  a  Sorval  H400  TC6
centrifuge (American Instrument Exchange, Inc.). The actual centrifugation
speed  and  duration  varies  depending  on  the  cell  type.  Following
centrifugation the clarity of the suspension and the visibility of the pellet
was checked. Thereafter the supernatant was aseptically decanted without
disturbing the pellet that was formed following centrifugation. The pellet
was then re-suspended in complete growth media and transferred to a T25
cell culture flasks and incubated at  37 °C in 5% CO2 for 24 -72 hours
depending on the cell line
 Counting cells using a haemocytometer
The  procedure  below  provides  a  general  description  on  the  use  of  the
hemacytometer.  The  chamber  and  cover  slip  was  cleaned  with  alcohol,
thereafter it was dried and fixed in position. Cells were then harvested  and
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10 μL  of cells were added to the cover slip. The chamber was then placed
under  an  inverted  light  microscope (Nikon TMS-F)   with  a  Leica  EC3
digital Camera (Leica Microsystems Ltd) attached and visualised using  the
10X magnification setting and  phase contrast to distinguish the cells. Cells
were then counted in the large, central gridded square (1 mm2).  In order to
estimate the amount of cells per mL the counted cells were then multiplied
by 107. Duplicates were prepared in order to average the cell count
 Cryopreservation of mammalian cells   
Mammalian  cells  are  cryopreserved  to  avoid  loss  by  contamination,  to
minimize genetic change in continuous growth of  cell lines, and to avoid
ageing and transformation in finite cell lines. Before cryopreservation, cells
were  characterized  and  checked  for  contamination  through  visual
inspection. 
Cryopreservation  media  generally  consists  of  a  base  medium,
cryopreservative,  and a protein source.  The cryopreservative and protein
protect the cells from the stress of the freeze-thaw process. A serum-free
medium has generally low or no protein; but can still be used as a base for a
cryopreservative medium. Cryopreservation was carried out on suspension
as well as adherent cultures.
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 Suspension cultures 
For suspension cultures the number of viable cells to be cryopreserved was
counted. Cells should be in the log phase of the growth cycle. The cells
were centrifuged at ~200 to 400 × g for 5 min to pellet the cells. Thereafter
a pipette was used to remove the supernatant down to the smallest volume
without  disturbing  the  pelleted   cells.  Cells  were  then  re-suspended  in
preservation media to a cell count of 1 x 107 to 5 x 107 cells/ml for serum
containing medium, or 0.5 x 107 to 1 x 107 cells/ml for serum-free medium.
Cells were then aliquoted into cryogenic storage vials and placed on ice in
order  to  start  the  freezing  process.  Cells  were  then  frozen slowly  at  -1
°C /min, this was achieved by placing the vials into an insulated box and
placing it in a -70 °C to -90 °C freezer.
 Adherent cultures   
Cells were detached from the substrate with a dissociation agent namely
trypsin, this procedure was done as gently as possible to avoid irreparable
damage to  cells.  Trypsinisation is  the  process  of  cell dissociation  using
trypsin,  a  proteolytic  enzyme which breaks  down proteins,  to  dissociate
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adherent  cells from the  vessel  in  which  they  are  being  cultured.  When
added to a cell culture, trypsin breaks down the proteins which enable the
cells to  adhere to  the vessel.  Cells  were then re-suspended in  complete
growth medium and a viable cell count was established. Cells were then
centrifuged  at  ~200  g  for  5  min  to  pellet  cells.  Using  a  pipette,   the
supernatant was removed down to the smallest volume without disturbing
the pelleted cells. Cells were then re-suspended  in preservation media to a
concentration  of  5  x  106 to  1  x  107 cells/ml  and  then  aliquoted  into
cryogenic storage vials. Vials were then placed on ice in order to start the
freezing  process.  Cells  were  then  frozen  slowly  at  -1°C /min,  this  was
achieved by placing the vials into an insulated box and placing it in a -70°C
to -90°C freezer.
3.2.2 Preparation of sample material
Preparation  of  cells  for  RNA extraction  was  done  as  follows.  Cultured
animal  cells  were  harvested  at  a  cell  count  of  106   cells.  Cells  were
transferred to  a  centrifuge  tube  and transported  on ice  to  the extraction
laboratory. Cells were centrifuged at a low centrifugal force of 200 × g for
10 min at 15-25 °C. Thereafter, the supernatant was removed carefully to
not disturb the pellet that was formed. The cells were then lysed by adding
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150 µL of a 20 % binding buffer solution and homogenised by pipetting the
suspension up and down until the solution become clear. The lysate was
then passed through a 20-gauge needle of 0.9 mm thickness which was
attached to  a sterile syringe. The homogenate was then centrifuged for 2
min at maximum speed using a bench top centrifuge to ensure that all cells
were homogenised and the  supernatant was transferred to a sterile tube for
step one of the RNA isolation process. Similar procedures were used for
sample preparation of suspension and adherent cultures.
All the cell lines were grown under specific conditions as described above
in  section  3.2.1.  Briefly,  cell  lines  were  cultured  under  general  tissue
culture  conditions  at  37°C. in  5%  carbon  dioxide  for  24-96  hours
depending on cell type. Cells were cultured until confluency was reached.
Once  cells  reached  confluency  cells  were  divided,  sub-cultured  or
cryopreserved as described above in section 3.2.1. The remainder of the
cells were used for further experimentation. Cells in the remaining flasks
were prepared for miRNA extraction as described in section 3.2.3. A cell
count  was  done  using  a  haemocytometer  as  described  in  section  3.2.1
Flasks  containing  no  more  than  1000000  cells  were  used  for  miRNA
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extraction
3.2.3 miRNA isolation technique: two column protocol 
For the two column protocol 150 μL of  the cell lysate was transferred to a
sterile micro-centrifuge  tube. A volume of 312 μL  of the binding buffer
was added to the lysate  and the tube was vortexed briefly thrice at 5 s
intervals.  A high pure  filter  and collection  tube  was combined and the
homogenate and binding buffer was placed into the upper reservoir of the
filter. The combined tubes were then centrifuged for 30 s at 13000 × g and
the flow-through collected. Thereafter 200μL  of  binding enhancer was
added to the flow-through. A new high pure filter and collection tube was
assembled and the mixture was transferred to the filter tube in the upper
reservoir. The tubes were then centrifuged  for 30s at  13000 × g and the
flow-through was discarded. Thereafter 500 μL of wash buffer was added
to the upper reservoir and the tubes were centrifuged  for 30s at 13000 × g
and again the flow-through was discarded. Following this step,  300 μL  of
wash buffer was added and once again the tubes were centrifuged for 30 s
at 13000 × g and the flow-through discarded. Once the filter is optimally
washed the filter was dried by centrifuging for 1 min at  13000 × g. The
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filter was then transferred to a clean 1.5 ml microcentrifuge tube and 100
μL  of Elution buffer was passed through the filter. The filter and elution
buffer was subsequently incubated for 1 min at 15-25  °C. Thereafter the
tube  and  filter  was  centrifuged  for  1  min  at  13000 ×  g.  The
microcentrifuge tube  containing the eluted miRNA was used in upstream
molecular techniques and was stored at  -80 °C.  After completion of the
miRNA extraction the quality and concentration of the miRNAs extracted
was  measured  using  the  Qbit  assay  (according  to  the  manufacturer's
instructions),  as  the  miRNAs  could  not  be  visualized  by  normal  gel
electrophoresis due to its small size.
3.2.4 Primer Design
Parameters for Primer design of miRNAs for RT-PCR were obtained using
the  Cotton  estate  Database  which  is  available  at  the  following  URL:
http://www.leonxie.com/miRNAprimerDesigner.php#.  MiRNA sequences
were  used  as  the  input  for  this  primer  design  database.  The  database
identified primers specific for the sequences uploaded by using a built in
algorithm that scans available public data that have been experimentally
validated. The miRNA primer designer has been developed for favouring
designing of miRNA primers and qRT-PCR primers for miRNA expression
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profile assay. The following parameters were used to design primers for the
identified  miRNAs  (Table  3.2).  All  primers  were  designed  to  have  an
average Tm of 60 ºC.
Table 3.2 : Tabular representation of the parameters used for in silico
primer design 
Reverse primer: ATCCAGTGCAGGGT
CCGAGG
RT adaptor GTCGTATCCAGTGCAG
GGTCCGAGGTATTCGC
ACTGGATACGA
Forward adaptor: GCGGCGG
Length of RT primer 6
Optimum length of forward primer: 13
Minimum length of forward; primer: 15
Maximum length of forward primer: 17
3.2.5 Reverse transcription of miRNA to cDNA using stemloop 
sequence specific primers
For cDNA synthesis the protocol used was according to the manufacturer’s
instruction,  with  the  only  alteration  being the  use  of  specific  stem-loop
primers as opposed to the oligo-dT and random hexamers provided by the
manufactures  (Transcriptor  First  Strand cDNA synthesis  kit,  Roche Life
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Science).  In a total volume of 20 μL, 1 µg miRNA was mixed with 2.5 µM
stemloop primer, 1 x Transcriptor Reverse Transcriptase Reaction Buffer
(containing  8  mM  MgCl2),  20  U  Protector  RNase  Inhibitor,  4  mM
Deoxynucleotide Mix and 10 U Transcriptor  Reverse Transcriptase.  The
reaction was incubated at 55 °C for 30 min followed by a final inactivation
step of  5 min incubated at  85 °C. The concentration of the synthesised
cDNA was determined with a NanoDrop Spectrophotometer ND1000.
3.2.6 Validation of miRNA expression levels in cancer and control cell 
lines using PCR and  qRT-PCR. 
◦ End-point PCR protocol
For the end point protocol a PCR master mix was prepared by scaling down
the  volumes  to  20  μL.  In  order  to  overcome  pipetting  errors,  a  10%
coverage was included. Internal controls were prepared by adding nuclease
free water in place of the cDNA products. Nuclease free water, PCR buffer
with a final concentration of 1X, dNTP mix with a final concentration of 10
mM, forward and reverse primers with a final concentration of 1μM each
and  Taq Polymerase 2 (1X), was added to a microcentrifuge tube to make
up the master mix. aliquotes of 19 μL of the master mix and 1 μL of cDNA
with a final concentration of 250 ng/μL was added to individual PCR tubes.
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Reactions were then placed in a preheated (94°C) thermal cycler heating
block and incubated at 94°C for 2 min, followed by 20–40 cycles of 94°C
for 15s and 60°C for 1 min and 72ºC for 10 min. The reaction products
were then  analysed  by electrophoresis  on a  2% agarose  gel  in  1× TAE
buffer.
◦ miRNA SYBR Green I assay protocol for qRT-PCR
A  5×  LightCycler  FastStart  SYBR  Green  I  master  mix  was  prepared
(Kappa Sybr fast Master Mix) according to the manufacturers instructions.
In all qRT-PCR reactions, a standard reaction mix was prepared containing
KAPA SYBR FAST® Optimized for  LightCycler®480 (KAPA Biosystems).
miRNA-specific stem-loop primers were designed as described in section
3.2.4 and optimised  with a standard end-point PCR using a TA of 60°C  for
all  primers.  PCR  master  mixes  were  prepared  by  scaling  the  reaction
volumes to 20 μL. In order to overcome pippetting errors a 10% coverage
was  included.  Internal  controls  were  prepared  by  adding  nuclease  free
water in place of the cDNA products. Nuclease free water, Kappa Master
Mix and 1μM of both the  forward and reverse primers  were added to a
microcentrifuge  tube  to  make  up  the  master  mix.  Master  mixes  were
prepared for each primer set that was to be tested. A  96 well Real Time
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PCR plate was placed on ice and used for the RT-PCR reactions. Aliquotes
of 16 μL master mix was pipetted into each well of the 96 well plate, 4  μL
of the respective  cDNAs was added to each of the wells. The plate was
then covered with a clear foil seal and centrifuged to bring all the solutions
to the bottom of the wells of the plates . The plate was then transferred to
the Light Cycler 480 instrument and incubated at 95°C for 5 min, followed
by 45–50 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 10 s.   For
melting curve analysis, the samples were  denatured at 95°C, then cooled to
65°C at 20°C per second. Fluorescence signals were collected at a 530 nm
wavelength  continuously  from 65°C to  95°C at  0.2°C per  second.  The
results  were  analysed  using  the  REST  software  package  (Pfaffl  et  al.,
2002).
◦ Standard Curves
A standard curves for each primer set  was prepared by using a dilution
series of the experimental sample expected to have the highest expression.
Alternatively, standard curves could be prepared from a dilution series of an
appropriate RNA oligonucleotide, e.g. when detecting artificial miRNAs or
siRNAs.
                                    153
 
 
 
 
◦ Relative Quantification
The  relative  standard  curve  quantification  method  was  employed  to
quantify the expression levels of miRNA in all the cell lines. This method
relies on the use of both a target and reference gene(s) to be measured in a
serial dilution format, in order to construct a standard curve which will be
used to calculate the relative expression of each miRNA. Standard curves
were generated using a dilution series in the concentration range 500 ng-
0.05  ng.  The  data  generated  was  analysed  using  the  publicly  available
Microsoft® Excel®-based software REST© (Pfaffl et al., 2002).
Pfaffl  developed  a  mathematical  formula  widely  used  for  the  relative
quantification of gene expression in Real-time PCR (Pfaffl, 2001a). This
model  combines  gene  quantification  and  normalization  with   an
amplification efficiency of the target and reference genes. This calculation
can be based  on one sample (Souazé et al., 1996;; LightCycler® Relative
Quantification Software, 2001) or  multiple samples (Pfaffl, 2001a,, 2001b)
and their  formulas  are  given in  Eqs.  1-6 respectively. Reactions  for  the
determination of efficiencies of the genes should be run in a 5 or 10-fold
serially diluted sample. In new approaches, multiple reference genes is used
to  obtain  more  stable  and reliable   results  (Pfaffl,  2002).  An efficiency
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corrected  calculation  models,  based  on  multiple  samples  and reference
genes  (so-called  REF  index),  should  consist  of  at  least  three  reference
genes (Pfaffl, 2001b). 
Analysis  of the raw data  in  precise mathematical  and statistical  manner
should be performed rationally in gene expression analysis. To calculate the
expression of a target gene in relation to an adequate reference gene various
mathematical  models  are  established.  Calculations  are  based  on  the
comparison  of  the  distinct  cycle  determined  by  various  methods,  e.g.,
crossing  points  (CP)  and  threshold  values  (Ct)  at  a  constant  level  of
fluorescence;  or  CP  acquisition  according  to  established  mathematics
algorithm Two types  of  relative  quantification  models  are  available  and
published: (1) without efficiency correction (see Eqs.1 and 2) (Livak and
Schmittgen, 2001 )
              (1)
             (2)
and (2) with kinetic PCR efficiency correction (Eqs.3-6). For a group-wise
comparison for more samples (up to 100), e.g.,  REST and REST-XL. The
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relative expression ratio of a target gene is computed, based on its real-time
PCR efficiencies (E) or a static efficiency of 2, and the crossing point (CP)
difference (∆) of one unknown sample (treatment) versus one control (∆CP
control - treatment). Using REST and REST-XL, the relative calculation
procedure is based on the MEAN CP of the experimental groups (Eq. 4) 
(3)
(4)
In these models the target-gene expression is normalized by a non-regulated
reference  gene  expression,  e.g.,  derived  from  classical  and  frequently
described  housekeeping  genes.  The  crucial  problem  in  this  relative
approach is that the most common reference-gene transcripts from so-called
housekeeping genes, whose mRNA expression can be regulated and whose
levels vary significantly with treatment or between individuals (Pfaffl et al.,
, 2002, Pfaffl et al., 2001). However, relative quantification can generate
useful and biologically relevant information when used appropriately. 
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            (5)
            (6)
The selection of an appropriate constitutively expressed reference gene for
qRT-PCR analysis  is  crucial  when  determining  the  expression  levels  of
genes and miRNA. It is necessary to compensate for differences, such as
inter-sample variances and amplification differences which can easily affect
the reliability  of qRT-PCR results.  An appropriate  reference gene would
exhibit constant expression in all tissues and under all conditions and would
thus allow for the comparison of samples (Kubista et al., 2006; VanGuilder
et  al., 2008).  Quite  a  large  selection  of  reference  genes  is  available
however,  none  are  as  effective  in  miRNA  studies  when  compared  to
measuring normal gene expression levels. In this study two housekeeping
miRNAs, Mir191a and miR17a, were selected and the housekeeping gene
(HKG),  GAPDH,  was  used  as  an  additional  control.  PTEN  expression
levels were also measured as an additional control for expression of a gene
under cancerous conditions. The results of the analysed data were plotted as
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X  versus  Y and  included  the  mean/  standard  deviation  (SD)  for  each
analysis.
3.3 Results
Conventional  PCR  was  performed  to  determine  whether  the  stem-loop
primers  designed  were  capable  of  exponentially  amplifying  the  miRNA
fragments  in  the  cDNA synthesised   from the  RT method  described  in
section 3.2.5. The PCR products were separated on  a 2 % agarose gel and
visualised using the UVP system. In Figure below  it is clear that miRNA 1-
8 fragments were amplified successfully and that different intensities in the
bands produced is visible as indicated in Figure 3.2.
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AB
Figure  3.2:  Representation  PCR  amplification  of  miRNAs  with
sequence specific primers for each cell line used in this study.  Bands
represent   miRNA 1-8  in  various  cell  lines.  In  (A)  BPH1,  LNCaP and
PNTC2 represent prostate cell lines, HePG2 and  A549 represent a colon
and a lung cell lines respectively. In (B) MCF7 and MCF12 represent breast
cell  lines  and  HepG2,  CaOV3  and  Caski  represents  lung,  ovarian  and
cervical cancer cell lines respectively.
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3.3.1 Determining the PCR efficiency for miRNAs 1-8 using a standard
curve:
In order to normalize the relative quantification of the miRNAs to internal
controls  (miRNA191A,  miRNA17A,  GAPDH  and  PTEN),  the  sets  of
crossing points for the reference genes were imported into REST (Relative
Expression  Software  Tool).  The chosen crossing points  were considered
during  the  calculation  process  of  the  software,  which  allowed  for
normalization  of  the  target  genes  with  the  reference  genes.  The
amplification plot for the reference gene GAPDH is shown in Figure 3.3
(a).  Figure 3.3 (b) shows the amplification plot for the miRNA5, plots for
the rest of the miRNAs and controls are present in Appendix B. In both
Figure 3.3 (a) and (b), evenly spread out slopes were observed. 
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3.3.2  Calculating the PCR Efficiency
The amplification efficiencies of the qRT-PCR reactions, performed with
serial dilutions of the templates, are based on the slopes of the standard
curves obtained. Table 3.3 shows the efficiencies of all the miRNAs and
housekeeping genes in the normal-, prostate cancer- as well as the other
cancer cell lines. These values range from 91-98 % and are highly similar,
indicating that a similar rate of amplification occurred for each miRNA.
The  amplification  efficiency  for  each  miRNA  was  used  in  the  REST
software to determine whether they were differentially expressed in cancer
cell lines when compared to their control non-cancerous cell lines. 
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3.3.3  Melting curve analysis
A melting curve ranging from 60°C to  95°C was constructed  for  every
reference  and  target  gene.  The  obtained  melting  curves  were  used  to
determine  whether  any  contamination,  mis-priming  (referring  to  the
annealing  of  primers  to  complementary  sequences  on  non-target  DNA),
primer-dimers (primers annealing to themselves), or other inconsistencies
occurred relating to the amplification process. The melting curve for the
reference gene GAPDH and miRNA5 are shown in Figure 3.4 (a) and 3.4
(b).  From the results it is evident that only one peak is observed (one Tm
per gene/miRNA) for both GAPDH and miRNA5. Melting curves for the
rest of the miRNAs as well as the controls is present in Appendix B.
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Figure 3.4 (a): Melting curve for the housekeeping gene, GAPDH, ranging
from 65 °C to 95 °C. 
Figure 3.4 (b): Melting curve for miRNA5, ranging from 65 °C to 95 °C.
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3.3.4 Expression Profiling
3.3.4.1 Determining the expression levels of internal controls across cancer
cell lines and control cell lines.
Figure  3.5:  Relative  expression  of  internal  controls  in  the  BPH1,
LNCaP and PNT2C2 prostate cell lines.  Where BPH1 is shown in blue
bars, LNCaP is shown in red bars and PNT2C2 is shown in green bars.
From Figure 3.5 the housekeeping miRNA's miRNA191A and miRNA17A
remain stable across the 3 tested prostate cell lines. GAPDH a known house
keeping gene shows no change in its expression in any of the cell  lines
tested.  Similarly  PTEN  a  known  general  cancer  biomarker   (Chu  and
                                    166
 
 
 
 
Tarnawski, 2004),   also showed no change in expression levels in the 3
tested prostate  cell lines.
Figure  3.6:  Relative  expression  of  internal  controls  in  MCF7  and
MCF12A breast  cell  lines.  Where  MCF7  is  shown  in  blue  bars  and
MCF12A is shown in red bars. 
Figure 3.6 shows the relative expression of the  4 internal controls which
included  2  miRNA  controls  namely  miRNA191A  and  miRNA17A,
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GAPDH  as well as PTEN in MCF7 and MCF12 A. From the graphs in
Figure 3.6 it is clear that GAPDH, miRNA191A and miRNA17A remained
stable across cell lines. PTEN showed a slight increase in expression in the
MCF7 (breast cancer) cell line however it  was not considered significant.
Figure 3.7: Relative expression of internal controls across 5 cancer cell
lines namely A549 (lung), HT29 (colon), HepG2 (liver), Caski (cervical)
and CaOV3 (ovarian) and KMST1 (normal) fibroblast cell line. 
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Figure 3.7 shows the relative expression of the 4 internal controls namely,
miRNA191A,  miRNA17A,  GAPDH  as  well  as  PTEN,  across  several
cancer cell lines compared to a KMST a normal cell line. From the data in
the  graph  it  is  shown  that  GAPDH,  miRNA191A  and  miRNA17A
expression remained stable  across  cell  lines.  The internal  control  PTEN
showed increased level  of expression across all  of  the cell  lines.  PTEN
showed a 2.46  fold expression ratio in the Caski cell line. In the HT29 and
CaOV3  cell  lines  an  expression  ratio  of   2  .35  fold  for  PTEN  was
observed . A549 and HepG2 showed a 1 fold increase in  expression for this
marker.
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3.4.1.2 Differential Expression analysis of MiRNA 1-8 across cell lines 
when compared to normal cell lines.
Table 3.4 Differential expression of miR1-8 in BPH1 in comparison to 
PNT2C2 cell lines.
MiRNA/ 
Gene Cell line Mean Ct Std error
Fold 
regulation
p-
value
GAPDH PNT2C2 18.19 0.04 0
BPH1 18.05 0.11 0 0
miRNA1 PNT2C2 34.67 0.33
BPH1 34.67 0.33 -1.098 0.178
miRNA2 PNT2C2 34.67 0.32
BPH1 34.67 0.27 1.046 0.214
miRNA3 PNT2C2 27.74 0.06
BPH1 25.24 0.21 5.129 0.002
miRNA4 PNT2C2 31.97 0.07
BPH1 31.93 0.03 -1.073 0.156
miRNA5 PNT2C2 28.17 0.03
BPH1 26.61 0.18 2.686 0.001
miRNA6 PNT2C2 35 0
BPH1 35 0 -1.098 0.321
miRNA7 PNT2C2 29.2 0.06
BPH1 29.03 0.03 1.022 0.551
miRNA8 PNT2C2 31.21 0.12
BPH1 31.84 0.19 -1.707 0.416
Table 3.4 is a representation of the descriptive statistical analysis performed
following the determination of the  expression levels for each miRNA. In
this table the expression levels of miRNA1-8 was compared between the
control prostate cell line, PNT2C2, and the benign prostate cell line, BPH1.
The data is represented by bar graphs in Figure 3.8 with the specific fold
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change  ratio  indicated  for  each  miRNA.  The  data  showed  that  two
miRNAs,  miRNA3 and  miRNA5 were  significantly  up-regulated  in  the
benign prostate  cell line by factors of 5 and 2.6 respectively as seen by the
highlighted values in Table 3.4 and blue bars in Figure 3.8. These identified
miRNA using a bioinformatics pipeline  were not shown to be up-regulated
in the prostate  previously by  in silico expression analysis using GEA as
described in section 2.2.7 and shown in Figure 2.10. 
Figure 3.8: Relative expression ratio plot comparing the expression of
miRNA  1-8  in  the   BPH1  (Benign  Prostate  Hyperplasia)  cell  line
compared to PNT2C2 (normal). 
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Table 3.5 Differential expression analysis of miR1-8 in LNCaP  in 
comparison to PNT2C2 cell lines.
miRNA
Cell line Mean Ct Std error
Fold 
regulation
p-
value
GAPDH PNT2C2 18.19 0.04 0
LNCaP 18.05 0.11 0 0
miRNA1 PNT2C2 34.67 0.33
LNCaP 35 0.17 -1.38 0.170
miRNA2 PNT2C2 34.67 0.32
LNCaP 34.57 0.09 -1.02 0.201
miRNA3 PNT2C2 27.74 0.06
LNCaP 26.30 0.21 2.47 0.003
miRNA4 PNT2C2 31.97 0.07
. LNCaP 32.03 0.09 -1.15 0.150
miRNA5 PNT2C2 28.17 0.03
LNCaP 25.96 0.04 4.263 0.001
miRNA6 PNT2C2 35 0
LNCaP 35 0 1.1 0.301
miRNA7 PNT2C2 29.2 0.06
LNCaP 29.07 0.07 -1.0 0.540
miRNA8 PNT2C2 31.21 0.12
LNCaP 28.05 0.12 8.1 0.001
Table 3.5 is a representation of the descriptive statistical analysis performed
for the  expression levels of miRNA1-8 for LNCaP and PNT2C2 cell lines
and the data represented as a bar graph as shown in Figure 3.9. The data
shows  that  three  miRNAs,  miRNA3  miRNA5  and  miRNA8  were
significantly up-regulated in the cancer cell line by factors of 2.5, 4 and 8
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respectively as seen by the highlighted values in Table 3.5 and the blue bars
in Figure 3.9 below. Tables containing the descriptive statistics for miRNA
1-8  across  the  remaining  cell  lines  tested  in  the  study  are  available  in
Appendix B. From the in silico expression analysis using GEA as described
in chapter 2 section 2.2.7 in Figure 2.11 miRNA3 was shown to be up-
regulated  in  PC however, miRNA5 and miRNA8 were not  found to be
previously up-regulated in PC using in silico analysis. 
Figure 3.9: Relative expression ratio plot comparing the expression of 
miRNA 1-8 in the LNCaP (Metastatic prostate carcinoma) cell line 
compared to PNT2C2 (normal prostate)
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Figure  3.9  shows  the  comparative  expression  analysis  of  miRNA1-8
between the control cell line, PNT2C2, and the prostate cancer cell line,
LNCaP. The cell line LNCaP is different from the BPH1 prostate cell line,
in  that  it  is  an  adenocarcinoma,  whereas,  BPH1  is  a  benign  prostatic
hyperplasia. The expression of miRNA8 differs in these two cell line, as it
is highly up-regulated in LNCaP, whereas it is unregulated in BPH1. The
two miRNAs, miRNA3 and miRNA5 are also up-regulated in LNCaP. This
finding is very important as it allows one to differentiate between Benign
prostatic hyperplasia and metastatic prostate cancer when compared to the
normal PNT2C2 prostate line using miRNA8. 
PTEN as shown in Figure 3.5 is also stably expressed between these cell
lines and the control cell line, indicating that it is not a useful biomarker to
distinguish between the benign (BPH1),  malignant (LNCaP) and normal
prostate  (PNT2C2)  cell  lines.  MiRNA8  is  also  highly  specific  to  only
LNCaP as it does not show any differential expression in any of the other
cancer cell lines evaluated in this study. However, this miRNA must still be
evaluated in prostate tissue to ensure its specificity and sensitivity. Also,
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additional cancer cell lines need to be tested to ensure that miRNA8 is not
up-regulated or down-regulated in other cancer cell types.
Figure 3.10: Relative expression ratio plot comparing the expression of 
miRNA 1-8 in the MCF7 (Breast) cell line compared to MCF12A.
Figure  3.10  shows  the  comparative  expression  analysis  of  miRNA1-8
between the normal breast control cell line, MCF12A, and the breast cancer
cell line, MCF7. Only one of the miRNAs, miRNA7, showed differential
                                    175
 
 
 
 
expression between the two breast cell lines. The rest of the miRNAs are all
expressed at the same levels between the MCF7 and MCF12A cell line. 
Figure 3.11: Relative expression ratio plot comparing the expression of 
miRNA1-8 in the A549 (Lung) cell line compared to KMST1 (normal)
Figure  3.11  shows  the  comparative  expression  analysis  of  miRNA1-8
between the KMST1 control cell line, and the lung cancer cell line, A549.
Three  of  the  miRNAs:  miRNA2,  miRNA3  and  miRNA7,  showed  up-
regulation  in  the  lung cancer  cell  line.  The rest  of  the  miRNAs are  all
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expressed at the same level. 
Figure 3.12: Relative expression ratio plot comparing the expression of
miRNA  1-8  in  the  HT29  (Colon)  cell  line  compared  to  KMST1
(normal) fibroblast cell line.
Figure  3.12  shows  the  comparative  expression  analysis  between  the
KMST1 control cell line, and the  colon adenocarcinoma, HT29. Three of
the miRNAs: miRNA-3, miRNA-4 and miRNA-7, showed up-regulation in
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the colon cancer cell line. The rest of the miRNAs are all expressed at the
same level when comparing their expression in HT29 to KMST.
Figure 3.13: Relative expression ratio plot comparing the expression of
miRNA  1-8  in  the  HepG2  (Liver)  cell  line  compared  to  KMST1
(normal)
From the data shown in Figure 3.13  two of the miRNAs: miRNA3 and
miRNA7, showed up-regulation in the liver cancer cell line. The rest of the
miRNAs  are  all  expressed  at  the  same  level  when  comparing  their
                                    178
 
 
 
 
expression  in  HepG2  to  KMST. The  known  cancer  marker  PTEN  was
significantly up-regulated in HepG2 as seen in Figure 3.7.
Figure 3.14: Relative expression ratio plot comparing the expression of
miRNA 1-8 in the Caski (Cervical) cell line compared to KMST1
Figure  3.14  shows  the  comparative  expression  analysis  of  miRNA1-8
between the KMST1 control cell line, and the  cervical carcinoma, Caski.
Three  of  the  miRNAs:  miRNA2,  miRNA4  and  miRNA5,  showed  an
expression  fold  change  of  5.4,  3.6  and  6.8  respectively  in  the  cervical
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cancer  cell  line.  miRNA3 was up-regulated  by  a  factor  of  2  and needs
further  investigation as to whether it  can be considered a biomarker for
cervical cancer. The rest of the miRNAs are all expressed at the same levels
when comparing their expression in Caski to KMST. The known cancer
marker PTEN (Chu and Tarnawski, 2004) was significantly up-regulated in
Caski as shown in Figure 3.7.
Figure 3.15: Relative expression ratio plot comparing the expression of
miRNA 1-8  in  the  CaOV3 (Ovarian)  cell  line  compared to  KMST1
(normal)
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Figure  3.15  shows  the  comparative  expression  analysis  of  miRNA1-8
between the KMST1 control cell line, and the ovarian carcinoma, CaOV3.
Only one of the miRNAs, miRNA5, showed up-regulation in the ovarian
cancer  cell  line.  The known cancer  marker  PTEN was significantly up-
regulated in CaOV3 as shown in Figure 3.7.
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Table 3.6 Summarized table of expression profiles for each miRNA in 
the different cancer cell lines  investigated.
PNT2C2 LNCaP BPH1 MCF7 MCF12 KMST1 CaOV3 Caski HepG2 A549 HT29
miRNA1 0 0 0
miRNA2 0 0 0 + +
miRNA3 0 + ++ 0 0 + + + +
miRNA4 0 0 0 + +
miRNA5 0 + + 0 0 + +
miRNA6 0 0 0 +
miRNA7 0 + 0 0 + + +
miRNA8 0 ++ 0 0
miRNA1
7A 0 0 0
miRNA1
91A 0 0 0
GAPDH 0 0 0
PTEN 0 0 0 + + + +
KEY: 0     - no expression
+     - over-expression
++   - highly over-expressed
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3.4 Discussion
The aim of this chapter was to molecularly validate the putative miRNA
biomarkers identified in Chapter 2 using qRT-PCR. The 8 miRNAs studied
in vitro were selected from an initial 40 based on their association with PC.
Based on the identified miRNAs strong association with PC, these miRNAs
were selected as potential biomarkers. The relative expression levels of the
miRNAs were  determined  with  qRT-PCR as  described  in  section  3.2.6.
Based on the number of variations in expression patterns that could occur
as a result of  (a) method of sample preparation or (b) cDNA synthesis, it is
pivotal to select good control miRNAs and/or genes to compensate for such
variations and to improve the reliability of qRT-PCR experiments.  
An  appropriate  reference  gene  would  exhibit  constant  expression  in  all
tissues and under all conditions and would thus allow for the comparison of
samples  (Kubista  et  al.,  2006;  VanGuilder  et  al.,  2008).  Quite  a  large
selection of reference genes is available however, none are as effective in
miRNA  studies  when  compared  to  measuring  normal  gene  expression
levels.  During the course of this study 4 controls were selected namely
miRNA191A,   miRNA17A,  GAPDH and  PTEN.  GAPDH is  a  suitable
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housekeeping gene as it is present in all nucleated cell types and mRNA
expression  of  this  gene  was  found  to  be  stable  in  different  cell  lines
including cancers (Hao et al., 2011; Mattie et al., 2006). 
The PTEN gene is known as a ‘tumour suppressor gene’ because deletion
of  the PTEN gene increases  the likelihood of developing cancer. PTEN
makes a protein that switches off the PI3K/AKT/mTOR signalling pathway,
which is  responsible  for cell  growth,  survival,  and movement (Chu and
Tarnawski, 2004). Cells require two copies of the PTEN gene to ensure that
they function properly. In prostate cancer cells, one or both copies of the
PTEN  gene  is  frequently  lost,  thus  allowing  the  PI3K/AKT/mTOR
signalling  pathway  to  trigger  uncontrolled  cell  growth,  survival,  and
movement. Recently, doctors have found that a loss of PTEN that occurs in
combination with an abnormal fusion of the genes TMPRSS2 and ERG is a
prognostic indicator of poorer outcomes (Chu and Tarnawski, 2004). PTEN
deletions have also been reported in glioma, melanoma, endometrial cancer,
kidney  cancer,  breast  cancer,  lung  cancer,  prostate  cancer,  and  upper
respiratory  tract  cancers.  As  a  result  of  the  above  evidence  PTEN  is  a
currently known cancer biomarker (Chu and Tarnawski, 2004).
Conventional PCR as shown in Figure 3.2 shows clear bands in each lane
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which is an indication of optimal amplification of cDNA using stem-loop
sequence specific primers. PCR results revealed that the RT method works
successfully for samples from cell culture as well as from tissue samples
(tissue results not shown here). Preliminary results showed that miRNAs
extracted from both cell  lines and tissue sample  are reverse transcribed
successfully as shown in Figure 3.2. It is evident from the figure that the
miRNA 1-8 differentially expressed across cell lines  based on the intensity
of the bands seen. The next step was to evaluate their expression levels in
three  prostate  lines  BPH1,  LNCaP and  PNT2C2  a  benign,  cancer  and
normal prostate cell line respectively. In addition, 6 other cell lines (five
cancer and one control) were also evaluated to determine the expression
levels and specificity of the miRNAs investigated. 
The identified biomarkers were molecularly validated using qRT-PCR as
described in section 3.2.6. PCR efficiencies were  calculated and tabulated
as indicated in Table 3.3. These values for each of the miRNAs as well as
the  controls, ranged from 91-98 % and are highly similar across cell lines.
These results indicate that a similar rate of amplification occurred for each
miRNA as well as for the controls.
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During the qRT-PCR assays performed, amplification efficiencies between
3.3 and 3.5 were obtained for the respective miRNAs as seen in Figure 3.3
(a) and 3.3 (b).These results indicate that an optimised qRT-PCR reaction
was performed for all primer sets tested in this study. All results for this
part of the analysis is displayed in Appendix B.
The  melting  peak  and  curve  analysis  for  all  the  miRNAs  showed  one
distinctive peak,  Melting peaks for GAPDH and miRNA5 are shown in
Figure 3.4 (a) and 3.4 (b), melting curves for the rest of the miRNAs can be
viewed in Appendix B.  As a result of the similarity between the  distinctive
peaks produced for both GAPDH and miRNA5 it can be deduced that only
the  expected  amplicon  was  amplified  and  that  no  contamination,  mis-
priming  or  primer-dimers  occurred  or  are  present  in  the  PCR reaction.
Therefore,  no  non-specific  amplification  occurred  and  it  is  evident  that
accurate quantification of the targets of interest has been achieved through
optimized qRT-PCR. 
The randomization test were performed using the REST software  (Pfaffl,
2002), to determine whether normalization via the reference miRNAs and/
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or genes were useful.  The results of the randomization test displayed the
factor of regulation of the standards and level of significance at which the
genes are being expressed, which indicated that the reference genes used
were suitable in this experimental trial (see Appendix B).  
The relative expression of the 4 controls were measured across all cell lines
tested in this study. Figure 3.5 shows the expression of the 4 controls in  the
3 prostate cell lines tested.  From the data shown  it is evident  that the
expression of all the controls remained stable in benign (BPH1), cancerous
(LNCaP) as well as in the normal prostate cell line (PNT2C2). Similarly in
the breast cancer cell line MCF7 the expression patterns of the 4 controls
remain  stable  as  seen  in  Figure  3.6.  However  when  investigating  the
relative expression of the 4 controls in the remaining cell lines tested during
this study, a different expression pattern was observed for PTEN, whilst the
rest of the controls remain stable across cell lines. PTEN was found to be
up regulated in all 5 of the additionally tested cell lines as seen in Figure
3.7. This finding was expected as PTEN is a known cancer biomarker (Chu
and Tarnawski, 2004)  and its expression levels are expected to be higher
in most cancer cell lines.
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In this part of the study we determined the expression levels of all eight
miRNA in two prostate cell lines, BPH1 (benign) and LNCaP (metastatic),
and compared it to the expression levels in the prostate control cell line,
PNT2C2 as seen in Figure 3.8 and 3.9 . This was to establish whether the
miRNAs were differentially expressed in benign and prostate cancer. The
data  showed  that  miRNA3  and  5  were  up-regulated  in  the  BPH1  and
LNCaP when compared to PNT2C2 (Figure 3.8). In addition miRNA8 was
also  shown to be up-regulated  in  LNCaP (Figure 3.9).   Based on these
results  we  could  establish  a  miRNA profile  to  distinguish  between  the
BPH1 and LNCaP prostate  cell  lines.  miRNA8 was  specific  to  LNCaP
(Table 3.6), and this result is supported by a study conducted by Coffey et
al., 2002, where CLFAR a target of  miRNA8 as indicated in table 2.4 was
strongly  associated  with  androgen-sensitive  human  prostate  cancer
(LNCaP). This study indicated that the androgen receptor pathway directly
targets CFLAR although the molecular mechanisms are not clearly defined.
MiRNAs 3 and 5, are implicated in cell growth and apoptosis regulation
respectively, which  are  common molecular  mechanisms  associated  with
cancers in general suggesting that BPH1 could be a very early precursor of
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PC.  This  notion  is  further  established  by  a  recent  study  by  Hung  and
associates where the association of BPH and PC was demonstrated in men
with  an  ethnic  low-risk  of  PC.  Asian  men  who  were  diagnosed  with
prostate cancer over a 10-year period and all of whom were over the age of
50 years had a strong association with prostatitis and/or BPH . There was a
higher odds ratio (OR) for prostate cancer associated with BPH (26.2, 95%
confidence interval (CI) 20.8-33.0) than with prostatitis (10.5, 95% CI =
3.36-32.7) (Hung et al., 2013).
Recent studies have further re-iterated the link between BPH and PC with
genetic  evidence.  With  the  utilization  of  technology,  such  as  next-
generation sequencing, it has provided us the ability to uncover disease-
related  variants  by  processing  large  genomic  intervals  in  a  rapid  and
thorough manner. Mutations in the HBOX13 gene have been established to
be  associated  with  the  development  of  prostate  cancer.  Saaristo  and
colleagues  assessed 100 single-nucleotide polymorphisms (SNP) in  over
500  men  with  BPH  who  either  remained  with  this  disease  or  later
developed prostate cancer (Saaristo et al. 2013). As expected, a mutation in
HBOX13  was  strongly  associated  with  the  prostate  cancer  specimens.
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However, BPH patients carrying this mutation had a 4.6 times greater risk
of developing prostate cancer compared to non-carriers (OR 4.56, CI 95%
1.29-16.11,  P = 0.0098). Interestingly, the average PSA levels at baseline
biopsy in both groups were very similar (BPH = 7.3 μg/l  (range 0.5-44
μg/l) and 8.0 μg/l (range 2.1-75 μg/l) respectively). This was the first study
to report genetic predisposition to developing PC in BPH patients and gives
a future potential of predicting those men with BPH who will later go on
develop PC (Saaristo et al. 2013).
In addition, we also determined the expression of the identified miRNAs in
breast cancer by comparing their expression profiles in MCF7, a cancer cell
line,  and  MCF12A a  normal  breast  cell  line  (Figure  3.10).  In  MCF7
miRNA7 was shown to be up-regulated when compared to the control cell
line, MCF12A.  In  the breast cancer cell line the effect of miRNA7 on the
development of cancer is not clear as the molecular mechanisms underlying
its target CLN8 is not defined. However, studies have suggested its role in
the  possible  regulation  of  apoptosis  as  one  of  CLN8's  main  functions
(Szafranska-Schwarzbach  et  al., 2011).  Numerous  studies  additionally
indicates the genes involvement in altered lipid metabolism, oxidative and
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ER  stress,  mitochondrial  dysfunction  and  inflammation  which  have
previously been described as hallmarks of cancer in chapter 1. This result
indicated that we could differentiate between breast cancer and PC by using
a combination of miRNA 3, 5 and 7.
Furthermore, we also compared the expression levels of the miRNAs in 5
other cancer cell lines which included A549 (lung), HT29 (colon), HEPG2
(liver),  Caski  (cervical)  and  CaOV3  (ovarian)  and  compared  it  to  the
control cell line, KMST1 derived from human fibroblast as seen in Figures
3.11-3.15. The data as depicted in Figures 3.11-3.15 showed that miRNA2
was up regulated in the A549 and Caski cell lines. It was further evident
from  the  data  in  the  above-mentioned  figures  that  miRNA3  was  up-
regulated  in  all  the  additional  cell  lines  tested  except  CaOV3  when
compared to the normal KMST1 cell line. MiRNA 4 was found to be up-
regulated in  the HepG2, HT29 and Caski cell lines. MiRNA 5 was shown
to be up-regulated in the Caski and CaOV3 cell lines as seen in figure 3.14
and  3.15  similarly  this  miRNA was  seen  to  up-regulated  in  BPH1 and
LNCaP (prostate cell lines), these results may suggest that miRNA5 may be
a regulator of  reproductive mechanisms that may lead to tumour formation
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and disease progression. MiRNA7 which targets the CLN8 gene as seen in
Table 2.4 was found to be up-regulated in the HepG2, HT29 and A549 as
seen in Figures 3.11-3.13 as well as in the MCF7 cell line as depicted in
Figure 3.10. Based on the key function of its target gene CLN8 being the
regulation of apoptosis as previously mentioned (Szafranska-Schwarzbach
et al, 2011), these results may suggest that miRNA7 could also  play an
integral role in the regulation of the the apoptosis process. 
Finally, the present study has shown as indicated in Table 3.6 that we can
use an individual as well as a  combination of all eight miRNA to create
unique profiles for all the cancer cell lines tested in this study. For example,
we could distinguish between Caski, a cervical cancer cell line, and CaOV3
an ovarian cancer cell line using a combination of different miRNAs e.g.
miRNAs2,  3  and  4  for  Caski  (Table  3.6).  Similarly  a  combination  of
miRNA2 and 3 as opposed to miRNA3 and 6,  could be used to distinguish
between A549 and HepG2 respectively. This is an important finding which
could have potential diagnostic applications in clinical practice.
The  results  obtained  suggest  that  one  miRNA  on  its  own  could  be
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sufficient to differentiate between benign and  cancer cell lines, however it
should not be disregarded that by creating a unique profile for each cancer
cell line by using a combination of miRNAs is a possible approach as well.
The results also suggest that some of these cancers could share common
molecular mechanism as the same miRNAs were differentially expressed
across cancerous cell lines (Table 3.6). The identified miRNAs were shown
to regulate the expression of  the same target genes as depicted in Table 2.4
in chapter 2 .
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CHAPTER 4
General Discussion
Prostate cancer (PC) is the most frequent tumour in men and a major cause
of cancer-related morbidity and mortality. The current marker of choice is
PSA,  but  this  marker  lacks  sensitivity  and  specificity.  The  recent
controversial recommendation against the use of PSA in PC screening has
highlighted the importance of developing new clinical biomarkers for PC
(Gulati  et  al., 2012).  The  diagnostic  application  of  PSA  has  led  to
widespread  over-diagnosis  and  subsequent  over-treatment  of  clinically
insignificant tumours (Simmons et al., 2011; Stavridis et al., 2010; Wolf et
al., 2010. This problem will  very likely increase with rising life expectancy
as more men become more elderly (Simmons et al., 2011). 
The  use  of  biomarkers  in  PC detection  and  screening  is  crucial  to  the
diagnosis and management of the disease. Currently, no biomarker on its
own is  able  to  overcome the  issue  with  specificity  with  regards  to  PC
detection, and in particular early detection of PC (Dayeti et al., 2012). This
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study attempted to address some of the concerns surrounding the need  of
novel biomarkers that can aid in the early detection of PC. In this study  the
aim was to identify miRNAs that are implicated in PC and to utilize these
miRNAs as  a  tool  to  identify  the  presence  of  PC by  determining  their
expression profiles  in  PC cells  and comparing it  to  non-PC cells.  Their
expression levels in other cancer cell lines were also evaluated to determine
specificity of these markers in PC.
There is considerable excitement surrounding the use of miRNAs in the
biomarker field,  which is  well  founded given their  stability  and relative
ease  of  detection  (Li  et  al.,  2007;  Park  et  al.,  2009).  Unlike  mRNA,
miRNAs  show  high  stability  in  different  types  of  biological  samples,
i.e.,formalin-fixed,  paraffin-embedded  clinical  tissue,  fresh  snap-frozen
material, plasma or serum, saliva and urine (Li  et al.,  2007; Chen  et al.,
2008; Mitchell et al.,  2008;  Park et al.,  2009) . This high stability is due
to their resistance to endogenous and exogenous RNAse activity, extreme
temperatures,  extremes  of  pH (pH 1 to  13),  extended storage  in  frozen
conditions, and reheated freeze-thaw cycles (Mitchell et al.,  2008; Gilad et
al.,  2008). Resistance to such hazardous conditions has been attributed to
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the encapsulation and association with protein complexes (Vickers  et al.,
2011;  Arroyo  et  al.,  2011;  Valadi  et  al.,  2007;  Collino  et  al.,  2010
Zernecke  et  al.,  2009  ).  However,  currently  their  use  is  limited  by
conflicting  data  between  studies,  due  to  the  lack  of  standardisation  in
methodology  and the  lack  of  suitable  reference  genes  for  normalisation
(Dayeti et al., 2012). It is unlikely that any single miRNA will achieve the
desired level of diagnostic or prognostic accuracy, as evidence is indicating,
that increased levels of particular miRNAs can be associated with several
different types of tumours (Vickers et al.,  2011; Arroyo et al.,  2011; Valadi
et al.,  2007; Collino et al.,  2010 Zernecke et al.,  2009 ). However a panel
of these biomarkers can serve as a signature of specific cancers.
There is evidence from in vitro and in vivo studies that alteration in miRNA
function plays a role in prostate carcinogenesis (Berger  et al., 2014 and
Murata et al., 2012). MiRNA dysregulation influences a number of critical
cellular processes involved in carcinogenesis, including but not limited to:
stimulation  of  the  cell  cycle,  avoidance  of  apoptosis,  epithelial-
mesenchymal transition and modulation of AR-mediated signalling (Ozen
et  al., 2008;  Clape  et  al., 2009;  Fu  et  al., 2010;  Schaefer  et  al., 2010).
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Further  understanding  of  the  functional  importance  of  miRNA
dysregulation  may  allow  the  development  of  novel  diagnostic  and
therapeutic strategies involving miRNA augmentation or inhibition in the
future.  Circulating miRNA profiling in prostate cancer patients has been
carried  out  by  various  investigators,  but  studies  thus  far  have  involved
small  numbers  of  patients,  and  a  variety  of  methodologies,  and  have
yielded heterogeneous results (Dayeti et al., 2012). The potential to detect
circulating miRNAs in serum and potentially, in urine, clearly exists  (Chen
et al.,  2008; Mitchell  et al.,  2008; Li  et al.,  2007; Park  et al.,  2009).
Furthermore,  despite  the  variability  of  results  in  previous  studies,   the
present study indicates that there are a number of miRNA targets that have
both  a  demonstrable  functional  role  in  prostate  pathogenesis  and  have
demonstrated over- or under-expression when comparing normal prostate
cells to prostate cancer cells (Coffey et al. 2002 and Ishiguro et al., 2009).
Further  investigation of these miRNAs, either singularly or as part  of a
panel,  in  larger,  prospective  patient  cohorts  will  help  to  define  their
potential role as diagnostic and prognostic biomarkers in the future. It is our
belief  that  it  will  not  be  long  before  a  miRNA-based  diagnostic  test  is
launched  for  prostate  cancer,  as  has  recently  been  done  for  pancreatic
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adenocarcinoma (Szafranska-Schwarzbach et al., 2011).
Initially, a  rigorous  bioinformatics  approach  was  used  to  identify  novel
miRNA biomarkers associated with PC. The study identified 40 miRNA
using an “in-house” generated bioinformatics pipeline compared to the 20-
30 miRNAs already  housed in public databases using alternative methods.
The  pipeline  established  “in-house”  allowed  for  the  identification  of
additional miRNAs that were not present in the public databases or showed
a connection to PC previously.  These 40 miRNA were narrowed down to
13 potential  PC miRNA biomarkers  based  on the  gene  targets  of  these
miRNAs that are linked to PC, or other processes that are important in the
development of cancers. This prioritization was done by Gene Ontology
analyses and Functional Annotation studies performed using DAVID. These
included  processes  such  as  cell  growth,  proliferation,  regulation  of  cell
death  and  apoptosis.  STRING  analysis  was  also  performed  to  identify
possible  protein-protein  interactions  based  on  experimentally  validated
data, amongst the 21 gene targets of the identified miRNAs. 
Of these 13 miRNA, 8 miRNA were tested in this study. The remaining
                                    198
 
 
 
 
miRNAs formed part of a parallel study within our group. 
QRT-PCR analysis  was  performed  to  determine  the  expression  of  each
individual miRNA in PC cell lines, as well as other selected cancer cell
lines.  Our  results  suggest  that  we  could  identify  one  specific  miRNA
biomarker that is unique to a specific cancer for example miRNA8 which
was  found  to  be  specific  for  the  LNCaP  prostate  cancer  cell  line.
Additionally, we could also establish  unique miRNA profiles or fingerprint
for each of the cancers investigated in this study as indicated in Table 3.6.
This finding could potentially lay the groundwork for future and additional
studies within the group to refine a definitive fingerprint/miRNA profile for
each cancer, and specifically for the early detection of PC. Although the
study  has  managed  to  create  unique  profile  to  distinguish  between  the
cancer cell lines investigated in this study, the study needs to be expanded
to a larger cancer panel. Furthermore, these identified miRNAs should also
be  tested  in  both  tissue  and  biological  fluids  such  as  urine.  This  will
determine if these markers can be of clinical significance in the future for
PC risk management, diagnosis, prognosis as well as response to treatment
of PC.
                                    199
 
 
 
 
CONCLUSIONS AND FUTURE WORK
A comparative  bioinformatics  analyses  performed  using   an  “in-house”
pipeline  to  retrieve  information  from  databases  using  slightly  different
parameters from those used in public databases,  identified  miRNAs that
have  not  previously  been  described  nor  showed  association  to  PC.  In
addition miRNAs were identified that were not found in miRNA databases. 
In  the  present  study  the  expression  profiles  of  eight  potential  miRNA
biomarkers for the possible detection of PC was determined,  to distinguish
PC  from  other  cancers.  These  selected  miRNAs  were  identified  using
different  bioinformatics  tools,  and were confirmed to be novel  miRNAs
associated with PC. The pipeline has been optimized to identify miRNAs in
a very short space of time. This allows for the identification of miRNAs as
these databases are updated regularly, permitting a cost effective and less
labor intensive miRNA identification pipeline possible. 
In the panel of cancer cell lines that were investigated in this study it is
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clearly shown that miRNA8 over expression is unique to LNCaP, giving
some indication that in isolated incidences one miRNA may be sufficient
for the detection of a condition.  However, additional cell lines as well as
patient samples must still  be evaluated to establish the specificity of the
over-expression  of  miRNA8 in  PC.  Our  hypothesis  is  that  a  profile  of
miRNA expression in each cancer cell line should be unique. 
The  study  suggests  a  unique  profile  of  miRNAs  for  the  cell  lines
investigated, and recognize the need for additional analysis on a larger set
of cell lines to confirm their specificity. In addition, future experiments on
the  expression of  these  miRNAs in  urine samples  will  be  performed to
determine their efficiency as potential markers for PC. 
This study positively contributes to the field of molecular biomarkers that
can  aid  in  the  detection  of  PC.  While  none  of  the  recently  identified
biomarkers  in  literature  can  confidently  replace  PSA as  the  marker  of
choice for PC, we propose to evaluate the efficiency and the specificity of
the  identified  miRNAs  in  urine  samples  by  comparing  it  to  PSA.  The
advantage of using miRNA biomarkers are that they are non-invasive as
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they  are  present  in  urine,  whereas  the  PSA test  requires  blood.  From
literature it is also suggested that miRNAs are stable in urine  (Chen et al.,
2008; Mitchell  et al.,  2008; Li  et al.,  2007; Park  et al.,  2009) and this
negates the use of tissues and plasma to determine/verify the presence of
the miRNA markers. Given the heterogeneity of cancers and in particular
PC, the use of singular or a combination of miRNA as performed in the
miRNA  profiling  in  this  study  will  potentially  improve  the  predictive
accuracy or prognostics as well as treatment outcomes in PC. The use of
these markers will play an important role in screening for PC, however the
fundamental goal remains to reduce the number of unnecessary biopsies
performed and to limit the invasive procedures performed to differentiate
between normal cells, benign tumours  and aggressive PC.  
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APPENDIX A
Supplementary Information for Chapter 2
1. Scripts
Extract Expression Data.pl
#######################################################
#!/usr/bin/perl                                                                                    #
#Firdous Khan                                                                                   #
#BRG LAB                                                                                         #
#Biotechnology Department                                                             #
#University van wes-kaapland                                                          #
#Generates a tab delimited file of mean expression, gene id        #
#and     probe name                                                                           #          
#######################################################
use strict; 
use warnings; 
#Absolute path of infile2 
my $infile2 = "path"; 
open (IF2, $infil2) || die "cannot open $infile2:$!"; 
open(OF2, ">mean.csv"); 
my @line2 = <IF2>; 
for each my $line2(@line2) 
{ 
#Removes the new line character at the end of each line 
chomp $line2; 
#Slits each line into an array using tab meta-character  
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my @col2 = split(/\t/, $line2); 
my $geneid = shift@col2; 
my $probe name = shift@col2; 
my $len =scalar@col2; 
my $total = 0; 
while (my $num = shift@col2) 
{ 
$total += $num ; 
} 
my $mean = $total/$len; 
print OF2 $geneid."\t".$probe name."\t".$mean."\n"; 
} 
close OF2 
Data_Formatting.pl
############################################################
#Firdous Khan                                                                                            #
#BRG LAB                                                                                                  #
#Biotechnology Department                                                                      #
#University van wes-kaapland                                                                    #
############################################################
#Converting csv-txt and removing unnecessary delimiters                    # 
############################################################ 
sed 's/"//g' filename.csv > filename2.txt 
sed 's/,/\t/g' filename2.txt > filename3 
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#### Repeat this for each dataset to ensure all the files 
####in the same format
 Annotation_graphs.R
###########################################################
#Firdous Khan                                                                                          #
#BRG LAB                                                                                                #
#Biotechnology Department                                                                    #
#University van wes-kaapland                                                                 #
###########################################################
#Initializing R and attaching input files                                                 #
#Plotting annotation graphs                                      # 
###########################################################
##Initialize R 
R 
library(lattice) 
getwd() 
#Ensure you are in the directory where the files are located# 
input=read.table(file=file.choose(), header=T, sep="\t") 
input path 
eg:  /home/user/annotation_data/catergory 
attach(input) 
###Plot graph
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barchart(Heading1 ~ Heading2 | Heading3, data=input, col = "colour1", 
main="title1", ylab="label", xlab="%")) 
barchart(Heading1 ~ Heading2 | Heading3, data=input, col = "colour2", 
main="title2", ylab="label", xlab="%") 
barchart(Heading1 ~ Heading2 | Heading3, data=input, col = "colour3", 
main="title3", ylab="label", xlab="%") 
png(filename="filename.png") 
plot(filename) 
dev.off() 
rm(input)
Gene_expression_graph.R
###########################################################
#Firdous Khan                                                                                          #
#BRG LAB                                                                                               #
#Biotechnology Department                                                                   #
#University van wes-kaapland                                                                 #
########################################################### 
##converting csv-txt and removing unnecessary delimiters                 #
#Initializing R and attaching input files                                                 #
#Plotting Gene expression graph                                                            #
########################################################### 
##converting csv-txt and removing unnecessary delimiters 
sed 's/"//g' filename1.csv > filename2.txt 
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sed 's/,/\t/g' filename2 > filename3 
##Initialize R 
R 
library(lattice) 
getwd() 
#Ensure you are in the directory where the files are located# 
input=read.table(file=file.choose(), header=T, sep="\t") 
input path 
eg:  /home/user/annotation_data/catergory 
attach(input) 
###Plot graph in R 
barchart(Heading2 ~ Heading1 | Heading3, data=input, col = "colour", 
horizontal=FALSE, scales=list(x=list(rot=90)), 
index.cond=list(c(1,2,3,4,5,6)), main="title  ", xlab="label1", ylab="label") 
barchart(Heading1 ~ Heading2 | Heading3, data=input, col="purple", 
layout =c(1,2), main="Title", ylab="name1", xlab="name2")
Remove_duplicates.pl
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############################################################
# Firdous Khan                                                                                           #
#BRG LAB                                                                                                  #
#Biotechnology Department                                                                      #
#University van wes-kaapland                                                                    #
############################################################
##converting csv-txt and removing unnecessary delimiters                   #
#Catalogue gene ids                                                                                    #
#Eliminate duplicates from files                                                                 #
############################################################
 ##converting csv-txt and removing unnecessary delimiters 
sed 's/"//g' filename1.csv > filename2.txt 
sed 's/,/\t/g' filename2 > filename3 
## Initialize the terminal and catalogue gene lists
cat [options] [filenames][-] > [filename] 
##Eliminating duplicates 
cat [option][file1][file2] | [sort-u] > [file3]
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2. Genelist
Table 3: Tabular representation of the 551 target genes identified using in 
silico methods.
Target genes identified
USP32 HBP1 DTHD1 SH3TC2 MBOAT1 FMR1
USP6 IFI30 FAM105A SLAMF1 NAA50 GTF3C3
ZNF24 IL1RL1 FMR1 SLC30A7 ZNF26 HDHD1
RBFOX1 FOXE1 DUSP4 PRR16 ZNF562 FERMT2
SLC2A5 FOXP4 F2RL2 PTPN12 AFF4 SLC5A12
RARRES3 FA2H SOCS6 ZNF148 CHD4 PDE1A
RNF170 LRRTM3 SRPK2 LPP CSNK1G3 PRKCB
SH3TC2 OSBPL2 TULP4 AHCYL2 EIF4H RBMS2
SLC31A2 PAFAH1B
2
PGR ZNF652 FAM46A RFFL
SNRNP48 RAPGEF2 RSPO4 ONECUT2 INO80D RIMKLA
UNC80 SLC12A2 SDHC PKP2 LIG4 RUNDC3
B
VAPA SPTLC2 STAG2 PAPOLA LMO7 SH3TC2
VAPB SRSF11 ZNF673 PICALM MIB1 ZNF589
ZBTB8A TNPO1 PRKCI PPFIA1 PAK7 BRWD1
ZNF780B TXLNG FAM86B1 PTPRC PLSCR1 CHAC1
MAPK1IP
1L
ITFG3 FAM86C1 PLXNA4 PPARG CHORDC
1
RAB27A FOXN2 SAR1A DAZ4 GNAL SGIP1
RASAL2 FZD5 SBNO1 DCAF7 GPR180 SUB1
RBPJ GADL1 SFMBT2 E2F7 GSDMC TAPT1
RFK UBQLN2 DCX ENTPD1 HDAC9 TNFSF13
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BSH3TC2 VEZF1 ING4 ZFP3 KCMF1 TOX
ACOX1 UQCRB MPEG1 RAPGEF2 KCNT2 TSPAN2
CLMN USP37 LPP GLCCI1 KIAA2022 UQCRB
ENPP1 ZNF721 BRWD1 TNPO3 LMAN1 USP10
FAM20B ANKRD52 C12orf73 URGCP LOC10050
7161
UTRN
G3BP2 C1orf190 DKK2 ZFP106 ACVR1C RRAD
HNF4G CNTNAP1 CACNG8 ARL17A ADNP SH3TC2
MAGEA1
1
CREB1 CLN8 BACE1 AQP4 SLC5A12
PIAS2 CXADR DDAH1 BCAT1 BCLAF1 SMAP1
PKNOX2 ELK1 TCP11L1 PPP1R9B BMPR2 TLK2
SLC24A2 FOXC1 UBTF RSU1 BTBD11 TMTC4
SLC39A14 SLC28A1 WIZ CEPT1 CEP112 USP45
ENTPD4 ZNF704 IL5RA FNDC3B CLNK USP46
ERBB4 COX11 IREB2 FYTTD1 CPEB2 VEZF1
EIF4H ZNF559 LRRTM2 WDR33 SNRK RIMS3
EP300 ZNF681 MED13 WWTR1 SYNPO2 SH3TC2
ESRRG FAM46D JAZF1 GUCY1A3 TAL1 SPECC1L
FMNL3 NKTR LYSMD1 KCTD21 TSPAN2 SUPT3H
GABARA
P
SLC17A8 NID2 KIAA0232 VANGL1 ZDHHC8
GCA SLC25A21 PLEKHG7 KIF5C ZBTB38 BCKDHB
MAVS TOX RABEP1 LYPLAL1 ZNF608 RNF41
MCART6 ACPL2 RLF MGA ANKIB1 RPRD2
MICAL3 ANKRD27 RRAS2 MLLT4 ARL17A ACVR1C
MTPN ATAD2B SESTD1 MMS22L C2orf63 AMD1
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OAS2 BTG2 SMTNL2 NECAP1 CBX8 ARAP2
PARK2 C1orf96 SPARC NEMF LOC10029
4341
ASB8
PCNX CCNT2 ADSS NIPSNAP
3B
LOC10050
6255
ATM
PDC CEP97 AFAP1L2 OTX2 NHSL1 C5orf24
PURA COL1A1 AFF1 PCDHAC2 PDK3 C5orf47
RAB5C COL1A2 BFAR RAB3B SALL1 CALCR
RC3H1 COL3A1 BTBD7 RAB9B TMX1 CCBL2
SIM2 COL4A1 C16orf52 RANBP2 UTP23 CCDC88A
SLC22A23 COL4A5 CNBP RAP1A ASB1 CGGBP1
SLC31A2 COL5A2 CNTNAP3
B
RAPH1 C20orf177 CHML
SMG6 DYNLT1 CPLX3 RBBP6 INPP5A COL6A6
SMU1 EIF3J DDX17 RSBN1 KCND1 DEXI
SUFU FOXJ2 DIS3 RTF1 KSR2 ENOPH1
SYK GOLGA7 DOK6 SESTD1 LRRC4 FAM120A
EPC2 ADAM22 MGP XPO1 PAM AAK1
FASTKD2 AMMECR
1L
MR1 YWHAZ PAN3 AFF3
GBP3 ASF1A MTX3 ZFX PCDHB16 ATP2B4
HDX ASPH NOVA1 ZNF236 PRDM10 BSN
IGSF10 BET1 NSL1 ZNF492 PRKACB CDK6
LAMP2 C22orf39 PAK7 DDAH1 RAB11A COL4A4
LSM14B C9orf123 PI15 DDX18 RAB8B DAZ1
MIER3 CCDC34 PSMA8 DENND1
B
RNF144A DAZ2
MILR1 CREBZF NRCAM CYTIP
                                    211
 
 
 
 
3. Pathway information
Table 2: Tabular representation of significant pathways associated with 
miRNA1-8 silico methods
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KEGG pathway p-value #genes #miRNAs
ECM-receptor interaction <1e-16 14 1
Prion diseases <1e-16 3 1
Amoebiasis <1e-16 14 1
Protein digestion and absorption 1.187939E-014 15 1
Focal adhesion 2.055885E-010 29 2
Colorectal cancer 5.361692E-010 19 4
PI3K-Akt signaling pathway 1.408314E-008 51 3
Endometrial cancer 9.908088E-008 13 3
Glycosaminoglycan biosynthesis - chondroitin sulfate 1.737486E-007 2 2
Wnt signaling pathway 0.000010579 29 3
Pathways in cancer 0.0001553293 61 4
Glycosaminoglycan biosynthesis - heparan sulfate / hepari 0.0001909948 6 2
Hypertrophic cardiomyopathy (HCM) 0.0002814309 12 2
Dilated cardiomyopathy 0.0004519795 12 2
Adherens junction 0.000476915 13 2
Hedgehog signaling pathway 0.0005539027 14 3
Neurotrophin signaling pathway 0.000855797 26 4
Prostate cancer 0.0009389909 13 2
Basal cell carcinoma 0.002328241 12 3
Axon guidance 0.004194514 16 2
Mucin type O-Glycan biosynthesis 0.004534804 3 1
Endocytosis 0.00574708 8 1
Thyroid cancer 0.006504963 3 2
Ubiquitin mediated proteolysis 0.007459014 26 3
Small cell lung cancer 0.009583545 6 1
TGF-beta signaling pathway 0.009684528 5 1
Regulation of actin cytoskeleton 0.01302628 12 1
Melanoma 0.01380284 9 2
Glutamatergic synapse 0.01984405 14 2
Renal cell carcinoma 0.02505617 13 2
Toxoplasmosis 0.03384567 7 1
HTLV-I infection 0.03759023 23 2
Other types of O-glycan biosynthesis 0.04270389 3 2
 
 
 
 
Table 3: Tabular representation of additional identified pathways associated
to miRNA1-8
                                    213
KEGG pathway p-value #genes #miRNAs
ErbB signaling pathway 0.05102382 7 1
p53 signaling pathway 0.05323238 8 2
mRNA surveillance pathway 0.05493907 14 2
Transcriptional misregulation in cancer 0.06032142 10 2
Measles 0.06556488 7 1
Influenza A 0.0683851 8 1
Valine, leucine and isoleucine biosynthesis 0.07245746 1 2
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.08613729 6 1
Adipocytokine signaling pathway 0.09080646 11 2
Cytokine-cytokine receptor interaction 0.1103693 4 1
Hepatitis B 0.1216237 11 1
N-Glycan biosynthesis 0.1407615 2 1
Shigellosis 0.1483155 10 2
Hepatitis C 0.1505176 6 1
Long-term potentiation 0.1707405 4 1
Fc gamma R-mediated phagocytosis 0.174731 3 1
T cell receptor signaling pathway 0.1762456 10 1
Cholinergic synapse 0.1771551 12 1
Glycosaminoglycan biosynthesis - keratan sulfate 0.1906681 1 1
Melanogenesis 0.2044662 8 1
Acute myeloid leukemia 0.2193944 4 1
RNA degradation 0.2241099 8 1
Non-small cell lung cancer 0.2306316 5 1
Drug metabolism - cytochrome P450 0.2575857 1 1
Dopaminergic synapse 0.259873 10 1
Spliceosome 0.265297 6 1
Epstein-Barr virus infection 0.2709317 7 1
Dilated cardiomyopathy 0.3149708 13 1
Pantothenate and CoA biosynthesis 0.319202 2 1
Tuberculosis 0.3267261 14 1
RIG-I-like receptor signaling pathway 0.3275958 7 1
HIF-1 signaling pathway 0.3532609 9 1
B cell receptor signaling pathway 0.3727899 8 1
Insulin signaling pathway 0.4067456 10 1
Protein processing in endoplasmic reticulum 0.4514956 13 1
Dorso-ventral axis formation 0.464945 3 1
Valine, leucine and isoleucine degradation 0.4992077 4 1
Bacterial invasion of epithelial cells 0.5384656 10 2
Lysine biosynthesis 0.5471215 1 1
Herpes simplex infection 0.5661742 8 1
Fatty acid elongation 0.5756327 1 1
Oocyte meiosis 0.5758602 10 1
Retrograde endocannabinoid signaling 0.5802484 8 1
Calcium signaling pathway 0.6007089 13 1
Viral carcinogenesis 0.6146964 10 1
Nicotine addiction 0.6633905 3 1
Mineral absorption 0.6807361 4 1
Toll-like receptor signaling pathway 0.6830615 4 1
Homologous recombination 0.7044528 2 1
Folate biosynthesis 0.750011 2 1
Malaria 0.796024 3 1
Metabolism of xenobiotics by cytochrome P450 0.8069897 3 1
Viral myocarditis 0.8287709 4 1
Glycerolipid metabolism 0.8361433 3 1
One carbon pool by folate 0.8499083 2 1
Bile secretion 0.8583768 3 1
Gap junction 0.865365 7 1
Tyrosine metabolism 0.8672197 2 1
Gastric acid secretion 0.8715899 7 1
Purine metabolism 0.9279241 5 1
Selenocompound metabolism 0.9685885 2 1
Thiamine metabolism 0.9784377 1 1
 
 
 
 
APPENDIX B
Supplementary Information  for Chapter 3
1. Amplification Curves
MiRNA 17A – Amplification curve
MiRNA 191A – Amplification curve
MiRNA 1 – Amplification curve
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MiRNA 2 – Amplification curve
MiRNA 3 – Amplification curve
MiRNA 4 – Amplification curve
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MiRNA 6 – Amplification curve
MiRNA 7 – Amplification curve
MiRNA 8 – Amplification curve
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2. Melting Curves
MiRNA17A – melting curve
MiRNA 191A- melting peaks and curve
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MiRNA 1 – Melting curve
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MiRNA 2- Melting curve
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MiRNA 3 – Melting curve
MiRNA 4 – Melting curve
MiRNA 6 – Melting Curve
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MiRNA 7 – Melting Curve
MiRNA 8 – Melting Curve
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3. Descriptive Statistics
Table 3.7: Descriptive statistics used to determine the differential expression of miR1-8 in BPH1 in comparison 
to PNT2C2 cell lines.
 
 
 
 
Table 3.8: Descriptive statistics used to determine the differential expression of miR1-8 in LNCaP in comparison
to PNT2C2 cell lines.
 
 
 
 
Table 3.9: Descriptive statistics used to determine the differential expression of miR1-8 in MCF7 in comparison 
to MCF12A cell line.
 
 
 
 
Table 3.10: Descriptive statistics used to determine the differential expression of miR1-8 in A549 in comparison
to KMST1 cell line.
 
 
 
 
Table 3.11: Descriptive statistics used to determine the differential expression of miR1-8 in HT29 in comparison
to KMST1 cell line.
 
 
 
 
Table 3.12: Descriptive statistics used to determine the differential expression of miR1-8 in HepG2 in 
comparison to KMST1 cell line.
 
 
 
 
Table 3.13: Descriptive statistics used to determine the differential expression of miR1-8 in Caski in comparison
to KMST1 cell lines.
 
 
 
 
Table 3.14: Descriptive statistics used to determine the differential expression of miR1-8 in Caski in comparison
to KMST1 cell lines.
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